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This report describes the study results achieved over two periods of related
activity, June-December 1977 and March-October 1978. It is organized in three
volumes to meet the needs of different audiences. The first, an executive summary,
serves as an overview aimed at those responsible for committing public and private
resources to new ventures. The second recounts the activities of the study and
presents fundamental lessons learned. This volume is intended to serve two
groups: those in the aerospac,,- industry who may wish to have a model for , their
efforts to attract participation in space processing by other industries; and
those in nonaerospace industries who want to learn more about the possibilities of
space processing. The third volume contains the detailed product data collected
and reviewed to support the activities in Volume II.
The report has been organized to take the reader through the chronology of
the study process. Although many of these steps were accomplished simultaneously,
we have -- for simplicity and clarity -- organized them into discrete segments,
moving first through the plan established to target and contact pharmaceutical
companies, then the laboratory work needed to support the expanding company-to-
company cooperation and technology interchange, through the literature search and
analysis of potential products and finally through the production engineering
analysis. The report then summarizes the study by identifying the lessons learned
during the course of its execution. Before the enormous potential benefits of
space processing can reach the public -- the basic goal of NASA's Materials
Processing in Space program -- industry must be willing to participate in the
development of processes. Such investment, however, will not follow until industry
itself is made aware of the promise of space processing and is supplied with hard
data supporting such promises. It is to this purpose that we have directed our
efforts.
This report is submit4ed under NASA Contract Number NAS8.31353. The work was
performed by McDonnell Douglas Astronautics Company - St. Louis Division under the
direction of William R. Marx and Dr. Ronald A. Weiss, Study Managers during the
first and second period• of the study respectively. This contract was administered
by the NASA Marshall Space Flight Center, Huntsville, Alabama.
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This report was prepared under the direction of Dr. Ronald A. 14eiss with the
assistance of the principal contributors listed below:
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	 David W. Richman
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FOREWORD
As the principal result of this study activity, the McDonnell Douglas
Astronautics Company - St. Louis Division, elicited and fostered the participation
of several pharmaceutical firms, to varying degrees, in exploring the potential
benefits which may accrue from processing pharmaceuticals in space.
One of the conditions for their participation, however, was that the companies
not be linked with any potential product or process because of the highly competi-
tive nature of the industry. With NASA concurrence, therefore, and participating
company approval, we have deleted the names of any company associated with this
study in order to be able to emphasize the important product data and technology
interchange achieved with them.
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1.0 INTRODUCTION
The environment of space holds great promise for new manufacturing processes which
take advantage of the absence of such earthbound phenomena as natural convection
and sedimentation. Using these processes, space manufacturers cannot only produce	 +
products superior to those produced on the ground, they can produce entirely new
classes of products. Though characteristics of space -- including high vacuum and
radiation - can be duplicated on earth, the most important characteristic, weight-
lessness, can be achieved only for an extremely brief period. In the microgravity	 t
of space, molten materials can be suspended without containers -- eliminating a
major source of contaminants. More importantly,, in space we can escape gravity
induced convection. Convection currents -- which are caused by the thermal
gradients in fluids -- can lead to undesirable structural differences in the solid
materials produced. Having escaped the problems posed by these currents, space
manufacturers will be able to grow crystals of great purity with highly control-
.
lable characteristics; they will find it much easier to mix and homogenize liquids,
to cast metals, and to separate and purify the elements of mixtures.
The question immediately arises, why is not industry activFiy pursuing opportuni-
ties to develop materials and processes in space? The first reason is that
industry is not generally familiar with the potentials of space. NASA and key
aerospace organizations are working continually to rectify that situation. The
second, and by far the dominant, reason is that observation of basic phenomena
with potential application is only the start of the industrial process. -A major
body of data on applied research into processes ar:d materials characteristics,
material applications potential, potential markets and their probable growth, and
the characteristics of production systems and logistics must be developed as a
vital decision base. Before private industry will invest the money required to
begin such untried processes, it must be reasonably confident that the product
will have a high value, that the benefits of processing in space will be substan-
tially greater than processing on the ground (i.e., capable of producing less
expensive, more useful products, or producing products that cannot be made on
	
s
earth). The investor must also be reasonably confident: that the space process
can be developed in a given time at an affordable cost; that a market exists at a
..	 price which assures a reasonable return on investment; and that this market will
1-1
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not disappear because a new product appears and captures the market, or because a
breakthrough in the technology occurs that permits competitive ground production.
Because these risks are so difficult to assess, and because the required initial
investment is so large, most industries adopt a "wait and see" attitude. Until
more data are available, industries find it extremely difficult to assess the
potential of new processes and products.
To address this problem, we approached NASA with a proposal to study the feasibil-
ity of commercial manufacturing of pharmaceuticals. The coal of this undertaking
was to induce pharmaceutical firms to participate actively, on a continuing basis,
in exploring the possibilities of using the unique environment of space to produce
new products. The MDAC-St. Louis' approach was, first, to secure the initial
commitment of these firms by providing key management and technical executives
with preliminary data and forecasts of the business and technical potential of
space processing. The second aspect of the approach was to foster- the initial
commitments; by establishing continuing technical and management exchanges with the
interested pharmaceutical companies to our mutual benefit.
Our enthusiasm for space processing focused on the promise shown by our company
funded efforts with electrophoresis. In order to accomplish the facets of this
goal, we had to expand the data base we had developed -- including significant
laboratory work and an awareness of the state-of-the-art -- and we had to target
companies potentially interested in the benefits of the process.
In our early company funded work with electrophoresis, we learned how to separate
relatively large quantities of test materials. We also experienced the adverse
effects of gravity on the process -- causing the vertically flowing stream to
collapse on itself (if the sample were denser than the carrier fluid) or to ball
up and float to the top of the chamber (if the sample is less dense than the
carrier fluid). On the basis of these experiences we began developing, with
MDAC-St. Louis funds, our own mathematical models of these effects so that we
could predict effects of design changes and operating conditions, and ultimately
forecast the benefits of operating in space. We also ran company funded prelimi-
nary mass balance calculations; these activities assured us that we could define
1-2
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and demonstrate the types of requirements needed to characterize conceptual 	 space 4
and ground production systems, with their requisite logistics capabilities, in
presentations to NASA and industry.
i.
r
-	 Under the contrast, we addressed the problem of targeting pharmaceutical companies.
Our first step was to engage the services of Price Waterhouse and Company to
provide important drug industry data. 	 The overall drug industry analysis provided
by Price Waterhouse included: 	 detailed assessments of the trop twenty companies in
`i
the industry, focusing on their apparent commitment to innovation, their research
and production emphasis on products having high potential	 for space production,
and the prcTiinence of their executives. 	 Price Waterhouse also helped us prepare
the presentation to be made to these companies, recommending a "businessman to
businessman" approach.
Letters were written to the selected companies,, 	 These letters gave an overview of
the feasibility study, listed some of the potential 	 benefits to pharmaceutical
manufacturing by processing in space, and requested an opportunity to malke a
4
presentation.	 Ten of fourteen companies requested the presentation.
Although the pharmaceutical company personnel were generally skeptical at first,
once they understood the benefits of microgravity, the implications of the prelimi-
nary results of continuous flow electrophoretic separation, and the potential of an
integrated s pace pharmaceutical production system manufacturing products of great
value, they became 'increasingly intrigued. As a result of these initial contacts,
six companies responded positively to our invitation for assistance and coopera-
tion in this study. Two companies agreed to participate actively in the form of
	
r
laboratory testing a product of specific interest to themselves. Four additional
x	 '^
companies agreed to participate in a more passive mode by suggesting products,
providing marketing information and reviewing the analysis of results. One of the
conditions for their participation, however, was that the companies not be linked
with any potential product or process data because of the highly competitive
nature of the industry. With NASA concurrence, therefore, and participating
company approval, we have deleted the names of any company associated with this
study and, instead, emphasized the important product and process information
obtained from them.
Nt,
1-3
INu:7iaONNNLL OOUOLAS A0rN0NAUT/CS COMrANY-Or. LOU/a 0/V/0fCW
s
.;..s ^rssar^c ^^t^r .Ka.^	 ,r ..w	 sr,	 ^e¢r6rin	 ^_	 _	
^ww.^^	 ^^	 -0âd'YfY6YuJ99_ 7.kP.'^+.., ^u!u_rwx^e+cr..vscrw..: w, a..' $^ li .'^.	 _
REPORT MOC E2104	 !t
'tSFACEVOLUME11
 9 NOVEMBER 1978ANUFACTURING
This report describes our method of obtaining pharmaceutical company involvement,
the development of protocols with two of these companies, laboratory results of
'the separation of serum proteins by the continuous flow electrophoresis process,
the selection and study of candidate products, and their production requirements.
From the twelve candidate products discussed with, or suggested by, the visited
pharmaceutical companies, six were selected for further evaluation; anti hemophi 1 ic
factor, beta cells, erythropoietin, epidermal growth factor, alpha-1-antitrypsin
and interferon. Production mass balances for antihemophelic factor, beta cells,
and erythropoietin were compared for space versus ground operation. Selection of
the best mode of operation for these three representative products permitted a
conceptual description of a multiproduct processing system for space operation.
Production requirements for epidermal growth factor, alpha-1 -antitrypsin and
interferon were found to be satisfied by the system concept.
In the technical interchanges that occurred with these phartimaceutical companies,
significant data were generated and many valuable lesnons were learned. These
data and lessons, detailed in this report, are intended to serve others interested
in exploring the possibilities of space processing.
J^	 REPORT MOC E2104
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2.0 INTRODUCTION
The aspiration of this task was to obtain the participation of one or more promi-
nent ethical drug manufacturers in this study and gain their evaluation of product
FM
and process commercial feasibility. The industrialization of space, and any
!1-^
	
	 resultant social benefits, would not be realized at any early date without the
cooperation, endorsement, and initiative of commercial industry. Thus, the
ultimate effect of securing the initial participation of ethical drug producers
`.	 and establishing a foundation for their continued involvement would be to assure
the timely commercialization of pharmaceutical processing in space.
The approach to this task consisted of an analysis of the drug industry and identi-
fication of primary candidate companies for potential study participation. Commun-
ications were then established with a number of these companies for the purpose of
gaining the assistance of one or more of them in product selection and evaluation.
Some ethical drug companies chose to participate in different ways ranging from
}	 suggesting candidate products to actual laboratory participation. The unanimous
condition, however, for their participation was, as noted in the Foreword and
i
	
	 Section 1, that company names be in no way linked with products or processes. In
order to focus on our technological exchange with these firms and on the joint
learning process through which we passed, company names are avoided in this and
following sections.
I
2.1 COMPANY SELECTION
4	 Selection of potential pharmaceutical company participants was limited to domestic
t	
United States ethical drug producers. The task was principally accomplished
through subcontract with the St. Louis office of the business consultant firm of
Price Waterhouse and Company. This firm has considerable knowledge of the pharma-
ceutical industry, its key personnel and the environment in which they operate.
After preliminary discussions between both the MDAC-St. Louis marketing and aero-
space medical representatives and the subcontractor, an overall approach to this
i'	 selection process was established. This selection process is summarized in Figure
2.1-1. The work was accomplished in two steps. First, a preliminary screening
® REPORT MOC E2104
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process identified the American drug firm candidates based principally upon ethical
drug sales. A final screening process ranked 20 for initial contact (within the
limits of the study travel budget) based upon evaluation criteria including tech-
nical and market leadership and product characteristics, among others. 	 j
During preliminary screening, a file of basic financial and "line of business"
data were collected. It consisted of nonproprietary and publicly available infor-
mation concerning individual major pharmaceutical companies as well as the ethical
drug industry as a whole. The 100 companies which came under consideration were
grouped according to the following Standard Industrial Classifications:
2801 - Major Chemical Producers
2802 - Intermediate Chemical Producers
2803 - Specialty Chemical Producers
2834 - Pharmaceutical Preparations
2835 - Ethical Drugs
2836 - Proprietary Drugs
2837 - Drugs-Medical and Hospital Supply
2899 - Chemical Preparations
Active producers of ethical drugs were identified through analysis of product line
and related business data found in company annual reports, "10-K reports," and
other publicly available sources of information. This analysis resulted in a
reduction from 100 to 42 potential candidate companies. The ten largest pharma-
ceutical firms (in terms of 1976 consolidated net sales) were then identified.
The largest firms were selected because: 1) prominent names associated with this
effort would provide visibility and recognition; and 2) major companies would
more likely have the resou°ces to conduct experimentation and initial financial
investment.
Additional drug or chemical company candidates were also identified for other
reasons such as: prior established contact with MDAC management, location, and/or
known company interest in space processed pharmaceuticals.
The 42 drug company candidates for study participation identified during the
preliminary screening process were evaluated in a final screening for the purpose
r	 2-3
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of first selecting, then ranking, the candidates for initial contact. A final
list of 20 candidate companies was compiled using several different selection
F
criteria. Among these were quantifiable factors of comparison such as industry
sales position, profitability, research and development expenditures, various
financial ratios and growth rates. Subjective criteria were utilized as well to
evaluate each company's leadership in new product development and other factors
including top management commitment to innovation.
This analysis of the 20 candidate pharmaceutical companies revealed that all were
potentially acceptable as participants in the study. However, time and travel
budget constraints prevented inclusion of all 20. Based on the ranking, companies
were contacted to offer a presentation on space bioprocessing until the 10 alloted
trips were scheduled. Fourteen companies of the twenty ranked companies were
contacted. The method by which these companies were approached is found in
Section 2.2.
The Price Waterhouse and Company report also included a brief overview of the
ethical drug industry and detailed information on the pharmaceutical companies
recommended as candidates for presentations. This information included line of
business data, results of operations and financial position, specific information
concerning ethical drugs currently produced, biographical data on key individuals
within the company, and preferred initial contacts at each company. Throughout
their consultantship, Price Waterhouse and Company stressed the need for MDAC-
St. Louis to initiate our contacts and communicate with pharmaceutical firms
strictly on a "businessman-to-businessman" basis. Only in this way could we
succeed in establishing the rapport which would permit us to address potential
areas of mutual business interest, in a common language and with a mutual under-
standing of our technical and business goals.
2.2 ESTABLISHMENT OF COMMUNICATIONS
Once 20 pharmaceutical companies had been identified for contact in rank order of
desirability, a program was established to develop the most effective method of
communication with them and eliciting their participation in this study. This
program, in summary, consisted of the following elements:
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Identification of persons to be contacted
Selection of initial contacts
Introductory letters
Follow-up telephone calls
Formal presentation material preparation
Formal presentations at the drug company
	
l
Establishment of follow-up communications.
Publicly available biographical information on each company's top management per-
sonnel was reviewed in order to identify individuals, who, due to organizational
position or prominence within the pharmaceutical industry, would be pivotal in
persuading their company, and perhaps the drug industry, to participate in commer-
cial space development.
i
Letters were prepared and sent to each selected pharmaceutical company contact.
These letters, from the Vice President-Space Programs, MDAC-St. Louis, introduced
the concept of pharmaceutical space processing, outlined potential benefits to the
drug industry, and stated the importance of their participation in the study.
Approximately one week after the letters were sent, telephone calls were made to
each of the pharmaceutical company officials who had received the letter. The
purpose of these telephone calls was to establish dates for formal presentations
on pharmaceutical space manufacturing. These follow-up calls were successful in
setting up meeting dates with 10 of the first 14 companies. The other four were
either already involved with NASA Space Processing or were uninterested in a
briefing on the subject.
The formal presentation was organized into two principal sections. The initial
section of the briefing established the meeting's objective, described MDAC-St.
Louis' product line and involvement in space as well as defined the NASA space
program and objectives. It also outlined the programmatic importance of early
involvement of drug industry participants to assure the success of commercial
space development. The second section of the presentation described technical
and business objectives of the pharmaceutical study and the process system concept,
described in detail the MDAC-St. Louis in-house experimental work accomplished to
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date on continuous flow electrophoresis for use in space bio,nrocessing, defined
the benefits of space improved biological separation, and identified candidate
products for space processing.
A series of vu-graphs were developed to support the formal presentation. In
addition, brochures incorporating these vu-graphs were prepared for distribution
at the conclusion of each drug company presentation. This brochure allowed the
drug company participants to review the material at their leisure after the formal
presentation, discuss it with their colleagues and come to a conclusion about
further participation.
During the course of this study, presentations were made to 10 pharmaceutical com-
panies at their facilities. After an introduction by an MDAC-St. Louis Director
of Marketing, the two sections of the formal presentation were made by the MDAC
Space Processing Program Manager and Bioprocessing Study Manager, respectively. A
member of the MDAC-St. Louis Aerospace Medical Departn,ent was also present to
comment on the processing system preliminary concept and its intended space utili-
zation during the informal question and answer period. The tone of the presenta-
tion was that of a progress report on an MDAC-St. Louis space bioprocessing program
with solicitation of the drug company's participation if they felt it would be in
their best interest.
In order to maintain an openness and flexibility of approach, no formal contractual
agreements for drug company participation were solicited. However, during post-
briefing discussions with drug company attendees, they were asked to send a letter
from drug company management to MDAC-St. Louis stating their decision to partici-
pate, defining their limits of study participation, and identifying the contact
within the drug firm for matters concerning the study. As a participation starting
point, assistance was requested in defining market potential for products previ-
ously defined as candidate products by NASA and MDAC. For this purpose, an infor-
mation sheet was prepared and distributed at the conclusion of each presentation.
About two weeks after the formal presentation, a telephone call was made to the
drug company contact. The purpose of this call was to determine if any participa-
tory action was to be forthcoming and whether the company needed any additional
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information from MDAC-St. Louis. If the response was affirmative, a two way
dialogue was developed between MDAC-St. Louis and the interested pharmaceutical
company. This dialogue was accomplished through exchange of correspondence,
telephone calls and facility visits.
2.3 DRUG COMPANY RESPONSE AND PARTICIPATION
Typically, the officials of each pharmaceutical firm were initially skeptical of
the benefits of space processing, but they were willing to listen. Following the
description of the MDAC-St. Louis laboratory experiments of continuous flow elec-
trophoresis and how microgravity may enhance the separation of cells or protein
substances in such a continuous flow electrophoresis system, most of the techni-
cally oriented officials perceived the potential capability of space processing to
produce higher purity and/or unique pharmaceutical products. Discussions concern-
ing this subject were fruitful and generally resulted in allaying of initial
skepticism.
Highlights of significant comments and concerns expressed by the drug company
officials during these presentations and subsequent follow-up communications are
presented in Figure 2.3-1.
Several significant accomplishments were achieved by these meetings. Probably the
most far reaching action was making the technical people present at these meetings
aware of the effects of gravity in their current and future chemical processing
activities. For one company in particular, this became an obvious answer to an
existing chemical processing problem. Because of this initial exchange, they
requested that another pharmaceutical division of their company also receive the
same presentation. Another major accomplishment was making these corporate deci-
sion makers aware of the existence of a space program in which they could partici-
pate for the benefit of their company. They were under the impression that the
space program was conducted primarily for astronomical research, political and
e
military reasons. The characteristics of space applicable to both a research and
manufacturing environment had never been elucidated for them until the formal
r	 presentation.
f
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A strong interest in the potential of continuous flow electrophoresis systems for	 {
separation and purification of pharmaceuticals was one of the major outcomes of
the meetings. Taking a relatively old, research oriented process such as this,
and applying a multi-disciplinary team to analyze, model and improve its potential
for commercial bioprocessing was indicative to these pharmaceutical companies of
the need for aerospace company participation in the total systems concept. A
number of the drug companies contacted in this study did not have the multi-
disciplinary talent to conduct such a systems analysis; they thought the MDAC-
St. Louis "team" approach to space bioprocessing might be beneficial as an approach
to many aspects of their company operations.
During the course of this study six of the ten companies contacted agreed to
r
participate. Of the six, two companies agreed to participate actively in the form
of laboratory testing a product of interest to themselves. More details of this
participation will be found in section three of this report. The four other compa-
nies agreed to participate in a different mode by suggesting products, providing
marketing information and reviewing the analysis of results. The products sug-
gested can be found in Section 4.3. Several weeks after the formal presentation,
a seventh company informed us that they had started investigating the space pro-
cessing feasibility of four products of interest to them. They indicated that the
results of this activity and a formal corporate decision to participate in the
MDAC-St- Louis study would take time. During the course of this study, however,
no formal comment to participate was forthcoming. Three of the companies contacted
chose not to participate.
The approach taken to obtain drug company participation in the study resulted in
the establishment of communications with the drug industry and general expressions
of interest. The reasons for this success are many, but of greatest importance
was the contribution of the in-house MDAC-St. Louis continuous flow electrophoresis
laboratory test results to the basic understanding of the potential benefits of
microgravity to the pharmaceutical industry. Other reasons include: 1) an
obvious commitment of MDAC-St. Louis to the program; 2) careful selection of
contacts and; 3) the fact that no immediate financial commitment was required of
the drug company participants. Their initial willingness to listen to the presen-
tation was probably tempered by curiosity about why MDAC-St- Louis was seriously
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w
considering space processing of pharmaceuticals. Also, an influence could be the
decreasing number of new pharmaceuticals being introduced; any process or concept
which couldroduce multiple new and innovative products must be investigated.P	 P	 P	 9
The -reasons why three companies have decided against participation are generally
related to a combination of the extremely long development time frame (10-15
years), long term commitment with unanswered proprietary right retention questions,
and the competition from dl^te'nati've products and processes for limited corporate
research and development resources. This latter factor was of paramount importance
in two companies responses.
The principle conclusion to draw from the decision of the three drug firms not to
participate in the study is that despite its promise, not enough is known about
potential space processed products to allow solid forecasts of how they would
compete with other currently promising product alternatives which can be developed
along more traditional lines.
Active participation, in the form of cooperative laboratory testing, indicates
company interest in applied scientific research in addition to the feasibility
analysis. Such an approach can be extended to space in the form of an applied
research/development laboratory analogous to a ground development laboratory, that
can serve to stimulate further drug company participation in space applied
research.
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3.0 INTRODUCTION
The initial interactions with pharmaceutical companies stimulated several of them
to participate in the study to various degrees. Two companies in particular
wished to cooperate with us in developing a better understanding of products of
interest to them. Therefore, we established the laboratory test goal of develop-
ing the data base necessary for intercompany technological exchange. In this
fashion we served the study goal by enhancing the cooperatini. companies' level of
participation.
Initial protocols for cooperative investigations were prepared for the two compa-
nies based on data previously obtained during in-house work at MDAC-St. Louis.
Specific cooperative experimental activities with antihemophilic factor VIII (AHF
VIII) were then accomplished to expand our data base on 'this material and to exer-
cise one of the test protocols. The second, multiproduct protocol will be imple-
mented during 1979 under company funded auspices. Throughout these interactive
processes a wide range of technology interchanges occurred between MDAC-St. Louis
and the pharmaceutical companies, particularly in the areas of product characteris-
tics, assay methods, state-of-the-art product research, sample handling logistics,
and day to day technical procedures.
3.1 PRECONTRACT COMPANY FUNDED RESEARCH
Prior to entering into this study for NASA, considerable work was conducted wit,, a
first generation electrophoresis chamber during which methods were established to
study the effects of gravity on the free flow electrophoresis process. These
studies showed, among other things, that protein and cell samples whose specific
gravities varied significantly from that of the carrier buffer could not be pro-
cessed at flow rates required to separate materials ha`W, ing small differences in
electrophoretic mobility. These data, documented in prev •rus MDC publications
(20,21) were used to demonstrate to the drug companies that laboratory test data
were available concerning proteins and cells which illustrate the limit that
gravity imposes on their processing by free flow electrophoresis.
In addition to these gravity effect studies, preliminary tests with AHF VIII were
conducted using cryoprecipitate as the starting material. Processed samples were
3-1
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sent to a local St. Louis hospital .blood coagulation laboratory for evaluation.
The results of these preliminary tests were encouraging because they showed that
the protein materials in cryoprecipitate could be separated from one another and
i that AHF VIII activity was found with the fastest moving protein peak. Additional
preliminary tests during this time with other partially purified materials showed
that AHF VIII could be separated from other proteins present even in the most
purified commercial products available. a
3.2 PROTOCOL DEVELOPMENT
After pharmaceutical company participation was obtained, a series of follow up
meetings with laboratory personnel from both MDAC-St. Louis and the participating
drug companies ensued. The choice of material to be tested, assays to be used and
the frequency of testing were established. Protocols were based on using previous
MDAC-St. Louis company funded research, the capabilities of the laboratories,
logistics of sample transport, and company policies concerning management of pro-
prietary data. One of the major considerations of the protocols was control of
the release of information. The protocols emphasized that the pharmaceutical
company would have final say as to how the data would be presented.
A preliminary protocol was sent to the first company for review. It was promptly
returned to MDAC-St. Louis with minor changes and a list of several tests they
would perform on the electrophoretically separated materials sent to them. After
their suggested changes were incorporated, the protocol was approved jointly by
both laboratories. A copy of this test protocol is included as Appendix A-1 of
this report.
Because the second company is multiproduct oriented, it has suggested participation
in the exploration of several possible candidate products. Beta cells, pituitary
growth hormone and granulocyte stimulating factor were submitted for their consid-
eration. A preliminary protocol, Appendix A-2 was prepared based on these
products. The final protocol will be prepared after the final selection of candi-
date products has been made by the drug company. Interlaboratory testing will
begin in 1979 under company-funded auspices.
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3.3 SEPARATION OF ANTIHEMOPHII.IC FACTOR VIII (AHF VIII)
Initial interlaboratory tests with the pharmaceutical company were conducted with
cryoprecipitate as a starting material. Protein assays and clotting times on the
electrophoretically separated cryoprecipitate were initially conducted at MDAC-
t
St. Louis. Early tests in which the separated samples were sent to participating
companies for antigen assays showed deterioration due to problems associated with
logistics. The cooperating company recommended and assisted MDAC-St. Louis in
establishing an MDAc-St. Louis capability to carry out the required antigen assays
eliminating delays and other factors tending to compromise test results. During
these early cooperative tests we determined that the many variabilities of cryopre-
cipitate made it unsuitable as a research tool for free flow electrophoresis.
Variable parameters included lipid and protein content, AHF VIII content, degree
4	 of solubility, and specific gravity. Consequently, the more uniform commercially
available product, Hemophil R , was chosen for laboratory testing. Cryoprecipi-
tate, however, remains a viable candidate for space bioprocessing since these
variabilities would be insignificant in large scale processing.
Hemophil R
 contains approximately 250 units of AHF VIII in 700 mg of solids, of
which about 50% is extraneous protein. The AHF VIII concentration is therefore
approximately 0.086 µg per mg of protein. Samples were prepared by dissolving 0.5
to 0.7 mg of femophil R in 0.0025M diethylbarbituric acid/sodium diethylbarbiturate,
pH 8.3. The same buffer was used as the carrier fluid for the electrophoretic
separation. A typical separation of Hemophil R is shown in Figure 1. In this
run sample concentration was 0.7 mg/ml, carrier flow was 20 ml/ min, and sample
t	 flow was 0.13 ml/min. Samples collected during sample streaming with no voltage
1
applied showed that all protein materials were exiting through tubes 19 and 20 of
a.	 96 outlet tubes. A field strength of 48.19 volts/cm was then established in the
chamber by applying 400 volts across the width of the chamber. The system was
y	 allowed to stabilize for 30 minutes, after which time samples were collected in
k	 tubes 20 through 56. Each tube was analyzed for total protein, AHF VIII clotting
activity, and AHF VIII antigen activity.
The solid black line in Figure 1 represents the total protein content (in µg/ml)
f	 of each fraction collected. The dotted line represents AHF VIII clotting activity
in seconds for each fraction. The black triangles along the abscissa indicate
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ELECTROPHORETIC AHF VIII SEPARATION
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those tubes in which AiIF VIII antigen was detected. Subsequent runs resulted in
separation curves in which the principle features were similar to those shown in
Figure I.
The results of these runs showed that AFIF VIIr migrated in the electric field and
that the antigen moiety and the bulk of the clotting moiety moved with the fastest
moving protein peak.
The wide distribution of clottiq,, activity indicates that this moiety has dissoci-
ated from the native AIIF VIII molecule. As a result of this dissociation, various
molecular forms of the clotting moiety appear to have separated due to their
different electrophoretic mobilities. It is a well recognized characteristic of
the A11F VIII molecule to undergo such dissociation. In order to determine the
degree of dissociation of the material which may have occurred during processing,
radioimm unological and radioautographic assays are being established at MDAC-
St. Louis for future company funded studies.
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Native AHF VIII possesses at least two characteristic activities which can be
measured by analytical procedures. These are the clotting activity and antigen
activity. After electrophoretic separation as shown in Figure 1, both antigen and
clotting activities appeared in tubes 41, 43, 44, and 45.
A small peak of clotting activity occurred in tube 32. This represented only a
small fraction (about 5%) of the total clotting material present in the sample
prior to processing. However, it is a highly purified material with regard to
extraneous protein content. It is possible that such a highly purified, although
dissociated, clotting moiety might provide an important source of material for
preparation of highly purified antibody to the AHF VIII clotting moiety.
The major protein in commercial AHF VIII preparations is fibrinogen. Since AHF
VIII antigen and the bulk of the clotting activities moved with the largest
protein peak, it is deduced the AHF VIII moves electrophoretically with fibrinogen.
Although this has not been verified, it is reasonable to hypothesize that this is
the case. Identification of fibrinogen as well as other materials in the starting
product are planned as part of the on-going company funded MDAC-St. Louis R&D
program.
3.4 HUMAN PLASMA AS A SOURCE OF AHF VIII
Since normal human plasma (including cryoprecipitate) is the only practical source
of AHF VIII, the ability of free flow electrophoresis to separate the various
human plasma fractions was investigated with company funding as an adjunct to the
contract effort. For these studies a commercially available human plasma product,
Standard Normal Plasma (SNP), was obtained from Dade Diagnostics, Miami, Florida.
The sample was diluted in the same buffer as used for the AHF VIII studies at con-
centrations of about 0.8 mg/ml. A typical plasma separation is shown in Figure 2.
The plasma protein was continuously collected in 45 fractions. In this case, ten
distinct protein concentration peaks appeared, at tubes numbered 22, 24, 27, 30,
34, 42, 46, 52, 56, and 60. Shoulders appeared at 19, 40, and 55. The peak at
tube number 46 was identified as albumin. Traces of alpha-1-globulins were found
in tubes 44 and 45. These materials were positively identified by immunological
procedures. Identification of other peaks is planned as part of the MDAC
St. Louis company funded R&D program.
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HUMAN PLASMA ELECTROPHORESIS
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Dilution of plasma AHF VIII by the carrier buffer in these early electrophoresis s	 r
U,
procedures lowered AHF VIII concentration at the outlet port significantly below
levels detectable by standard procedures.
	 Therefore, the location of AHF VIII in
'	 the sample collections was deduced by relating its mobility to that of a key
plasma component.	 This rationale is based on the observation that the bulk of the
AHF VIII	 in Hemophil R moved with the major protein peak of that purified prepara-
tion.	 Since fibrinogen is known to be the major protein component of HemophilR,
it was reasonable to assume the working hypothesis that AHF VIII moved with, or t'
near, fibrinogen in the p'iasma separations. 	 Then the mobility of human fibrinogen
was determined empirically under the same conditions as used for human plasma.
Assuming that under identical 	 separation conditions, fibrinogen in purified form
or in the plasma will migrate approximately the same distance, the probable loca-
tion of AHF VIII could be predicted for a given plasma separation. 	 Samples
collected in this location could then be tested using high sensitivity techniques.;'
F	 ,
'	 Human fibrinogen was obtained from Sigma Chemical	 Company and dissolved in the a
same buffer used in the previous studies at a concentration of 0.5 mg/ml.
	
This
sample was processed under the same conditions as the human plasma samples and the
results are shown	 in Figure 3.	 In this test, with no voltage applied, the sample
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FIGURE 3.2-3
exited primarily in tube 22. After electrophoresis the bulk of the sample was
found to have moved a distance of 17 tubes. The superimposing of this distance on
the plasma separation curve indicated, according to the above rationale, that
plasma fibrinogen would occur in tube 37 or 38, and that AHF VIII should be found
in about the same tubes.
Immunological techniques for detecting and identifying fibrinogen and other plasma
components, and sensitive radioimmunological and radioautographic assays for
detecting position and output of plasma AHF VIII are being established in our
laboratories as part of the MDAC-St. Louis continuing company funded R&D program.
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3.5 SUMMARY AND CONCLUSIONS
A data base concerning AHF VIII and other blood components was developed on which
MDAC-St. Louis established a technology interchange with the participating pharma-
ceutical companies. As a result of this exchange a preliminary characterization
of AHF VIII and other important blood components by free flow electrophoresis was
accomplished. This in turn, we believe, has enhanced the level of interest of
those companies in the potential offered by processing pharmaceuticals in space.
Two test protocols were developed, one of which led to a technological exchange of
AHF VIII analytical test data with a participating drug company. Interlaboratory
testing in conjunction with the second protocol will begin in-house during 1979
with several additional products.
The results of intercompany communication and laboratory testing provided data of
interest both to the pharmaceutical companies and to MDAC-St. Louis concerning AHF
VIII and other important blood components. The exchange of technological informa-
tion with the companies resulted in the following findings.
o AHF VIII can be separated from a portion of the unwanted proteins found
even in the most highly purified commercial preparations. This is of
interest to the pharmaceutical companies because additives (required in
their purification procedure, and which may cause liver damage) are riot
needed in the electrophoresis process.
o Although molecular dissociation of AHF VIII occurs, the clotting properties
are still intact. Since the patient with classic hemophilia lacks only the
clotting moiety, its dissociation is not a deterrent to further investi-
gation of this product. Both participating pharmaceutical companies
expressed interest in a purified clotting moiety as a possible product.
o A small amount of highly purified, slow moving material showing clotting
activity was noted in typical AHF VIII separations of Hemophil R . This
fraction is of particular interest to one of the companies since it
provided a unique form of clotting materials which could be used to study
AHF VIII by new immunological techniques.
o Preliminary tests revealed that use of cryoprecipitate as a product source
will require development of special handling procedures to assure day to
day uniformity of sample. This does not pose a critical technology
obstacle.
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o One sample sent to the participating laboratories was concentrated at
MDAC-St. Louis by lyophilization. The resultant rehydrated sample con-
tained no antigenic activity, indicating the possible removal, during
processing, of a cryoprotective material. We are now investigating this
loss of activity in-house by recombining several separated fractions.
This finding highlighted the logistical problems to be encountered in
transporting materials from one laboratory to another for conducting
specialized tests. It emphasizes the need for MDAC-St. Louis to establish
a broad base biological capability for complete in-house product evaluation
of separated materials.
0 Starting with human plasma as a product source, it may be possible to
obtain all of the important blood fractions of medical importance in puri-
fied form in a single continuous process. Gamma globulins, used to
protect against bacterial and viral diseases, are slow moving materials
whereas albumin, used as a plasma expander, is very fast moving. These
materials are currently obtained commercially by precipitation methods,
but in such methods many important components, such as Aff VIII, other
clotting factors, alpha antitrypsin, etc., may be neglected, lost or
denatured by the process. A process in which all blood components can be
obtained in a single step is of significant interest to both participating
companies from the standpoint of economics as well as expansion of their
product line.
s
r t.
"
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4.0 INTRODUCTION AND SUMMARY
The objective of this phase of the study was to identify pharmaceutical products
that might uniquely benefit from space manufacturing, select six to serve as
"models" for further indepth analysis and then determine bioprocessing system
requirements for a multiproduct space manufacturing facility needed to commercially
produce them. Several candidates for space production were designated by NASA,
MDAC-St. Louis, the pharmaceutical industry, and the academic community. The
field of candidate products was narrowed to twelve over the length of the contract.
Detailed technical and marketing analysis of each product was performed to provide
information essential to an optimally defined multiproduct process.
Results of this activity included the six "model" products chosen, production
quantities, product characteristics, product technical requirements and marketing
data. In selection of the six model products, considerations for additional
influences were incorporated: humanitarian needs, adaptability to a multiproduct
facility and short timespan for research and development. The market evaluation
established market need and market characteristics, as well as projected market
value and associated market risk. Each of the six selected products were evalu-
ated separately in order to provide the technical and marketing data as described.
These market data provide the basis for determination of the production rate.
The six model products selected were anti-hemophilic factor (AHF), erythropoietin,
beta cells, epidermal growth factor, alpha-l-antitrypsin and interferon.' (Growth
hormone, urokinase, immunoglobulins, somatomedin, granulocyte stimulating factor
and transfer factor were the candidate products not chosen.) The analyses and
evaluations conducted characterized each product sufficiently to allow defini-
tion of production system requirements.
4,1 APPROACH
The purpose of this task was to gather a list of candidate products, evaluate
their potential for space processing and select six to serve as models for
further indepth analysis.
4-1
M000NNtLL 00V0LA0 ANrN0NAiJTICS COMPANY-ST. LCW10 00VIS/ON
REPORT MOC E2104
VOLUMEII
• x SPACE	
9 NOVEMBER 1975MANUFACTURING
A list of potential products, assembled by MDAC-St. Louis from many sources and
coordinated with the participating drug manufacturers, for each major area of
b
	
	 space bioprocessing including pharmaceuticals, cells for transplantation, diagnos-
tic components, and basic research were evaluated with respect to humanitarian
benefits, technical aspects and market needs. These products consisted of pharma-
ceutical products with no Earth processed substitute for a treatment regimen,
improved pharmaceuticals for the diagnosis of disease, and products with signifi-
cant, but indirect benefits such as those for medical research or agricultural
use. Six representative products were then selected according to the following
criteria: 1) the six selected products must represent the major types of products
that would be produced in space, 2) the products must be improved in space, and
3) the selected products should have a major identifiable market. These products
serve as the baseline pharmaceutical group for the purpose of this study. Techni-
cal aspects associated with process development for the selected products were
also considered to identify possible roadblocks to early space processing implemen-
tation. The extent of the market for each selected product was then assessed to
determine production rate morphology for a baseline system.
4.2 ANALYSIS AND RESULTS
To make a rational choice of six model products, a systematic selection procedure
was used. First a list of candidate products was assembled and then reduced to a
manageable group for evaluation purposes. Technical and economic data was then
compiled for each product followed by a comparative numerical ranking of the candi-
dates. This numerical ranking, when combined with the requirement to exercise the
processing system in differing modes of operation (e.g. tissue culture, protein
separation, etc.), allowed the final choice of the six model products to be made.
Finally a market analysis was performed for each selected product. The following
sections describe this selection procedure.
4.2.1 Candidate Products
The candidate products to serve as our analytical models for this study came from
a number of sources. Starting with eight candidate pharmaceutical products compiled
primarily from the results of previous NASA studies, this initial list was expanded
during discussions with the company flight surgeon, local practicing physicians,
faculty members at St. Louis University Medical School and Dr. Leonard Naeger at
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the St. Louis College of Pharmacy. (Dr. Naeger is the editor of a biweekly
national pharmacology newsletter sent to physicians for the purpose of dissemi-
nating new trends in pharmaceutical products.)
	
This initial list of candidate
products included blood coagulation factors VIII and IX, erythropoietin, growth
hormone, granulocyte stimulating factor, pancreatic beta cells, stem cells, thymic
hormone complex and urokinase. Additions to the list included immunoglobulins,
glucagon, prolactin, epidermal growth factor, alpha antitrypsin, interferon, trans-
fer factor, somatomedin, heparin and a number of hypothalamic releasing factors.
A review of the medical literature of the last ten years then resulted in a short-
ened and more pertinent list of products. The thymic hormone complex, glucagon,
prolactin and stem cells were eliminated, primarily because of a lack of readily
available data on, and urgent clinical need for, these products.
Initial discussions with the various pharmaceutical companies visited confirmed
the commercial interest in the shortened list of products. Other products were
suggested by these companies and are listed in Section 4.3. They could not be
included in this initial analysis due to limitations of time and manpower.
The final list of products is given in Table 4.2-1. A brief summary of the charac-
teristics of each product is included in this section of the report. More detailed
information on each product can be found in Volume III of this report.
TABLE 4.2-1 FINAL CANDIDATE PRODUCT LIST
Alpha-l-Antitrypsin
Antihemophilic Factor VIII
Epidermal Growth Factor
Erythropoietin
Granulocyte Stimulating Factor
Growth Hormone
Immunoglobulins
Interferon
Pancreatic Beta Cells
Somatomedin
Transfer Factor
Urokinase
Alpha-l-Antitrypsin
Alpha-antitrypsin probably functions as a major control protein against the tissue
damaging effects of both endogenous and exogenous enzymes. It, is the major inhibi-
tor of two leukocyte enzymes having the ability to destroy human pulmonary tissue
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resulting in emphysema. About 800,000 people in the United States have been diag-
nosed as having emphysema or chronic bronchitis. Because of the wide disparity
in the literature with regard to patients afflicted with both alpha-antitrypsin
deficiency and emphysema or chronic obstructive pulmonary diseases, we have con-
servatively estimated that approximately 100,000 people of this group have a severe
alpha-antitrypsin deficiency, usually less than 20% of normal circulating blood 	 L
levels. It has been suggested that raising the circulating blood antitrypsin
levels to about half that of normal values might be useful in arresting the
further progression of emphysema. Alpha-antitrypsin is administered intravenously
in a dosage of 20 mg/Kg body weight at four to six day intervals. The metabolic
f:
w a.
half-life of this protein allows spacing between treatments similar to the clini-
cal regimen for antihemophilic factor treatment. Previous attempts at treating
patients with alpha-antitrypsin contained in whole plasma created side effects
which necessitated discontinuance of the procedure. It is expected that purifica-
tion of alpha-antitrypsin in large quantities will rejuvenate this treatment
method and control the progression of the disease. No other specific treatment n
now exists for the treatment of emphysema. W
Three companies produce alpha-antitrypsin for laboratory research and diagnostic
purposes at $0.17 to 0.20/mg. This material is from botanical sources and is not
considered acceptable for clinical purposes. Human material as an alpha-
antitrypsin standard can be obtained from the American subsidiary of Berhingwerke,
Darmst:edt, Germany. If human plasma were the sole source of this product, in its
clinical form it would require the simultaneous extraction of both alpha
antitrypsin and antihemophilic factor from almost all the blood collected annually
in the United States.
This product is a single chain glycoprotein produced by hepatocytes. Twenty-four
alleles of alpha-antitrypsin have been determined by electrophoresis, each with
its own mobility. Because of the number of variants the isoelectric point ranges 	 ri
from 4.5 to 4.9. The molecular weight is about 50,000. The chemical composition
of three variants can be found in Volume III, Section A.1. The molecule is
unusual in that it has more than one carbohydrate side chain, probably as many as
four. Alpha-antitrypsin is soluble in many solvents but it can be salted out. It 	 u
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loses its biological activity when in acid solutions below a pH of 5.0. The
protein can be lyophilized and stored for 12-13 months at 5°C. To our knowledge,
human hepatocytes have not been cultured for the purpose of producing this protein.
It may be possible to do so, however. Reports of both human and animal liver cell
cultures of this product in both monolayer and suspension form are described in
Volume III, Section A.I. A detailed procedure is presented for a monolayer culture
that was viable for 14 months at the time it was reported.
There are two major methods for the ground based isolation and purification of
this product. Each depend on the use of dialysis, "salting out" phenomenon and
affinity chromatography to remove impurities. The main impurity is albumin which
has a very similar solubility and electrophoretic mobility to alpha-antitrypsin.
The usual laboratory yield is about 22% of the alpha-antitrypsin found in crude
plasma.
Antihemophilic Factor VIII
Approximately 20-25,000 people in the United States suffer from a disease in which
their blood does not clot readily when blood vessels are injured. The disease is
called hemophilia. We have assigned a disease severity index value of 6. The
major problem usually is not externally caused bleeding such as that from contu-
sions, puncture and lacerations (all of which can be life threatening in them-
selves), but rather simple tissue injury due to movement of joints during normal
walking, playing, etc. Blood loss from these simple activities can cause major
hemorrhage into the surrounding tissue resulting in shock, permanent damage to the
joint, immobilizing the patient and possibly death. The disease is hereditary,
being passed by the genes of the mother but almost exclusively affecting the male
children. Spontaneous development rather than heredity is now becoming a signifi-
cant source of new hemophilics. It is only since the second world war that
a	
children afflicted with this disease can expect to reach young adulthood. Many of
the oldest hemophilics have not yet reached their fortieth birthday.
The disease is due to a deficiency in one or more of thirteen different substances
that must sequentially interact to stop the bleeding. The two most common defi-
ciencies are antihemophilic factor VIII and plasma thromboplastin component IX.
Only AHF VIII is considered for this analysis. The usual prophylactic treatment
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is 250 units of AHF every day for life for severe or mildly severe hemophiliacs.
The dose is also dependent on the rate and quantity of blood lost as well as exter-
nal weather conditions and age; rapid alterations in environmental temperature
will cause capillary bed hemorrhaging, requiring more AHF, and the older the
subject the less product is required because he will tend to take better care of
himself. During surgery or treatment for hemorrhaging as the result of an
injury, a severe hemophiliac can consume about 17,000 units per episode. The unit
of product is defined as that amount of substance found in one milliliter of
blood of a normal person. The half life of AHF VIII after infusion is approxi-
mately 12 hours necessitating frequent replacement as a preventive procedure.
The only source of AHF is from human plasma. It is species specific and has no
competitive products to share the market. Approximately 9,000,000 pints of blood
are collected annually by the Red Cross, five pharmaceutical producers of AHF and
those hospitals treating this disease in order to supply the deficiency factors
needed by about 20,000 patients. AHF is a protein of about 195,000 molecular
weight but its amino acid sequence has not been identified. McDonnell Douglas
Astronautics Company has determined an electrophoretic mobility value for the
product of 8.6 x 10 -5 CM2/volt-second. The current ground based production
method utilizes the development of cryoprecipitate followed by the modified Cohn
fractionation procedure I at very low temperatures. An elaboration of the produc-
tion method can be found in Volume III, Section A.2. The actual site of AHF
synthesis in the human body is not known. Therefore production by tissue culture
is not relevant at this.time. The current assay technique uses a wet chemistry
procedure which measures the time required for the sample to cause clotting of AfIF
VIII deficient serum.
Epidermal G rowth Factor (EGF)
h	
This product is a single chain Ipolypeptide produced in the subutaxillary glands.
It can also be found in the urine. Its normal physiological function is to stimu-
	
late the production of ectodermal tissue. It is currently undergoing investigation 	 i
as a pharmacological agent to increase the rapidity of autologous skirl replacement
i
in those areas damaged by burns or injury. The annual number of patients with
third degree skin burns covering at least rive percent of their body surface is
estimated to be at least 14,000. We have assigned a disease severity index value
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of nine to this product category. There is no competitive product to serve the
i
	
	 function of this protein. Because of "foreign" tissue rejection problems histori-
cally inherent in the use of skin grafts to cover the burn areas, the potential
capability of EGF for this pathological condition may eventually shake it the drug
and procedure of choice. The dosage used for treatment has neither been esta-
blished nor published by the two companies conducting clinical research with EGF.
For the purpose of providing a rough order of magnitude comparison dosage with
other products in this report, we have chosen a value of 20 ndnograms/cm 2 of
damaged skin area. It has been reported in the literature that this concentration
of EGF causes epidermal cells in tissue culture to proliferate and spread into a
fibroblast network.
Besides the clinical aspects of burn and wound healing of the skin, EGF appears to
have many uses for the production of cells in culture. Investigators have reported
that this product lengthens the life of cell cultures from 50 to 150 generations
above controls and also drastically reduces the need for fetal calf serum as a
nutrient in tissue culture. Use of EGF to supplement a reduction in fetal calf
serum requirements for tissue culture could stretch the current annual supply of
serum about five hundred fold.
Collaborative Research, Inc. is the only company commercially supplying the mate-
rial for nonhuman research purposes. Their current market price for EGF is
$495/mg.
Epidermal growth factor has been biochemically characterized and the amino acid
sequence established. Using male mouse submaxillary glands as the source, this
protein molecule has a molecular weight of 6045 based on 53 amino acid residues.
When EGF is extracted from human urine, the molecular weight is 5400 with 49 amino
acid residues. The chemical composition and amino acid sequence can be found in
Volume III, Section A3. It has been separated for analytical purposes by various
electrophoretic techniques and its rate of mobility depends on the pH of the
buffer used. While its upper solubility limit in water has yet to be established,
a concentration of 0.4% in 0.01M sodium acetate buffer has been reported. The
u.	
product can be lyophilized and is stable at room temperature in that form. It is
subject to bacterial and enzymatic degradation but is stable to boiling water.
is
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Heating in either dilute alkali or acid will destroy EGF. Research has focused on
the effect this product has on other cells in culture and not how to produce it in
large quantities. Three methods of assay are used for the detection of EGF. They
range from an in vivo assay involving the precocious eyelid opening of new born
mice in the presence of EGF to the competitive binding radioimmunoassay technique
capable of detecting the product in one nanogram per ml quantities.
The current ground based production method involves affinity chromatography and
density gradient chromatography techniques. This procedure usually takes 7-10
days and yields about 700 micrograms of EGF from 10 grams of a benzoic acid/acetone
extract of human urine.
Erythr°opoi et i n
This product is a natural glycoprotein hormone of the kidney cortex. A deficiency
in its production results in a severe anemia that could be corrected on a temporary
basis by red blood cell transfusions at regular biweekly intervals. These trans-
fusions, however, are not used as a continuous treatment regimen because of the
potential for virus hepatitis infection. We have assigned a disease severity
value of 6 to this product category. The anemia is primarily found in patients
with kidney failure. There are approximately 20,000 people in the United States
afflicted with frank kidney failure and the anemia secondary to this disease.
At the present time erythropoietin is not commercially available as a pharmaceuti-
cal product for human use because of the current inability to purify the product
from extraneous organic material. No known pharmacological substitutes are avail-
able to compete with this product. Based on extensive laboratory test data
collected from a number of animal species including man, it is anticipated that
the pharmacological dose of erythropoietin will be 20-200 units per kilogram body
weight given once each week for the life of the kidney failure patient. In the
less severe, chronically anemic patients, the dosage may be the same but the
rate of medication may be once or twice per year.
i
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^- Erythropoietin in a partially purified form is available for research purposes
from the Connaught Laboratories in Toronto, Canada. 	 Their current price for Step
`- III partially purified hormone is $0.83 per unit or about $69,000 per year when
i4
applied to a 176 pound	 adult.	 A second commercial source of erythropoietin is
from the Erythropoietin Collection Center in the Department of Physiology of the
School	 of Medicine, Northeast University, Corrientes, Argentina. 	 Neither organi-
zation has filed an Investigational
	
New Drug (IND) application for clinical 	 trials
with the United States Food and Drug Administration. 	 Most researchers in this
ii country, however, obtain erythropoietin in small quantities from the urine of
aplastic anemia patients and attempt to purify it themselves.
^i
Erythropoietin is a glycoprotein of between 27-100,000 molecular weight. 	 Sialic-
cR.; acid is the carbohydrate moiety which must be present for stimulation of red blood
cell	 production in-vivo but not in marrow tissue cultures.	 The amino acid content
of the protein moiety has been elucidated but not the sequence. 	 Erythropoietin
has been separated electrophoretically into two active but diffuse bands between
albumin and alpha, globulin.
	 Subsequent electrophoretic separation of the two
h
active bands has resulted in the elucidation of six bands suggesting depolymeri-
zation of the hormone into smaller but still
	
active units.
	
These electrophoretic
k techniques have concentrated the pharmacological	 activity to 8,300 units/mg.	 It
is anticipated that further purification can concentrate this activity to even
a higher levels per unit weight.	 Erythropoietin is highly soluble (18%) in water
and also soluble in relatively mild acids.
The hormone is known to be produced in the kidney cortex possibly by the cells
located in the glomerular tufts. These cells have been separated electrophoreti
cally and also grown in monolayer and suspension tissue cultures for periods up
to several years. Production of tissue culture is feasible and may eventually be
the method of choice for commercialization of this product. At the present time,
however, the far simpler method for small research quantities of the material is
to extract it from the urine of either anemic people heavily infested with hook
worm parasites or sheep that have been made anemic artificially using whole body
radiation followed by phenylhydrazine injections. Details of the extraction and
partial purification procedure can be found in Volume III, Section A-4. The stan-
dard technique for quantitative analysis is the starved rat bioassay calibrated
against the values obtained from erythropoietin international reference standard B.
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Granulocyte Stimulating Factor
The function of granulocytes is to control and remove tissue damaging material
from the mammalian organism. Agranulocytosis, a condition in which these cells
are present in the body in abnormally low concentrations, can be caused by radia-
tion therapy, chemical toxicity and stressful situations; e.g., massive infections.
A natural protein found in human urine and produced in vitro from lung, embryonic
kidneys, macrophages and spleen tissue cultures is able to stimulate the production
of these granulocytes from marrow stem cells to restore them to their normal physi-
ological levels. Estimates of the annual number of potential recipients who could
benefit from this "granulocyte stimulating factor" vary from about 500,000 receiv-
ing radiation and chemotherapy for cancer, to about 2 million undergoing surgery.
It also has potential for treating coronary thrombosis and the massive sepis of
burns. A severity index value of 7 has been assigned to the above diseases. The
use of granulocyte stimulating factor is still in the experimental phase and there-
fore the clinical dosage has not been established. Effective treatment for the
diseases indicated above requires a circulating blood granulocyte concentration of
1000 cells/microliter (see Volume 1I1, Section A.5). This usually can be attained
with a dose of 2.5 x 108 units of granulocyte stimulating factor. With an intra-
vascular survival rate of about 6-10 hours, the dose would have to be administered
several times per day until the causative condition of the agranulocytosis is
resolved or the patient dies.
Granulocyte stimulating factor is not available commercially for research purposes
or clinical investigation. At the present time, all granulocyte stimulating factor
is produced in the laboratories of the research scientists intending to use it.
As a pharmaceutical product, granulocyte stimulating factor will be a direct com-
petitor of the recently developed procedure for the transfusion of granulocytes
obtained from matching human donors through continuous flow leukaphoretic centri-
fugation. Reactions to both the donor and recipient as well as the large number
of matching donors required for a course of treatment by the latter method would
make use of tissue culture produced granulocyte stimulating factor the drug of
choice.
Granulocyte stimulating factor is believed to be a protein but it is not certain
if carbohydrate side chains are present. Using Sephadex chromatography, four
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fractions have been obtained. Their molecular weights are approximately 79,000,
40,000, 23,000, and 2,000 daltons. The 79,000 dalton fraction may be a dimer of
the 40,000 dalton fraction. The material readily moves in an electrophoretic field
showing a 50-70% recovery of biological activity when using polyacrylamide gel. A
specific activity of 680,000 units/mg can be obtained with preparative gel electro-
phoresis as contrasted to 4,364 units/mg observed with hydroxyapatite chromatogra-
phy. Granulocyte stimulating factor is stable in the pH range of 6.5-10 and tem-
peratures of 56% for 30 minutes. It is unstable upon freezing and thawing unless
0.1% gelatin or 0.2% mg/ml albumin is added. It is resistant to trypsin and
neuraminidase but is sensitive to subtilisin, chymotryps-in and periodate. Assay
for the product is done by counting the number of colonies (greater than 40 cells)
formed ten days after the granulocyte stimulating factor is added to a culture of
about 200,000 human marrow cells. Cells producing granulocyte stimulating factor
also have been electrophoretically separated in space during the Apollo-,Soyuz
flight.
Growth Hormone (GH)
This product is a natural protein hormone of the anterior pituitary gland. A
deficiency in its production results in dwarfism. Its normal physiological func-
tion is to stimulate growth in children of short stature. The hormone is currently
undergoing investigation as a pharmacological agent to treat osteoporosis and
stress ulcers. Estimates of annual potential recipients who could benefit from
this product have ranged as high as 840,000 people. We have assigned a disease
severity index value of 5 to this product category. At the present time only 1000-
1500 children are being treated annually because of a lack of the raw material
from which the hormone is isolated. GH is species specific and must come from
other humans thus limiting the source of supply. There are no competitive products
y
to serve the function of this hormone. In the treatment of dwarfism the usual
k
	
	 dosage of growth hormone is 1 mg every other day over a several year period. In
the experimental treatment of stress ulcers the dosage is 10 mg/day over a 4-18 day
treatment period. The lack of material becomes obvious when the acetone-extracted
human anterior pituitary gland can only provide about 3-5 mg of the unpurified
A
protein.
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There is one commercial company plus the National Institutes of Health National
Pituitary Agency that are able to supply GH in 1978. Calbiochem has been approved
by the FDA to market it with the trade name ASCELLACRIN. That company is currently
charging $7.50/mg for the compound but its purchase requires acceptance of the
patient for such treatment by Calbiochem physicians. Company acceptance is
required primarily because of the short supply of the hormone and their goal of
trying to prioritize the patients who could benefit most from its application. A
second manufacturer, Serono, is expected to complete FDA clearance for marketing
some time within the Spring of 1979. The National Pituitary Agency provides the
hormone at cost for clinical and basic research. Because it is the national clear-
ing house for the collection of human pituitary glands by the American College of
Pathologists, it also distributes a portion of the extracted hormone material for
sale as a pharmaceutical product and as a standard for diagnostic assays.
Growth hormone has been identified as a 191 amino acid protein with disulfide bonds
and a molecular weight of 21,500. The amino acid sequence is shown in Volume III,
Section A.6. It was the first hormone separated by static electrophoresis from
homogenized pituitary material. The granules of the acidophil cells containing GH
have also been separated by static electrophoresis. In neither case has the pro-
cedure been considered adequate for commercial production but rather a simple
laboratory tool for identification and experimentation. The isoelectric point has
been located at a pH of 4.9. Its solubility is very low, 0.03% in water, but it
can be increased slightly in other solvents and also when additives, such as
mannitol, are included. The current production method is acetone extraction _vield-
ing 4-8% dry weight of the pituitary gland and its stalk. Growth hormone has been
produced by both monolayer and suspension tissue culture techniques for periods up
to several years. The acidophil cells may produce two hormones simultaneously,
i.e., GH and prolactin. A more detailed description of production and tissue
culture methods for this hormone can be found in the appendix. Qualitative and
quantitative analysis of GH is done by radioimmunoassy.
Immune Human Serum Globulins
Infectious agents generally induce the production of uniquely reactive proteins
called antibodies, which appear in the gamma globulin fraction of plasma subjected
to electrophoretic separation. Plasma rich in one or several specific antibodies
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is referred to as disease specific immune globulin; for example, a plasma rich in
specific antibody to chicken pox is referred to as "ZIG" or zoster immune globulin.
This is not purified antibody but a plasma with high levels of anti-zoster antibody.
Under limited circumstances it could be advantageous to have availability of highly
purified preparations of specific antibodies against, e.g., hepatitis, rubella,
rubeola, mumps, poliomyelitis, and others. As a general class we have assigned a
disease severity index of 7 to this product category.
About 300,000 cases, representing all of the above mentioned diseases are reported
to the National Center for Health Statistics annually in the United States. While
a dose of specific immune serum globulins may be given to modify or minimize the
effect of that specific disease in a person already afflicted, the usual procedure
is to immunize all the people who have or may come into contact with the patient
until the incubation period has been exceeded. Depending on the seriousness of
the disease, the number of subjects receiving this passive immunity can range from
1-6 close contact family members for mumps up to many thousands of individuals
threatened by serious epidemics. The number of patients given passive immunity
from year to year will depend on many variables but primarily the number and
location of people afflicted. This great annual uncertainty results in a large
quantity of specific products being made, stored and destroyed when the product
shelf life is exceeded if there is no threat of an epidemic.
The usual single dose of immune globulin given to a patient can vary with the
disease; it can range from 3.6 to 330 mg per injection. In the extreme case where
an infant is born with a gamma globulin deficiency he can receive up to 3.0 grams/
month. The average cost of a single dose of gamma globulin is between $3 and $5.
The Physicians Desk Reference lists at least ten manufacturers in this small but
competitive market'. The American Red Cross and some local hospitals also may
prepare specific gamma globulins for staff use from their own blood banks. At the
present time there are no known substitutes for human gamma globulin with the
ability to do the same protective function.
Antibodies are produced by plasmacytes and released into the blood stream. To
minimize homologous protein antibody reactions, the source of human immunoglobins
is from the gamma globulin fraction of human blood plasma. A "specific" gamma
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globulin means that a person has been subjected to a disease, built up antibodies
to that disease, and these antibodies appear among his protein gamma globulin
fraction. These gamma globulins can be extracted from pooled plasma by cryopre-
cipitation and alcohol fractionation as well as electrophoretic separation.
They have a very high solubility of 15 gms/liter. The standard assay technique is
by immunoelectrophoresis against specific antibodies. A more detailed description
of the processing procedures can be found in Volume III, Section A68.
Interferon
This natural protein substance appears to be the modern day pharmacological panacea
for almost all diseases of known viral origin as well as several other diseases in
which viral involvement has been suspected but not proven. Its clinical use is
still in the experimental stage with only a small part of its therapeutic potential
explored. Interferon has been used in the treatment of various forms of cancer,
	 1
lymphoblastic leukemia, influenza, common cold and viral infections. We have
assigned a severity index value of 7 to this product as an average value for the
	 a
variety of diseases showing response to interferon. If only specific diseases were
used in the application of this index, the value would range from 10 for osteo
sarcoma to 3 for the common cold and influenza. It is very difficult to estimate
Alm
the number of patients that could benefit from this drug and its annual market
value because the clinical trials have been -mall, therapeutic doses have not been
firmly established and only a few of the potentially responding diseases have been
tested. In the case of hepatitis A alone, it is estimated that 100 million people.,
worldwide are suffering from this disease. Over 380 thousand people die annually
in the United States from various forms of cancer. Prophylactic treatment with
x
interferon for influenza epidemics would also involve hundreds of millions of
patients. Each of these diseases has its own dosage schedule and treatment regimen
	 i
(see Volume III, Section A.7 for more specific details).
Several competing antiviral drugs are already on the market including amantadine,
vidarabine and idoxuridine, but are limited to the treatment of Herpes Simplex and
prophylaxis of Influenza A. Radiation therapy and a number of chemotherapeutic
products are already on the market for the treatment of cancer. While they
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offer some pharmacological protection, many patients develop a physiological resis-
tance to these compounds making them ineffective. A university research team is
exploring the use of a nucleic acid that will induce interferon production
endogenously without side effects.
Because of the tremendous market potential for this compound, approximately 100
industrial and university laboratories around the world are making interferon for
Li their own research purposes. The current source of leukocyte interferon is the
Interferon Department of the Finnish Red Cross Blood Transfusion Service in
Helsinki. It is the largest supplier at the present time with an annual production
`
	
	 of about 100 billion units. The Sloan-Kettering Institute has started a production
facility in Switzerland and expects to match Helsinki production in 1979. The
Wellcome Research Laboratories in England has also announced production of inter-
feron from lymphoblastoid cell lines cultured in 1000 liter fermentation vats.
They estimate their annual production will exceed that of Helsinki in 1979. HEM
Research in Maryland l and Cal biochem in California are the only commercial sources
of any type of interferon in this country. While interferon from all of the above
sources is only available for research and some FDA authorized human clinical
trials, none of the material is available to the average private physician for
treating pathology. There is some indication it may be an over-the-counter- product
in Russia (see Volume III, Section A.8). In the United States, all interferon for
clinical research purposes must be obtained through the Interferon Working Group
at the National Cancer Institute. While the present cost of interferon is $50/
million units, continued clinical success combined with the interest and technical
skills of the many'involved research laboratories will ultimately increase produc-
tion and lower unit cost.
^f
Interferon is a glycoprotein substance produced by cells in-vivo and in-vitro when
challenged by a virus. It is species specific and can be induced by normal and
attenuated virus or any substance that is equivalent to a double stranded RNA.
The current clinical trials have relied on only three tissues for interferon pro-
duction: (1) the human leukocytes collected from blood' donors, (2) fibroblasts
grown in tissue culture from human infant foreskin obtained at circumcision, and
(3) human leukocytes from a high yield lymphoblastoid Burkitt's lymphoma cell
strain. Three types of interferon have been isolated from these sources with more
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than one type coming from the same source.
	
Molecular weight ranges from 15,000 to
21,000, depending on the type of interferon.	 They have not been isolated in suf-
ficient purity and quantity to determine their molecular structure or amino acid
sequence.	 The backbone of the interferon molecule is a folded polypeptide of one
3
or more chains linked by disulfide bonds.	 One or more carbohydrate side chains i
containing sialic acid are attached to this backbone.
	
A number of electrophoretic
techniques have been used to purify interferon with varying levels of success. 	 It 1
is soluble in many solvents but it can be salted out.	 It cannot be dialyzed,.'
Cells producing interferon can be cultured by both monolayer and suspension culture
methods.	 These cells usually reach a peak interferon production level	 about 10
hours after induction with a virus and then become inhibited to further production
for several days after the interferon is removed from the culture media. 	 The
standard method for bioassay is to measure the ability of interferon to protect
cells in tissue culture against a challenge virus.
.f;
Pancreatic Beta Cells
The beta cells of the islets of Langerhans found in the pancreas produce a hormone
known as insulin whose physiological function is to aid in the regulation of carbo-
hydrate metabolism.
	
A deficiency in production of this hormone results in a form
of diabetes mellitus, often called juvenile onset or insulin dependent diabetes.
We have assigned a severity index of 5 to this disease.
	
For slightly over the
j
last fifty years this disease has been brought under control by daily injection of
insulin extracted from the pancreatic tissue of cattle and pigs.
	 Essentially the
extract of one animal 	 pancreas is sufficient to treat one diabetic for one week at
an over the counter cost of $3.00 per bottle.	 The present U.S. population of
known insulin dependent diabetics is believed to be 1.5-3 million people concomi-
tant with an additional 	 3.5-7.0 million adult onset (non-insulin dependent)
diabetics who may eventually require insulin as their disease progresses to an
►
insulin dependent state.	 An almost equal	 number of people are suspected of being
'	 undiagnosed diabetics in both forms. 	 The projected expansion of both the American
and world population has developed concern among pharmaceutical manufacturers due
to their inability to meet the future demand for insulin when they are currently
consuming almost the entire annual harvest of animal pancreatic tissue in the
United States, Australia and Argentina.`
i.
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Since there are no competitive products for this hormone in the treatment of
diabetes mellitus, a great deal of laboratory investigation has been involved with
transplantation of pancreatic tissue in whole or in part. The most promising con-
cept to date involves isolating the islets of Langerhans and injecting them into
the capillary circulatory system of the liver where they become wedged and start
to function as a "replacement" pancreas. Several experiments of this nature have
been conducted in both animals and humans with partially successful results.
Within a week after injection of the partially purified islets of Langerhans, the
recipients were able to greatly reduce and, in some cases, completely withdraw
from supplemental insulin injections. The rate of successful transplantation in
these studies may depend on the dose of islets or cells received and the ability
to suppress or eliminate the immune response to "foreign" tissue. Estimates of
the number of living islets required to cure one diabetic patient range from
60,000 to 200,000, a quantity difficult to obtain from one adult donor using
k	 current laboratory isolation methods. It is hoped that further improvement in
r	 beta cell production will result from continuous flow electrophoretic techniques
of separation. The cost of the transplant would be extremely high in comparison
to the current cost of insulin, but available evidence strongly suggests that a
beta cell transplant would protect diabetics from the devastating complications of
their disease far better than does insulin therapy.
The use of bacteria to produce insulin through the process of gene splicing and
recombinant techniques is also being investigated. A number of pharmaceutical com-
panies and research investigators have told us it will take 10-15 years to perfect
this process but it does not pose a threat to space bioprocessing because the
insulin must be separated from the other metabolic contaminants of the bacterial
cultures.
Insulin is a double chained protein of 6000 molecular weight. Its sequence of 51
amino acids is known and differs slightly from species to species. There is enough
similarity however that human, bovine, and porcine insulin can all be used as
human medication. The similarity among islet cells or beta cells of different
species is not known and therefore human adult and fetal pancreatic tissue are
being investigated to minimize homologous tissue reactions. The electrophoretic
mobility of both beta cells and islets is unknown but it is expected that they
will migrate in an electrophoretic field similar to all other cells. The beta
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cells and islets have been separated by enzymatic disruption from the surrounaing
acinar tissue in very cold temperatures to prevent enzymatic digestion of the
desired cells. The cells have been cultured in monolayer cultures for long
periods of time. The method of extracting and culturing islets of Langerhans can
be found in more detail in Volume III, Section A-9. The current method of choice
for assaying insulin is the radioimmunoassay procedure.
Somatomedin	 WS 1
This growth factor stimulates the incorporation of amino acids into cells for the
production of protein and a gain in weight. There issome evidence that it can
operate independently of growth hormone. A number of pharmaceutical companies
have suggested that periodic injections of the substance into feed lot livestock
might increase feed utilization by these animals. If such a situation could be
produced pharmaceutically the total amount of meat produced per pound of feed
consumed would be significantly increased. In the United States alone we slaughter 	 W
approximately 123 million cattle, sheep and hogs each year. While research along
these lines is being conducted in at least one industrial laboratory, the dosage
of somatomedin required has not been established. To provide a comparison ,dosage
with other products of this report we have arbitrarily chosen one half the dose of
growth hormone or one unit (0.5 mg)/40 kg body weight given three times per week
until the animal reaches maturity.,
Somatomedin is not available commercially for research purposes .or clinical
investigations. At the present time all of this material is produced in the
laboratories of the research scientists intending to use it.
y	 Three separate somatomedins have been identified by their biochemical characteris-
tics and biological activities. Somatomedin A is a neutral peptide of about 7000"
molecular weight which stimulates sulfate uptake by chick embryo cartilage.
Somatomedin 8 is an acidic peptide with a molecular weight of approximately 5000.	 r
It stimulates the incorporation of thymidine into glial cells in tissue culture.	 x
Somatomedin C is a basic peptide of about 7500 molecular weight that competes with
insulin for the same binding receptor on human placental membrane. The amino acid
composition has not been identified for any of the three substances. Somatomedin
C, however, is expected to have about fifty amino acid residues and be rich in
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arginine. Biochemical similarities and differences among the three somatomedins
has not been determined. 	 '
The site of somatomedin synthesis in man is not known but animal experiments
suggest that the liver may be important. The current source of this product is
from human plasma (Cohn fraction IV-b). The fractionated plasma is subjected to a
series of acidic ethanol, acetone-alcohol and formic acid extractions followed by
chromatographic separation on a Sephadex column. Twelve hundred liters of plasma
yield about 240 micrograms of somatomedin. The product is dialyzable and has been
separated by gel electrophoresis as well as isoelectric focusing with a sucrose
gradient. It is relatively stable to heat in the range of 50-100°C but becomes
partially denatured in the presence of mercaptoethanol. Besides the three assay
methods used to identify the three types ofsomatomedin, the product also can be
assayed by weight gain or tibial width change in hypophysectomized rats or the
incorporation of sulfate into porcine costal cartilage.
Transfer Factor
After a human leukocyte in vivo has been exposed to an antigenic type of material,
it has the ability to effect a delayed hypersensitivity to that material when
exposed on subsequent occasions. If these leukocytes or their dialyzable
polype^ptide-polynucleotide extract are injected into another person, the delayed-
type cellular immunity is transferred to the recipient. This "transfer factor" is
immunologically specific for the challenging agent. This transferred immunity
9
resides in the recipient for long periods of time, greater than two years in some
instances as compared to most antigen-antibody reactions which last only several
days to several months. The clinical effects of transfer factor are currently
being explored in many pathological conditions including multiple sclerosis,
leprosy, malignant melanoma, breast cancer, and immunodeficiency diseases. In
f
most of these studies only preliminary results on a small number of patients have
y
been obtained. The treatment regimen for each of these diseases is different and
has not been established as to optimal dosage making it difficult to predict annual
market requirements. Multiple sclerosis is the most common neurological disease
next to strokes in the United States affecting approximately 535,000 people. While
leprosy is found in only 130 new patients each year in this country, about 15
million are affected in tropical countries worldwide. We have assigned a severity
index value of 7 to this product resulting in an average value for the diseases
treated.	 4-19
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Transfer factor is not available commercially for research purposes or clinical
investigation. At the present time, all transfer factor is produced in the labora-
tories of the research scientists intending to use it. Transfer factor for a
specific immunological agent can be obtained from circulating human leukocytes
in the following ways: (1) concentrates of viable leukocytes, (2) leukocyte
extracts prepared by distilled water lysis or by repeated cycles of freeze-thawing,
(3) leukocyte extracts prepared by treatment with enzymes, (4) antigen liberation,
and (5) dialysis. Transfer factor in whole leukocyte preparations is stable at
-20°C for at least four years. Lyophilized transfer factor can be stored for at
least five years at 4°C without loss of potency.
It is still not known whether transfer factor is a single entity or a class of
closely related substances. It is believed to be a polypeptide-polynucleotide
complex that is different from interferon in chemical properties and biological
action. Several methods have been used for the isolation and purification of this
product including various forms of electrophoresis, chromatography- and dialysis.
Isoelectric focusing has resulted in at least 17 subfractions with isoelectric
points scattered over a pH range from 3.5 to 10.2. The molecular weight of trans-
fer factor is between 3,500 and 10,000. The amino acid composition is listed in
Volume III, Section A.11. Human lymphocytes in tissue culture are capable of pro-
ducing transfer factor after induction with a specific immunological agent. There
is only an eighty percent chance of induction. Once the cultures are producing
they can be cut back to one percent of the final cell concentration at the end of
a three to five week period and recultured for another transfer factor harvest
without using a second induction period. It is believed that this ability to pro-
duce transfer factor will last as long as the cell source is still viable in tissue
culture. The method for induction and culturing of transfer factor producing cells
is described in Volume III, Section A.11.
The most sensitive assay method for transfer factor at the present time is done
in-vivo on humans showing a negative reaction to a specific antigen when they are
challenged by that antigen. In vitro assay techniques have been besieged with
problems and reflect the detection of new receptors on the surface of the cell.
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Urokinase
An estimated one percent of the U.S. population annually is subjected to surgery,
broken bones and accidents damaging the vascular system. They are all potentially
subject to blood clot formation and movement as a result of this tissue insult.
If a clot plugs critical vascular pathways, the result can range from a slight area
of tissue necrosis through eventual amputation of a limb or organ to almost instant
death. We have assigned a disease severity value of 7 to this product category.
Urokinase is a fibrinolytic enzyme activator used to break up and dissolve these
blood clots disseminated throughout the body. National studies of the pharmaco-
logical activity of urokinase have been conducted for the past ten years under the
auspices of the United States National Institutes of Health and European country
members of NATO. The recommended dosage of urokinase for dissolving existing
pulmonary clots was established at 4400 CTA (Committee on Thrombolytic Agents)
units per kilogram of body weight per hour for 12 hours followed by heparin admin-
istration at 22 units per kilogram of body weight per hour for 14 days. Myocardial
infarction was treated with 7200 units/Kg body weight given intravenously followed
by half that dose hourly for 18 hours. The total quantity administered and dura-
tion of urokinase therapy may vary with the location and severity of the clot but
it is believed that a Lee-White Clotting Time of greater than 25 minutes should be
used as a criterion for optimum therapy rather than dosage of itself.
Three companies, Abbott Laboratories, Sero kno and Sterling-Winthrop, filed Investi-
gational New Drug (IND) forms with the U.S. Food and Drug Administration in the
late 1960s. In April of 1978, Abbott Laboratories was licensed to manufacture and
sell urokinase under their brand name of Abbokinase. A recent telephone communi-
cation to the medical staff of Sterling-Winthrop has indicated that they do not
expect New Drug Application approval for their brand of urokinase through next
year. Serano has withdrawn their application in the United States. Abbott is
currently marketing urokinase in the United States at a cost of $700 per million
units. A Japanese company, Green Cross Corporation, has marketed the substance in
its own country with 1977 sales reported to be 40 million dollars. These exces-
sively high costs (about $3,500 for a 12 hour treatment of urokinase alone) and
intense competition with much cheaper anticoagulants and fibrinolytic agents, e.g.,
heparin, warfarin, fibrinolysin, streptokinase, streptodornase, coumarin, etc.,
producing the same relative effect have greatly reduced the potential market for
urokinase.
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Urokinase is produced by cells in the kidney cortex and can be found in human
urine. Its protein structure and amino acid sequence are unknown but the molecu-
lar weight is estimated to be about 33,000. It is nonantigenic and can be treated
at 60°C for 10 hours to inactivate any contaminating virus present. Urokinase in
plasma has been separated by electrophoretic techniques in laboratory quantities.
This material is either mixed with or complexed to a 2 macroglobulin. The urokinase
producing cells have also been separated by electrophoretic techniques and the
resultant separated cells subjected to monolayer and suspension tissue culture
where they can survive and produce the enzyme over long periods of tine. A more
detailed description of the protein extraction and tissue culture technique can be
found in the appendix. Commercial production of Urokinase from cultured kidney
tissue is presently difficult because only a small fraction of the kidney cells,
some 5-10 percent, actually produce the enzyme. Production of urokinase from
urine is equally difficult, because the product ^:5 present in such minuscule
quantities that huge volumes of urine must be processed to obtain a usable yield.
P
1+
.l
4.2.2 Product Evaluation
Once adequate information was obtained on each of the candidate products, they
were evaluated with respect to several different parameters using a numerical
"value index". The objective of the evaluation was to rank the candidate products
with respect to their humanitarian value for the general population while con-
sidering the applicability of space processing to their production. The equation
for the value index was:
VI=P.SI.IF.0
T
where VI represented value index, P represented the number of patients treated,
SI represented the disease severity index, IF represented the improvement factor
anticipated by space processing, C represented the pharmaceutical competitive
factor and T represented the number of baseline electrophoresis production systems
required for annual production to meet anticipated markets.
The number of patients (P) treated by each of the candidate products is considered
to be the best estimate available based on the wide range of conflicting values
appearing in the literature. The National Center for Health Statistics at
National Institutes of Health indicated that the data needed for this feasibility
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study is not compiled by the Center because their charter is primarily to tabulate
communicable disease. Discussions with personnel in the marketing groups of
pharmaceutical companies reported that the usual numbers of potential patients
may vary by as much as +50 percent from marketing surveys. Their usual source of
info oration for potential sales volume of a new product is a company sponsored
survey of several hundred physicians across the country. Because we did not have
access to a survey group, our potential patient populations are based oil available
literature and discussions with personnel of state and national grolaps identified
with the disease (e.g., National Hemophilia Foundation)
An attempt was made to balance the potential patient population with the severity
of the disease being treated. If the disease was very severe and the product
treated a large number of patients, it would have a higher value index than a mild
disease that had a larger patient population. The classification of severity of
the diseases to be treated was expected to be obtained frori a nationally recognized
pathoiogical severity index. The Armed Forces Institute of Pathology indicated
there was no nationally recognized scale and this was confirmed by a literature
search at the National library of Medicine. The usual method of evaluating illness
is to assign a subjective evaluation of zero through four for an increasing level
OF illness. This method of classification does not take into consideration the
concept of the illness being chronic or acute.
As a result of the deficiencies mentioned above we have created our own severity
index (S1) for this feasibility study. The index and the diseases we wished to
rank were presented to several local physicians and the Armed Forces Institute of
Pathology. In general these physicians agreed within one index point on the
C
	
	 severity assigned to each disease. The value assigned to each disease can be
found with the candidate products in Section 4.2.1 and Figures 4.2-2 and 4.2-2A.
The point value and its related descriptive terminology can be found in Table
4.2-2.
tACE
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TABLE 4.2-2 DISEASE SEVERITY INDEX
POINT SEVERITY
0 HEALTHY
1 COSMETIC
2 CHRONIC UNRECOGNIZABLE
3 ACUTE MALAISE
4 CHRONIC MILD
5 CHRONIC SEVERE
G CHRONIC DEBILITATING
7 ACUTE DEBILITATING
8 CHRONIC PARALYTIC
9 ACUTE PARALYTIC
10 TERMINAL
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The unique characteristics of space are expected to lead to new products as well
as improve the purity and yield of currently existing products. Improvement in
throughput over ground electrophoresis of the latter group of products could
increase commercial feasibility. In the value index, the improvement factor (IF)
was assigned a value of two if it was a unique product only available commercially
as a result of space processing. A value of one was assigned to those potential
products in which some improvement in purity, yield or throughput was anticipated
over current earth based production techniques. A value of zero was inserted if
no improvement was anticipated. This zero value would effectively eliminate
unimproved products from consideration.
The competitive factor (C) takes into 'account the number of current or anticipated
pharmaceutical products or medical procedures that would be in competition with
the potential space processed pharmaceutical product during the first five years
of sales. It was also modified by a value judgement on our part for a possible
decrease in the projected, market resulting from patient and physician hesitancy
to try something "new" when a certain level of "amelioration" was currently
provided by an existing treatment. The competitive factor was also modified in
the opposite direction when it was anticipated that the potential product would
obtain such a vast improvement in treatment that it would become the drug of
choice for that particular pathological condition.
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The number of baseline electrophoresis production systems (T) required to satisfy
the need for a product to meet annual production of anticipated markets was found
as follows: the total annual requirement for each potential candidate product was
determined by the mathematical product of the number of annual patients for each
disease to be treated with the candidate product, the number of doses required for
cure or on an annual basis (if a chronic affliction) for each disease and the
quantity of product to be prescribed for each dose. This total annual requirement
was divided by anticipated annual production of the potential product using space
bioprocessing techniques. The annual production was based on an assumption of a
space bioprocessing production system consisting of forty continuous flow electro-
phoresis chambers working twenty four hours per day for 360 days, per year. The
sample flow rate was equivalent to 0.6 ml/minute through each chamber in the case
of proteins and 0.017 ml/minute when cells were being processed. The quotient of
the total annual market requirements divided by the annual production capability
of an assumed configuration production system presented an approximation of the
size of the production facility required by that particular potential product. An
extremely high value for this quotient would reduce the feasibility of space
processing of that product because of the tremendous logistics involved (ignoring
tissue culture). This evaluation of market and production for each product is
summarized in Figures 4.2-1 and 4.2-1A.
When the value index was applied to each potential candidate product, numerical
values were obtained as seen in Table 4.2-3. (The calculated values were divided
by 10,000 and rounded to provide easier understanding.) The higher the value
obtained, the more desirable the potential product would be as a candidate. This
evaluation of the value index is summarized in Figures 4.2-2 and 4.2-2A.
4.2.3 Product Recommendation and Rationale
While the value index provided a basis for comparing each candidate product's
relative potential for space bioprocessing and benefit to the American population,
additional subjective criteria had to be considered in a final selection and recom-
mendation of the six model products. These subjective criteria considered whether
the product would: a) exercise the analytical model in one or more different modes
of operation and, b) provide comparison data between earth and space if available.
1NUfACTURIRG
ACE
TABLE 4.2-3	 VALUE INDEX APPLIED TO CANDIDATES
PRODUCT V.I.
ALPHA-I-ANTITRYPSIN 24
ANTIHEMOPHILIC FACTOR 4
BETA CELLS 750
EPIDERMAL GROWTH FACTOR 18
ERYTHROPOIETIN 1700
GRANULOCYTE STIMULATING FACTOR 6
GROWTH HORMONE 10
IMMUNOGLOBULINS 72
INTERFERON 11
SOMMATOMEDIN 1
TRANSFER FACTOR 8193
UROKINASE 1
REPORT MOC E2104
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Alpha-antitrypsin may some day be used to replace the deficiency levels of this
protein in individuals with an inherited antitrypsin deficiency. Such people are
known to be more susceptible than others to emphysema. Alpha-antitrypsin is not
clinically available today primarily because of the inability to isolate and
purify the substance in commercial quantities. Other approaches to releasing
alpha-antitrypsin from hepatocytes of people with a circulating deficiency of this
protein have not been fruitful to the present time. Enough work has been accom-
plished on the ground to provide meaningful comparisons of space processing for
the analytical model when it is exercised in the electrophoretic separation of
protein mode. For these reasons the product has been chosen to exercise the
analytical model.
Antihemophilic factor had a low score on the value index primarily because of the
relatively small number of patients to be treated. It was considered a major
choice for space bioprocessing because of its significant pharmaceutical value and
large impact on the American population. To meet the needs of approximately
20,000 people afflicted with hemophilia, the production of AHF consumes almost 5-9
million pints from the 12-13 million pints of blood donated in this country
annually. If space processing could double the yield of antihemophilic factor
from each pint of blood at the same time as it increased product purity, about 2-4
million people less would be required to donate blood each year. The purified
u	 4-26
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PRODUCT MARKET AND PRA
-	 M A R K E T	 -
AVERAGE
TOTAL
NUMBER DOSAGE ANNUAL EL
PRODUCT DISEASE OF PER REQUIREMENTS PROD'
PATIENTS YEAR (UNITS) (ml/(UNITS) O
ALPHA-ANTI o EMPHYSEMA 100,000 264,000 mg 2.64 1010
TRYPSIN
AHF o HEMOPHILIA 20,000 25,000 5 x 108
BETA CELLS o DIABETES 600,000 3 x 105 CELLS/ 1.92 x
	
1011
DOSE
EPIDERMAL o BURNS 14,000 .02 8.8 x 106
GROWTH
FACTOR
ERYTHROPOIETIN o MALFUNCTION- 20,000 78,000 1.56 x	 109
ING KIDNEY
o ANEMIA 500,000 1,200 600 x 106
GRANULOCYTE o WOUND HEALING 500,000 1.05 x 1010 5.25 x 1015
STIMULATING
FACTOR
GROWTH o DWARFISM 1,500 300 units 450,000
o STRESS 100,000 60 mg 6 x 106
 mg
ULCERS
FIGURE 4.2-1	
a	 flnna-trj
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CT MARKET AND PRODUCTION SUMMARY
-	 PRODUCT ION	 -
TOTAL.
BASELINE
ELECTROPHORESIS PRODUCT PRODUCT
NUMBER
OF BASELINE
_ANNUAL
PRODUCTION CAPACITY
CONCENTRATION PRODUCTION
E UNITS
UIREMENTS
INITS) (ml/YEAR )(
	
DAY)
/ UNITS
`	
ml	 )
UNITS
( YEAR REQUIRED
10 ( 000,000 )) 2\	 Q (1)	 Q)
z.64 1010 12.44 3 mg/ml 3.7 x 107 7.1	 x	 102
x 108 12.44 30 3.7 x 108 1.34
92 x 10 11 0.311 3.75 x 106 1.16 x 1012 0.2
^3.8 x 10 6 12.44 5 mg/ml 6.2 x 10 7 0.14
.56 x 109 12.44 250 3.1	 x 109 0.5
500 x 106 12.44 250 3.1	 x 109 0.2
125 x 10 15 12.44 6.8 x 105 units/ml 4.2 x 1013 1.25 x 102
r
E450,000 12.44 2.0 2.5 x 107 0.02
106
 mg 12.44 0.12 mg/ml 1.5 x 106 4.0
,.rnT,T)0TTT FRAMP' 2^1
4-27/28
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PRODUCT MARKET AND PRODUCT.
I ^
PRODUCT
-	 MARKET	 -
NUMBER
AVERAGE
DOSAGE
TOTAL
ANNUAL
BASEL
ELECTROP
DISEASE OF PER REQUIREMENTS PRODUCTION
PATIENTS YEAR (UNITS) (ml/YEAR)(
(UNITS)
0 (000;
IMMUNO o DEFICIENCY 5,000 59,400 mg 3 x 108 12
GLOBULINS
o RUBELLA 459000 4,500 mg 2 x 108 12
o RUBEOLA 75,000 500 mg 0.38 x 108 12
o INFECTIOUS 60,000 750 mg 0.45 x 108 12
HEPATITIS
INTERFERON o HEPATITIS 100,000,000 6.6 x 108 6.6 x 1016 12
SOMATOMEDIN o MEAT 123,000,000 390 mg 4.80 x 10 12 12
PRODUCTION
TRANSFER o MULTIPLE 535,000 10.4 5.56 x 106 12
FACTOR SCLEROSIS
o LEPROSY 2,300 30 6.9 x 104 12'
o MELANOMA 14,000 26 3.6 x 105 12
UROKINASE o DISSEMINATED 1	 x 106 4,000,000 4 x 101 2 121
INTERNAL
CLOTTING
1
FIGURE 4.2-1A	 fOLDOUT FRAWV, I
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PRODUCT MARKET AND PRODUCTION SUMMARY (CONTINUED)
- PROD -UCTION
	 -
TOTAL BASELINE PRODUCT NUMBER
ANNUAL ELECTROPHORESIS PRODUCT PRODUCTION OF BASELINE
REQUIREMENTS PRODUCTION CAPACITY CONCENTRATION UNITS E UNITS
(UNITS) (ml/YEAR)(360 DAY) UNITS
(	 )
YEAR ) REQUIRED
1 (000,000) m1 O ( O
3 x 108 12.44 5 mg/ml 6.2 x 10 7 4.8
2 x 108 12.44 5 mg/ml 6.2 x 10 7 3.2
0.38 x 108 12.44 5 mg/ml 6.2 x 107 0.6
0.45 x 108 12.44 5 mg/ml 6.2 x 107 0.7
i
6.6	 x	 1016 , 12.44 5 mg/ml 6.2 x	 107 1.06 x	 103
e 4.80 x 10 12 12.44 5 mg/ml 6.2 x 107 7.7 x 104
5.56 x 106 12.44 5 mg/ml 6.2 x 107 0.09
6.9 x 104 12.44 5 mg/ml 6.2 x 107 0.001
3.6 x 105 12.44 5 mg/ml 6.2 x 107 0.006
4 x
	
10 12 12.44 2,500 3.1	 x	 1010 128.6
'0t'?
. 
T.)OICI ` FRAMI^ `7
4-29/30
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PAT;
VALUE INDEX = --,'
NUMBER SEVERITY SPACE
COMPS
COMPETITIVE COMP:
PRODUCT DISEASE OF INDEX Q IMPROVEMENT PRODUCTS PRO'
PATIENTS FACTOR Q (NUMBER) (NU
A
O
ALPHA-ANTI EMPHYSMA 100,000 5 1 1
TRYPSIN
AHF HEMOPHILIA 20,000 6 2 NONE
BETA CELLS DIABETES 600,000* 5 2 3-INSULIN N(
DIABINASE
ORINASE
EPIDERMAL BURNS 14,000 9 1 1
GROWTH
FACTOR
ERYTHRO- o KIDNEY 20,000 6 2 NONE
i
POIETIN FAILURE
o ANEMIA 500,000 4 2 NONE
GRANULOCYTE WOUND 500,000 7 2 NONE N(
STIMULATING HEALING
FACTOR
GROWTH DWARFISM 1,500 5 1 NONE
HORMONE
STRESS 1000000 5 1 NONE
ULCERS
FIGURE 4.2-2	
* 150,000 NEW CASES ANNUALLY + 20% OF ORIGINAL POPULATION OF DIABETES
4-31/32
MCOONNtLL OOUOLAS ASTMONAL/T/C! C0MPANV-07. LOWS ONVINSON
COMPETITION
NUMBER VALUECOMPETITIVE COMPETITIVE COMPETITIVE
`NT PRODUCTS PRODUCERS FACTOR OF BASELINE INDEX
(NUMBER) (,NUMBER) + REQUIREDT Q (Z) (D 0 1)(1	 + a
1 3 0.2 710 141
NONE 4 0.20 1.34 35,820
3-INSULIN NONE 0.25 0.2 7,5009000
DIABINASE
ORINASE
1 1 0.33 0.14 297,000
f
NONE 1 0.5 0.5 240.000
t
F
NONE 1 0.5 0.2 10,0009000
	
1.
NONE NONE 1 125 56,000
NONE 4 0.2 0.02 759000
l.i
NONE 4 0.2 4.0 25,000
x 107
I x 105
.POPULATION OF DIABETES
4-31/32
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	 NUMBER A
	 SEVERITY B	 IMPROVEMENT C	 COMPETITIVE DOF	 x	 INDEX'	 x	 FACTORS	 x	 FACTOR
PATIENTS
VALUE INDEX =
NUMBER OF BASELINE ELECTROPHORESIS
	 (E)
UNITS REQUIRED
wv
Iwo	 yN
SPACE
MANUFACTURING
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VALUE INDEX SUMMARY
NUMBER SEVERITY SPACE
COMPS
PRODUCT DISEASE OF INDEX IMPROVEMENT COMPETITIVE COMPEI
PATIENTS FACTOR PRODUCTS PRODi
O
®
© (NUMBER) (NUME
a
IMMUNO o DEFICIENCY 5,000 7 1 2 5
GLOBULINS
o RUBELA 45,000 7 1 2
o RUBEOLA 75,000 7 1 2 5
o INFECTIOUS 60,000 7 1 NONE NO
HEPATITUS
INTERFERON HEPATITIS 100,0000000 7 1 1 4
SOMATOMEDIN MEAT 123,000,000 2* 2 NONE NO
PRODUCTION
TRANSFER MULTIPLE 535,000 7 2 NONE NO1
FACTOR SCLEROSIS
LEPROSY 2,300 6 2 1 1'.
MELANOMA 14,000 9 2 NONE NO
UROKINASE DISSEMINATED 1	 x 106 7 1 3-HEPARIN 4;
INTERNAL
-UROKINASE
CLOTTING
-COU111ARIN
FIGURE 4.2-2A 	
solaum FR"ll ^
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1
i
VALUE INDEX SUMMARY (CONTINUED)
SPACE
'ROVEMENT
COMPETITION
NUMBER
OF BASELINE
VALUE
INDEX
COMPETITIVE
_
COMPETITIVE COMPETITIVE
'ACTOR PRODUCTS PRODUCERS FACTOR (E) UNITS
(NUMBER) (NUMBER) 1 REQUIRED
a b (I +a+ 6TQ 0
1 2 5 0.125 4.8 900
1 2 5 0.125 3.2 12,300
7.
1 2 5 0.125 0.6 109,000
r	
1 NONE NONE 1.0 0.7 600,000
1 1 4 0.16 1.06 x
	 103 110,000
2 NONE NONE 1 7.7 x 104 6,400
2 NONE NONE 1 0.09 83,220,000
2
e
1 1 0.3 0.001 91,100,000,000
2 NONE NONE 1 0.006 42,000,000
1 3-HEPARIN 4 0.125 128.6 6,800
-UROKINASE
-COU;IARI N
x105
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product would minimize, if not eliminate, antigen-antibody reactions with the
U'	 product providing a longer life span for the afflicted individuals. Government
regulatory problems with this product would be considered minimal. Comparison
data between ground and space production and purification can readily be obtained.
Because the site of cell production of antihemophilic factor is not yet known,
this product can only exercise the analytical model in the electrophoretic separa-
tion of proteins.
Antihemophilic factor is currently extracted from plasma cryoprecipitate. This
same material contains some of the immunoglobulins. Using cryoprecipitate as the
intia7 protein source, both products may be isolated and purified simultaneously
using the continuous flow electrophoresis process.
It is evident that the production of beta cells would have a dramatic effect on
the American population. Not only would it be used to treat a large number of
the populati7.,n (.12%) it could do so in a way that might result in a permanent
cure for the recipient. The regulatory problems with federal agencies could be
anticipated to be held to a minimum because the candidate product would be a
natural component from the body and should be considered in the same category as
a heart or kidney transplant. While it could not provide direct comparisons of
cost, production and technical data between earth and space processing because of
differing forms of the same pharmaceutical agent, the similarities are enough that
valid comparisons could still be obtained. Beta cell production would exercise
the analytical model in the mode of processing cells alone; i.e., electrophoretic
separation of cells from extraneous pancreatic cells, their tissue culture and
eventual separation of the cultured cells from nutrients and media by a second
electrophoretic step.
Epidermal growth factor has a potential use for both the treatment of burns and as
a supplement to tissue culture media replacing a large proportion of animal sera
currently required in them. A natural product of the body, it has been purified
and is currently being investigated by two pharmaceutical companies for its poten-
tial in burn treatment to supplement or replace skin grafting. Comparisons of data
between ground and space processing could easily be made with the analytical model
exercising it in both the electrophoretic separation of protein mode and in the
4-35
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electrophoretic separation of submaxillary gland cells, their culture and finally
the electrophoretic separation of the product from the culture media.
While erythropoietin is commercially available in minute quantities for laboratory
research, it has not succumbed to commercial techniques for large scale production
as a human pharmaceutical product. When available it would be of significant phar-
maceutical value for a number of pathological conditions and show a large impact on
the American population. Comparison data could be drawn between space and ground
production. As with the other products reviewed in this study, being a natural
product of the human body will minimize government regulatory activity. Erythro-
poietin can exercise the analytical model in two different modes: a) free flow
electrophoretic separation of partially purified erythropoietin and, 2) electro-
phoretic separation of kidney cells producing erythropoietin, tissue culture of
these cells and either return to earth of the cells for transplantation, or
rupturing the cell membrane and continuous flow electrophoresis of erythropoietin
from among the other cell constituents. Erythropoietin is a good model product
for exercising the tissue culture process.
Granulocyte stimulating factor was another product considered for use in exer-
cising our analytical model of space bioprocessing. While there is a potential
clinical°.Qed for such a product, research related to its biological activity and
clinical usefulness have not been given high priority status within the pharma-
ceutical production community. Not enough data is available to use the product to
exercise our model for a comparison of ground versus space production of granulo-
cyte stimulating factor.
Growth hormone, for its typical use, would ordinarily not be considered a life
saving drug and certainly would not have a large impact on the population. When
used in the treatment of stress ulcers, however, this product could be as impor-
tant as beta cells. This latter treatment is still in the experimental stage but
will require large quantities of the hormone for testing. Growth hormone is cur-
rently being marketed by one company and FDA approval for marketing by a second
company is anticipated during the Spring of 1979. Therefore, regulatory problems
would be greatly reduced if not eliminated. Because of current purity levels,
growth hormone could be improved by space separation. Comparison data could
4-36
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readily be obtained between ground and space conditions. Growth hormone could
r exercise the analytical model in two modes, a) electrophoretic separation of the
anterior pituitary cells producing growth hormone and, b) electrophoretic separa-
tion of the cells, their tissue culture and continuous flow electrophoresis of
protein hormone. Growth hormone would be a good candidate product, however
erythropoietin has a higher value index for a product exercising the system in the
tissue culture mode.
Immunoglobulins had a relatively low value index as the result of the large number
of production systems required to meet market demands and the existing competition
for this product. This annual market is transitory however. These immunoglobulins
are primarily used to offer passive immunity toindividuals wino have been exposed
to contagious disease that could reach epidemic proportions. In many cases these
products are produced, stored and eventually destroyed when their expiration date
is exceeded because the need for large scale immunizations does not materialize.
The annual critical need for these products is not envisioned at this time.
Sufficient isolation and purification of the various immunoglobulins may also bei
accomplished as by-products in the space processing of plasma cryoprecipitate to
obtain anti hemophi1ic factor, such that the market for routine individual iacmuniza-
tions may be satisfied. The immunoglobulins are currently extracted from human
plasma in impure fo rn7 and would offer comparison data between earth and space
processing. Current ground based production is favorable for reducing any govern-
ment regulatory problems. The immunoglobulins would exercise the analytical model
f °	 in the mode of electrophoretic separation of proteins alone.
L.
4 Interferon is probably the most investigated pharmaceutical product in the world
today with about one hundred companies examining its pha macological potential and
production problems. The Food and Drug Administration has issued a number of
Investigational New Drug Licenses to explore the clinical efficacy of interferon
in a variety of diseases ranging from cancer to virus infections. Pharmaceutical}•
companies contacted in this study have indicated that even if space processing
could only purify a small quantity of the interferon, it would give them the start
for characterizing the substance. This could lead to antibody production for diag-
nostic purposes and possibly the ground production of interferon through reconrbi-
pant DNA techniques. The major stumbling block for production of interferon is the
4-37
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tremendous quantity of cells that must be drown in tissue culture to provide a com-
mercial product. Better than half of tnese cells are killed by the challenging
f	 virus required to produce the interferon. The surviving cells are quiescent for
several days after the viral challenge, being unable to reproduce themselves as
well as synthesize interferon• The logistics problems currently anticipated for
cell culture and production of the product in space do not make this an ideal can-
didate for our analytical model in the cell culture mode. It is an excellent
example, however, for the electrophoretic separation of interferon from contami-
nating products. Interferon could provide direct comparison of cost, production
and technical data between earth and space processing.
^^	 1
t.
a
s
The United States slaughters approximately 123,000,000 cattle, pigs and sheep
annually to supply the protein nutritional requirements of its population. Pharma-
ceutical companies working in the veterinary market are interested in finding a
method for animals to extract a greater amount of nutrient from fodder, thus ulti-
mately improving the movement of calories through the food chain. Somatomedin is
one such product considered to increase the absorption of nutrients from fodder to
raise the weight of the animals. In view of the fact that very little information
is known about the dosage and treatment regimen required for a given animal weight
increase as well as the fact that this product does not have the highest priority
for utilization within the next twenty years, it was not considered a good example
for this analysis.
Preliminary clinical trials indicate that transfer factor has tremendous pharmaco-
logical potential for a number of crippling diseases affecting large portions of
the world population. It has been investigated for at least thirty-five years.
During this time the product has not been chemically characterized nor has it been
determined if it is a class of products rather than single entity. The method of
tissue culture production and harvest of the transfer factor for electrophoretic
separation could exercise the analytical model in two of its three modes of
operation. Unfortunately there is no basis for comparison of ground and space
production. Therefore, even though this product had the highest value index of
the twelve products considered, it was passed over for products with a greater
depth of immediate technical knowledge.
I	 R
4 moo
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Urokinase started clinical trials on a national scale in 1967. Abbott Laboratories
received Food and Drug Administration approval to market this product during the
spring of 1978. A second American company participating in these clinical trials
has not received approval to market urokinase as of this writing. Japan and
Switzerland are currently marketing this product overseas. Market penetration
would be difficult for any new version of this product unless it was cheaper and/
or purer. Intravascular blood clotting does affect a large portion of the
American population when they are treated for other physiological insults, i.e.,
broken bones, surgery, cardiac infarcts or strokes. Urokinase would be an addi-
tional, slightly improved pharmaceutical product in the field competing with
established leaders like streptokinase and steptodornase as fibrinolytic agents
and heparin as an anticoagulant to limit clot growth. Some comparison data
between ground and space production and costing could be obtained, but the actual
ground costs have not been completely defined. The analytical model would be
exercised in the electrophoretic separation of urokinase producing cells, their
tissue culture and continuous flow electrophoretic separation of cell constituents
including urokinase. Urokinase is not considered to be a good model product for
this study.
Based on the above information, the following six products were recommended for
further analysis: alpha-antitrypsin, antihemophilic factor, beta cells, erythro-
poietin, epidermal growth factor, and interferon.
4.2.4 Market Analysis of Selected Products
Preliminary market analyses of the six selected products (alpha-antitrypsin, AHF,
beta cells, erythropoietin, epidermal growth factor and interferon) were perfonlied
for the primary purpose of determining coarse estimates of the market potential
for each product. The derived market size estimates established production rate
requirements for use in subsequent space manufacturing plant sizing tasks. A
secondary purpose of analyzing each product market was to develop an initial undE;r-
standing of the market forces and risks involved in achieving a targeted market
share for space processed pharmaceutical products. A risk assessment was performed
assigning subjective probabilities to each market area subject to risk at appro-
priate program milestones.
i
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ALPIIA-I-ANTITRYPSIN
"T"Alpha-antitrypsin is a protein found in hunran•^iijood that inhibits the destructive
action of an enzyme, trypsin. In people genetically deficient in this protein,
the uncontrolled presence of trypsin in the lung can result in tissue damage
producing emphysema. People with this deficiency ordinarily have alpha-alit,(trypsin
levels less than 20% of normal control values. The isolation and purification of
alpha-antitrypsin through space processing may provide .Lilo first pharmacological
approach to containing the damage of emphysema. The results of a preliminary
market assessment of space processed alpha-antitrypsin are summarized in Figure
4.2-3.
Market Size - There are approximately 800,000 people in the U.S. currently
afflicted with emphysema or chro%ic bronchitis. A steady increase in this patient
population has been predicted by the Environmental Protection Agency caused by
increasing levels of air pollution. About 100,000 members of this group are
conservatively estimated to have a severe alpha-antitrypsin deficiency. This
protein product would have its major, and most immediate, effect in these severely
deficient patients. Alpha-antitrypsin may also present some therapeutic benefit
to persons suffering from osteogenic imperfecta, Marfan's syndrome and cutis laxa.
The number of patients in each of these categories is very low, probably less than
several thousand.
The average adult receiving alpha-antitrypsin would require an annual dosage of
264 grams of the substance. Using a cost figure of $0.02/mg (one-tenth of the
present ground cost of the plant origin material due to mass production in space),
this would result in an annual market value of 528 million dollars, if all 100,000
severe patients were treated. This reduced cost for mass production cat) be justi
-fied if the plasma source used for this product can supply many products sinn.11ta-
neously. As a conservative estimate for this analysis, 30,000 patients with a
severe alpha-antitrypsin deficiency were selected as the model baseline for annual
treatment with space produced material. Figure 4.2-4 shows the projected alpha-
antitrypsin market for years 1986-1991 and reflects a 1% per year population
ma
growth.
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Competitive Product - There are no known developed competitive products for the
treatment of-alpha-antitrypsin deficiency and the treatment and containment of
emphysema. Three companies currently provide an alpha-antitrypsin of plant origin
for biochemical research purposes. This plant material is not acceptable for clin-
ical investigations because of its potential antigenicity. Two other approaches
are currently being investigated that have long term potential competition. In
one series of investigations, chemical compounds are being screened for their
potential to release alpha-antic rypsin from hepatocytes. in date no compound has
worked. In a second series of investigations chemical compounds are being screened
for use as synthetic inhibitors of granulocyte elastase and trypsin. These in
vitro tests are toxic to cells,
e_
Competitive Process - While no large scale commercial ground processes capable of
separating and purifying alpha-antitrypsin have been developed, by the late 1980s
}	 competitive processes may be available. If a method is developed to extract the
alpha-antitrypsin from human plasma at the same time as albumin and/or antihemo-
philic factor is also being isolated, it will pose a competitive threat. The
extent of this threat will depend on the purity of the isolated product. The
various chromatography processes are not as serious a competitive threat because
of the long intermediate dialysis times involved.
Market Development - No specific treatment now exists for a severe alpha-
antitrypsin deficiency. The availability of a treatment for this disease would
i	
immediately open a market for alpha-antitrypsin. The market will be slow to
develop, however, because some people with this protein deficiency do not show
clinical symptoms of emphysema. Physicians and public health officials will be
very cautious in the long term use of a prophylactic treatment for a disease that
may probably develop. As sufficient data is collected demonstrating the safety of
alpha-antitrypsin, its use as a therapeutic agent should continue to grow. The
cost of the space produced material must be kept within the reach of potential
j'	 users.
Risk Assessment - An analysis was made of the market risks associated with attain-
{°	 ing the market share objective. This was accomplished by assigning a subjective
S	 probability of success (P S ) to the three market risk elements (competitive product,
	
a'
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competitive process, and market development) at four program milestones (today,
completion of ground experimentation, completion of flight experimentation, and
completion of the pilot plant demonstration). The results of this assessment are
shown in Figure 4.2-5. At each milestone, the product of the P S for each market
risk element defines the overall chances of market success. This assessment shows
that the chance of market success increases from one out of four today to eight
out of ten following pilot plant demonstration.
ANTIHEMOPHILIC FACTOR (AHF)
AHF, or Factor VIII, is one of the 13 factors which act together in performing the
blood clotting function. People whose bodies produce inadequate amounts of any
one of these factors, hemophiliacs, have blood which does not clot properly. A
significant fraction of these hemophiliacs have blood which will not clot at all
unless they receive periodic treatment with large amounts of AHF. However, there
are problems with this treatment regimen which includ?:
o Extremely high cost - patients with moderate hemophilia on home-care
treatment may accumulate bills of $10,000 to $20,000 per year.
o Immunological reactions - approximately 10% of the hemophiliac population
develop antibodies to current commercial AFIF preparations.
o Large blood collection requirements - partially due to the relatively
poor yield of existing AHF extraction processes.
The increased purity postulated for space processed AHF may eliminate the immuno-
logical reaction-producing impurities contained within existing preparations of
AHF. This, therefore, should be an important element of space produced AHF market
demand. In addition, because less blood plasma is required to process AFIF in
1	 space, greater care in the selgction of plasmaphoresis donors can decrease the
probability of hepatitis virus contamination of the end product.
The results of a preliminary market assessment of space produced AHF are summarized
in Figure 4.2-6. Market size information is presented as are principal market
elements subject to risk. These include competitive products and processes and
factors which may influence the rate of space product market growth.
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Market Size - An assessment was made of the potential AHF demand for the treatment
of hemophilia. A review of the literature identified a considerable disparity in
the reported prevalence rate of hemophilia. The reported prevalence rate varies
from about 1(6) to 2.58(7) per 10,000 males in the United States. To establish
a baseline, a prevalence rate of 1.5 per 10,000 males was selected because it is
conservatively low. This selected rate results in an estimated 1986 annual market
potential of about 500 million units of OF when using the average annual AHF
requirement of 31,200 units per hemophiliac as defined in reference (6). This
correlates well with the projections in the Qooz-Allen Repc ,t (7).
Due primarily to projected purity advantages, the space processed AHF should
readily capture the AHF market segment made up of immunologically sensitive hemo-
philiacs. This assumes the purified space product minimizes or eliminates antibody
reactions to contaminating substances in conventionally ground processed AHF and
would thereby be readily prescribed. The space processed material may have to be
priced higher than competitive products in order to absorb high transportation
costs. Additionally, the annual supply of cryoprecipitate (which would be the raw
material) is projected to be 3000 kg (7), which would contain only 30% of the
required AHF. There is enough plasma collected however, to supply the necessary
10,000 kg of cryoprecipitate if that became necessary. Therefore, at best, the
market share for space processed AHF probably would not exceed 30% of the total
market.
The AHF price per unit to the patient is currently 11 cents per unit (10) and is
expected to increase by 1980 because of increasing plasma costs (7). Using this
current 1978 price of 11 cents per unit results in a potential of $16.5 million
for space processed AHF in today's terms. Extrapolating this potential to the
late 1980s yields an annual market exceeding $17.9 million. Figure 4.2-7 presents
market projection.
Competitive Product - There are no known developed competitive products to AHF.
There are however, two extremely long range potential competitors. One is the
possible implantation of cells capable of synthesizing AHF if this production
source can be found. Another is the synthesizing of AHF itself after an amino
acid sequence has been determined. Neither process is considered a deterrent to
proceeding with space bioprocessing of AHF over the next 10-15 years.
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Competitive Process - A rapid rate of market develcpment will hinge on the ability
to effectively exploit the purity advantages of the space processed material.
Obviously, those hemophiliacs with developed immunological reactions to other
preparations will become immediate users of the space product. For other hemo-
philiacs, demand for the space product will be sensitive to price relative to the
purity. Some price cutting by existing AHF producers can be anticipated thereby
affecting the rate of space product market growth. Assuming both the yield
increases and by-products of the space process result in a cost advantage, then
competitor reaction should only have a short term effect.
Risk Assessment - An analysis was made of the market risks associated with attain-
ing the market share objective. This was accomplished by assigning a subjective
probability of success (P S ) to the three market risk elements (competitive
product, competitive process, and market development) at four progr-;.1 milestones
(today, completion of ground experimentation, completion of flight experimentation,
and completion of the pilot plant demonstration). The results of this assessment
are shown in Figure 4.2-8. At each milestone, the product of the P S
 for each
market risk element defines the overall chances of market success. This assessment
shows that the chance of market success increases from 11 out of 20 today to 19
out of 20 following pilot plant demonstration.
PANCREATIC BETA CELLS
Implantation of beta cells, processed and purified in space, may provide a long-
term remedy, and possibly a cure for juvenile onset diabetes mellitus. The
implanted beta cells produce the hormone, insulin, that is responsible for lower-
ing glucose in the blood by promoting its absorption into the cells for meta-
bolic activity. Elimination of the need for the current daily multiple insulin
injections and the necessary patient handling of the drug should provide an incen-
tive to purchase an alternative treatment regimen consisting of a single implanta-
tion injection which provides years and perhaps a lifetime of glucose control.
The results of a preliminary market assessment of space produced beta cells are
summarized in Figure 4.2-9.
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Market Size - As previously described in Section 4.2.1, there is considerable dis-
parity concerning the number of persons with insulin deficiencies. While the
leading manufacturer of insulin, Lli Lilly and Company, estimates 1.2-3 million
people require insulin injection, they also estimate there may be another 10
mullion with milder forms of glucose metabolism deficiency who are either uniden-
tified diabetics or are being treated with controlled diets and/or synthetic phar-
macological agents. A National Center for Health Statistics survey conducted in
1973 (see Volume III, Section A.9) indicates about 130 of the population over age
of 17 (approximately 26 million persons) were suffering from some form of diabetes.
Today's market for beta cell transplants will not likely exceed those requiring
insulin injections, or about 2 million patients. Lach year, however, there are an
additional 150,000 new patients found with juvenile diabetes, or 1.2 million by
1986. The total market at that tine, therefore, is projected to be about 3.2
million patients.
The next step of the analysis estimated a projected value for the space purified
beta cells. A person with juvenile onset diabetes will require a daily treatment
regimen of 30 to 80 units or more of insulin. At $0.0035/unit, this equates to
$0.105 to $0.28 per day in 1973. For a 5-year period, a savings range of $192 to
$511 would result from a single implantation of beta cells. A present value
analysis of a benefit annuity equivalent to the annual savings for a 5 year period 	
a ^
and discounted at 5%, resulted in a value range of $164 to $436 for the single
implantation for each diabetic. The value of the entire known diabetic population
on insulin medication is probably closer to the lower of the two dollar figures
and would total over $525 million. Assuming a discounted benefit period of 25 	 A
years, this present value exceeds $1.4 billion.	 v;r
A program to implant beta cells in all the nation's diabetics might be accomplished 	
ri
over a 5 year period. This appeared to be a reasonable assumption when compared
with the joint government-commercial polio vaccination program which virtually
eradicated polio within a shorter, three year period. The space produced beta cell
market would then approximate 630,000 patients per year for a five year period.
Assuming a lifetime cure results, implantations thereafter would be a function of
new cases and would be based upon incidence of diabetes - pancreatic deficiency in
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the newborn and aging population ( 150,000/yr). Figure 4.2-10 shows the projected
beta cell market for the years 1986-1991 and reflects a 1% per year population
growth. An average of 630,000 patients are treated annually with a corresponding
discounted market value exceeding $100 million.
Competitive Product - There are no known competitive products under development
which provide a multiyear control of insulin deficiency. As previously discussed,
insulin deficiences can be offset by stringent diet control, insulin injections
r'	 and sometimes other drugs. However, these remedies all involve significanta
measures of risk, inconvenience, and side effects not found in beta cells which
naturally and automatically control insulin levels. Although significant improve-
ments can be anticipated for insulin, including commercially scaled synthesization,
it is unlikely that a multi-year treatment competitor to beta cells will be
developed before 1986.
Competitive Process - Alternative ground methods for processing purified beta
cells may be developed before space processed material is ready for the market
place. Ground processing of beta cells using a continuous flow electrophoresis
device in combination with a tissue culture system may pose the greatest threat
to the space processed product. However, purity advantages may keep the space
product price competitive.
Market Development - With the capability for multi-year, and possibly a lifetime,
cure of insulin deficiencies, there should be a good chance of achieving the
targeted market for beta cells. The multi-year or lifetime cure will be strong
motivators for all diabetics to obtain beta cell implantations. There would also
be motivation for the government to sponsor a concurrent testing program to iden-
tify people with early signs of glucose metabolism deficiency. Also identified
during this test program would be the large number of suspected diabetics who are
not now undergoing treatment, yet are counted in the government statistics.
The greatest irket threat would probably be from ground production of purified
cells which would have similar product characteristics as the space processed
beta cells.
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Risk Assessment , - An analysis was made of the market risks associated with attain-
ing the market objective for space processed beta cells. As previously described
for AHF, this was accomplished by assigning subjective probabilities of success
(P S ) to the three market risk elements at four program milestones. The results of
the analysis are shown in Figure 4.2-11. This assessment shows that the chance of
market success increases from four out of ten today to 9 out of 10 following pilot
demonstration.
ERYTHROPOIETIN
Erythropoietin is a hormone produced by the kidneys, which controls the red blood
cell production in the body. With an average lifespan of just 120 days, red blood
cells must be continually produced to offset the loss of dying cells. Failure to
maintain an adequate level of red blood cells results in anemia and, if suffi-
cier;tly severe, eventual death. Major losses of red blood cells can be temporarily
made up by blood transfusions. Because of the potential for hepatitis virus }
infection, however, these transfusions are not used as a continuous treatment
regimen. Erythropoietin is not currently used clinically because of potential
hazards associated with other protein components contained in the impure extract.
If sufficient purification is achieved, as is postulated for space processed
erythropoietin, then there would be an immediate extensive market.
The results of a preliminary market assessment of space processed erythropoietin
are summarized in Figure 4.2-12.
Market Size - The market potential for space processed erythropoietin is defined
by two distinct market areas. These are: 1) anemia due to kidney failure and
2) other forms of anemia responsive to erythropoietin treatment. Of kidney related
disorders, kidney failure patients would have the greatest need for the purified
erythropoietin and were thereby selected as the major market segment.. It was
assumed that, as for kidney dialysis, not all kidney failure patients can effec-
tively utilize long term treatment. One third, or about 20,000 kidney failure
patients were selected as a baseline. Based upon an average annual dosage of
83,000 units per patient, annual requirements of 1.7 billion units of erythro-
poietin would be needed. A cursory assessment of the various types of anemia and
I
	
4-55
tit
MCOONNNLL DOLMLAa ASTRONAdirles COMPANY•T. La"w OIV/SION
VACE
ANUFACTURING
REPORT IMDC E2104
VOLUMEII
9 NOVEMBER 1978
u-
C)
W >- O F-
S F- J O CL'C 1 En ►-+ N
W -J Q CD Lo I- co►- cm	 to
X:
C co O O O C 
L = r~
d
CL
W W_
^
II
1-- U r
N
r	 4
C7 I (n zLL Z in E l)F- O	 O W a-Z f-wUOWW > QCLU -JCL'F- ^ F- ^-+	 O W ,^:W a_ f-+ 1-- u-i v)YO JZU	 W V)CY _J 0-+ WQC]O 001 00) 001
d W co W CL Z	 F-X:
ct W N d J Y O O O OWGa O LL W F- _,J w
LY ►-^SU=0- Im	 A LL
F- X
W
V) CL W
V) LL	 SNQ rr-C) 1V)-j ti J	 Lu L/I Na NLL j F- F- N F- -J	 O F-f	 YU W Y H W r-+OLD=LxJ N N CN Y C/J F- U J LL Z CL Via: lD I^ co m ll.
WF- d CL W En F- 0 4 O Q O O j
LLJ JCL dW WZ^F- m O =UCl= 1O4LLJ U OUm:OCr WO O = OCLEnUL7LL
Q X
^CL ,
W
LL	 = En C''
W O	 F- F- Z
>-	 U Cn nr-i F- >- J	 =F- L) F- _J	 cm
^= H =LDCD LLJ N M C71 L0F- 0 _! L.L. Z = ^14 I\ co co` 01
W O " N 1- 4 C1=CCL. = 03 cn F-	 Q O C C C
=- 0- dW LLJ tYm: rO coca_ WU O U X: = w
==OF- O
` CLcnC
-
)OLL,
1
c.7
N Z
F- LL I 1
Z O w Z Q ,n
LLJ ui
WM: W W c[ ^ ^ O V) C) C)Q Z F- E LL_ O F- W co O.-r
=CD =QL=>- n ZN ZC3.m ZE L0co F- d O L F- m O LU C) >< O W co w
OCL' W H W :-9; 1--1F- n-^ W r,r C7 0)J W WCL -j Ll. ^	 ^--^ W m— F- Z I---
^--i ^- W W co >- J Z N J S O J=ZimUQ Q 0L= c0 Cl. L!3" a- coCS	 d CL O 2: O 01 E i-r F- g r-i O►^ZC1Q O C)= r OJQ c:)-j
En"EnU F- UU' — ULLF- vLLI-
4-56 5
rt
a
MCOOOWNWLL OOUOLAI A0rW0NAVrlC0 C0MPANV-iT.L04J8W O!V/sION
2 =
Iva
	
	
REPORT MOC E2104
VOLUMEII
ACE	 9 NOVEMBER 1978ANUFACTURING
ZW
N
NW
III Z
Q f
k-
F-- W_
Y O
Q O
Q ^Z W
JW
a
NQ W	 IO Z ►-+
.J = C) -i
~Z 0-4 C:)
w ¢ F-+ o Lr,i^
F-	 F- LL v)os¢
a. c_ ^ F-W
" ►-4 = >-
z¢¢¢F¢--
O
c^
N	 F-- Z O W	 U I WH	 Z r-^ O Y	 = Z W YQXS w	 00 tnclY^
"z^saw	 aQ GF
~W	 a W J►- ^wz o
z F->.¢rcl O	 w or
F- W < -4	 J O + Q	 U F- U
W w Ln	 LU 1.L. F- W	 4 a F- F-Y d uj Z>
	
0. W LU
= O f- W a
	
W	 cn ]G W W_U
W F-iG	 N	 U-W cl:	 d
W 000 A.	 OLU	 C) -j ^
O WLU=	 Nd	 N V~7J C70:::-W 1.^Ln_I<Z	 OOCO ui
a73 MQ U ►-+	 U^Q SctO
O	 O O
cz
uia	 N OO	 ►^	 WLU
w	 Y C:) Ln w
N ^,	 N	 W F- ?F- N W	 U W O
WO RF-	 F-Eda
f0 d ui O O S QU W	 < LU =3 Wc	 W 5 O YO	 = W = = fQ
Z	 LD O O W N
O	 O
HZ
Q	 NW J	 Z Za	 ►-+ Q	 F- nr
F- N	 LL I- W	 Lo
^J Z	 OW >- O W E O W
^ O ^
w O H	 k--o a- p	 Y ► + a
m: a. >-	 w
	 o=oQ waO W	 J f S SU Z	 F- F-	 O W H F-C]	 Z >- O Cr > O Z >-
^-+	 >-	 r W W Z >-
hC	 N W — W,7 Q N W
O	 O O
Ln
W	 F-	 F- F-
LU ui
=	 =CDYIJ ^J+p OW
= ►-r Q O 0)	 M L= l0	 0) ko	 U'
< to Li- 0
	 O	 CD O	 O CDf r	 r F- r	 ^-- r B
X~W lt?	 X	 X W X	 >G
OA	 1^	 I	 d LLu r	 wt, C) U
N a N>- M p¢
N
r
N
W
O
LD
U-
4-57
MCOONM &L OOVOLAS AITQONAIJT/CS COMMANW-ST. L404A1S ZMWSMN
REPORT MOC E2104
VOLUMEII
9 NOVEMBER 1978
fin
SPACE
MANUFACTURING
their associated patient populations resulted in the identification of 1 million
patients per year for this potential market. Probably only 10-20% are severe
chronic anemics and would utilize this therapy. With an average annual dosage of
2,400 units per patient, this represents an estimated 360 million units of erythro-
poietin. The total projected space product market for erythropoietin is estimated
to be the sum of these, or 2.0E billion units/year. The space market value of
$245 million per year is obtained by placing a value of $10,000, and $300 for the
annual per patient costs of erythropoietin for kidney failure, and anemia, respec-
tively. Figure 4.2-13 graphically shows the 1986-1991 market projection for space
processed erythropoietin.
Competitive Product - There are no other known products with red blood cell produc-
tion stimulation and control capabilities similar to the natural hormone erythropo-
ietin. Since it has not yet been separated and purified sufficiently to determine
its chemical structure, there is little risk that erythropoietin can be synthe-
sized, extensive clinical tests completed, and marketed in the next ten years.
Competitive_ Proce ss - While no large scale commercial ground processes capable of
separating and purifying erythropoietin have yet been developed, by the late 1980s
competitive processes may be available. Specifically, a ;ground system capable of
purifying and tissue culturing ESF cells, and of separating and purifying the
erythropoietin hormone in a fashion similar to the space processing concept may
pose the greatest competitive threat.
Market Development - Cost consideration aside, there should be few obstacles pre-
venting the attainment of the space processing erythropoietin market share.
Erythropoietin is the natural stimulant and control hormone for red blood cell
production and will have virtually no competition for the kidney failure and anemia
market segments. Price may be a deterrent for the anemia market segment but those
on dialysis may have little alternative. Ground produced erythropoietin of
inferior quality may be available during the 1986-1991 marketing period. However,
assuming the space product can be priced within reach of the potential users, there
should be few constraints to quick market development. The biggest risk of market
development is the ability of erythropoietin to be economically produced in space.
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Risk Assessment - An analysis was made of the market risks associated with
attaining the market objective for space processed erythropoietin. As previously
described for AHF and beta cells, this was accomplished by assigning subjective
probabilities of success (P S ) to the three market risk elements at four program
milestones. The results of the analysis are shown in Figure 4.2-14. This assess-
ment shows that the chance of market success increases from two out of 10 today,
to seven out of ten following pilot plant demonstration.
EPIDERMAL GROWTH FACTOR
Epidermal growth factor is a protein produced by the salivary glands. It has the
fundamental property of stimulating the production of ectodermal tissue. In
clinical situations where the skin is damaged by burns and wounds of various
types, application of epidermal growth factor to the damaged areas could result in
their rapid restoration to normal function. This substance also has a tremendous
potential for both supplementing and partially replacing fetal animal serums in
tissue culture systems. The results of a preliminary market assessment of space
produced EGF are summarized in Figure 4.2-15.
Market Size - Discussions with directors of several hospital burn units throughout
the country have resulted in a consensus of approximately 14,000 people annually
receiving third degree burns over at least five percent of their body. The annual
market requirement to treat these patients is assumed to be 8.8 x 10 6
 mg. This
is based on each patient receiving a daily treatment of 20 nanograms/cm 2 damaged
surface area for a seven day period. The actual treatment regimen has not been
published but this dose is known to cause epidermal cells in tissue cultures to
proliferate and spread into a fibroblast network (see Volume III, Section A.3).
In addition to burn patients, an eventual market may develop for its use in the
rapid healing of all skin wounds. A third area of potential commercialization is
the-use of EGF to supplement a reduction in animal serum requirements in tissue
culture. Its use could stretch the current limited supply about five hundred
t4,nes. Even at the current ground based production cost of $495/mg for EGF, use
of 2 nanograms/ml mixed with 0.02% fetal calf serum would tremendously reduce the
cost of tissue culture production. It may even be the method of choice for
culturing in space in order to reduce to a minimum the costs associated with the
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transportation of supplies. This analysis used a space produced market cost of
$50A4^ based on anticipated production competition once large commercial quantities
became available for use. Figure 4.2-16 shows the projected EGF market for the
years 1986-1991 and reflects a 1% per year population growth.
Competitive Product - The current practice for treating extensively burned patients
is to cover the damaged areas with skin grafts, when available, or wet biocidal
wraps. Biochemical means for inducing epidermal cell proliferation are not being
used commercially at this time although two companies have already started clinical
trials. If these trials show positive treatment advantages, EGF would be almost
without competition in this field.
Competitive Process - Research quantities of EGF are currently isolated and puri-
fied by various exclusion and affinity chromatography techniques. They are costly
and time consuming, usually taking about 5-10 days to produce 19 mg of the product.
Processing the strained salivary gland extract or concentrated urine through a con-
tinuous flow electrophoresis device could considerably lower both the cost and time
required for production. A major competitive threat to processing the material in
space could come from the use of recombinant DNA techniques where genetically modi-
fied bacteria might produce the material in commercial quantities. Even though EGF
has been biochemically characterized and its amino acid sequence determined, many
researchers in this field as well as pharmaceutical companies contacted do not
anticipate this process being a competitive threat for at least ten years.
Risk Assessment - An analysis was made of the market risks associated with attain-
ing the market share objective for space processing. This was accomplished by
assigning a subjective probability of success (P S ) to the three market risk
elements (competitive product, competitive process and market development) at the
four program milestones used with the other products analyzed. The results of
this assessment are shown in Figure 4.2-17. This assessment indicates that the
chance of market success for epidermal growth factor increases from slightly more
than three out of ten today to seventeen out of twenty following pilot plant
production.
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INTERFERON
Interferon is a protein substance produced by lymphocytes and fibroblasts chal-
lenged by a virus. This interferon offers temporary immunity to other cells
against most challenge viruses when subsequently attacked. Preliminary human
clinical trials indicate this natural body product has great therapeutic potential
against many diseases of viral or suspected, but not proven, viral origin. It is
probably one of the most sought after candidate products today with about one
hundred pharmaceutical companies and universities actively conducting research and
development related to its potential therapeutic commercialization. The results
of a preliminary market assessmeri^, of space produced interferon are summarized in
Figure 4.2-18.
Market Size - As reported in Section 4.2.1 and Volume I11, Section A.7 dealing
with interferon, this product may be a modern day therapeutic panacea. It has
shown some clinical improvement or total remission in a number of diseases from
cancer to the common cold. It is very difficult to estimate the number of patients
1
that could benefit from this drug and its annual market value because the clinical
trials have been small, therapeutic doses have not been firmly established and
only a few of the potentially responding diseases have been tested. To simp?ify
this analysis, only one disease, affecting a very large population, has been used
for the calculations. If the patient population and annual dosage are in error by
even twenty percent, the numbers used in the evaluation could readily be filled in
with a patient load and annual dosage for another responding pathological condi-
tion. For this analysis infectious hepatitis was chosen because it is estimated
to affect approximately 100 million people worldwide. To treat this large a popu-
lation would require 6.6 x 10 15
 units annually. While the current ground produc-
tion cost is fifty to seventy dollars per million units, we have reduced the cost
to a conservative one dollar per million units. Even at this lower value the
total annual world market for interferon to treat this disease alone could be 66
billion dollars. The one dollar per million units was chosen because it was felt
both the quantity of the material needed annually and the tremendous industrial
competition for a share of this huge market would drive the price close to this
limiting level. A similar condition was seen in the expansion of the penicillin
market after its discovery and introduction into the medical armamentarium.
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Figure 4.2-19 shows the projected interferon market for the treatment of this one
disease over the years 1986-1991 and reflects a 1% per year population growth.
Competitive Product - Small scale clinical trials indicate that interferon is
effective against many diseases of viral origin and suspected, but unproven, viral
origin. In the case of cancer, radiation and che rmotherapy are currently being
used but they are not very effective. In other diseases, like hepatitis, there is
no pharmacological treatment and interferon may rapidly capture the whole market.
Since interferon has not been purified sufficiently to characterize its amino acid
content and sequence, there is little chance that this product can be synthesized
or made by recombinant DNA techniques within the next 10 to 15 years. Antiviral
agents are gradually becoming available, although their scope of effectiveness is
usually quite limited in comparison to that of interferon.
Competitive Process - Approximately one hundred pharmaceutical companies and
university research laboratories are vigorously pursuing research and development
with interferon. Large scale cellular biosynthesis is still the main production
problem at the present time. Activity in this area ranges from monolayer produc-
tion with roller bottles to use of dextran bead supports for suspension culture
growth. The use of super inducers, e.g., poly rI:rC, has increased the quantity
of interferon produced per cell. Current purification processes take up to ten
days per research quantity batch. The use of the continuous flow electrophoresis
separation process in space could readily capture this phase of the market if both
the purification and throughput can be achieved as anticipated by theory. The
largest threat to the dominance of space processed interferon is the development
of a substance that will endogenously produce interferon in the patient. Such an
approach has been tried several times before but was unsuccessful because of
cytotoxicity side effects. Researchers at Johns Hopkins University claim they
have de v eloped a synthetic inducer that is metabolized several minutes after
entering the patient, thereby circumventing cytotoxicity. They expect to start
clinical trials in 1979.
r $
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Market Development - Interferon should easily capture the lion's share of the
market for treatment of viral origin diseases because present associated therapeu-
tic procedures leave a lot to be desired. Preliminary clinical trials with
interferon for these saute diseases has shown tremendous potential therapeutic
effect. The field is highly competitive. Anyone who can get on the market first
with a highly purified product in sufficient quantity to satisfy even the smallest
consumer demands will probably dominate the market for a long time to come.
Risk Assessment - An analysis was triad,; of the market risks associated with attain-
ing market objectives for space processed interferon. As previously described for
the other prOdL!Cts, this was accomplished by assigning subjective probabilities of
success (P S ) to the three market risk elements at four program milestones. The
results of the analysis are shown in Figure 4.2-20. This assessment shows that
the chance of market success increases from about one out of four today to almost
nineteen out of twenty following pilot plant demonstration.
4.3 ADDITIONAL AREAS OF INTEREST
During our visit to the various pharmaceutical companies, several additional
products were suggested as potential candidates for space processing. These are
listed in Table t:,3-1. They are light weight proteins and would be readily
marketable to c large segment of the population.
TABLE 4.3-1 ADDITIONAL AREAS OF INTEREST
THYMIC HORMONE COMPLEX
SOMATOSTATIN
SOMATOMAMMOTROPIN
HYPOTHALAMIC RELEASING FACTORS
POLYVALENT VACCINES
SPECIFIC IMMUNOGLOBULINS
A cursory look at thymus physiology and immunochemi story has indicated that this
particular organ has the potential for producing many other pharmacologically
active agents to enhance tissue and organ transplantation. It -is thought to
contain lymphocyte stimulating factor which may increase antibody production.
.	 t
1
4-70
MCOONNLLL DOiJOLA• A/rIW0NA4Jr/CS COMPANY -sr.
 LCMAN VNIVOO ON
REPORT MDC E2104
VOLUMEII
p	 MACE
MANUfACT	 9 NOVEMBER 197611111Nfi
	 ;
U.
O
ulJ	 w	 ^- O
=42	J O DV N	 1-+ r-rl .,	
W J
	
co G7	 N	 to	 ONO	 ch►-r	 m Z to
Z:
	
°Darn	 °	
O	 O	 o
4i	
N	
=
aQ =
u
C`^ C9 1 N ZZ ClLn r--^1-	 O	 OWC.Z	 F-DUOW
r	 w	 >-¢C.0-JDl-f	 F- ti	 =wQwC.	 +-+ 1--- W N ^ 2YO	 JZ' U	 wN	 O	 M	 Ln	 471DJ	 r-4wQOO	 m	 Ol	 a)	 01W	 OO D C. Z	 F-aw VIQ `r WC)	 O	 O	 O
1
InmLj	 oU.wF-^o^c
0- tm - ^ 1^
xH
mC.	 W	 4
uiNO	 O>- ►~-rWN	 V	 3►--r to
	 >- J 3 U
P	 Q
Ln  
W	 F-	 F- N	 H J	 O j	 L-	 W Y	 ►-+ w	 1-4 = C7 D wY0:	 YN	 I- U	 Ju- ZC.Y	 M	 O	 O	 Lo	 LUN w	 D ►-r	 W O	 ^-+ N •-r	 a:	 M	 f\	 01	 ch	 D
~~D
	
^0.	 co W LiJZ^
	
O	 O	 O	 O	 =C9
co
F- ~ 	 v	 O c".yXOD	 u-
W	 D = O D O
lie X	 C.LnUC7LA-
Ln
wD
W	 F- I- SO
r-^ F--	 >-
l- U	 h- J	 L7 1-r-N _ CD CD 	 O	 Lo	 to	 mI- O	 J u. = = Y	 01	 0,	 01	 cnW O
	
^-4 N r-r C.
r	
C. D 	 am V) 	 O	 O	 O	 O
t	
OCL
	
muCL W
D =OF-OC.tnUOLL-
i
cz
N	 Z	 y
W O	 W
N	 W Z U	 Lt.	 u- 
QZ	 l-:E u-	 coO^	 O,w^	 OZ^D O	 Z C_ = Y	 f\	 Z(4	 = C- 0)	 Z	 tool-
	 crCD	 01	 O W	 OXr-	 Ow co
= w	 s.- W	 JH	 _	 i--	 1--	 r--
^ o4	 1"ui W m
	 >-	 J Z CV	 J 2 O
	 -jZGU¢	 Q	 C.^co	 0- CD 	 C czC3	 Q C.	 O	 f O 01	 2: —	 M " CD
•	 r--r Z C. Q	 O	 CD = -	 O _d Q
	
CD
Ln r NU
	 l-	 Ucm—	 u u-	 ciw
4-71
j	 MCOONNAML OOVOLA• ASTRONA#JTICS COMPANY-Sr. LOUIS OIVISIOW
.1
.+i..i<c_'^	 ,-.,.... ,^._...	 a
--	
•_.wx..	 —". .._
	
`dkweP "+..,..,gam.	
-
4-72
M'COONNtLL OOUOLAS ASTRONAUTICS COMPANY-ST. LOUIS O/V/a/ON
f
^f
f	 REPORT MOC E2104 	 `t
VOLUME II
Px^
SPACE	 9 NOVEMBER 1978MANUFACTURING
The pharmaceutical companies have expressed considerable interest in pharmacologi-
cal agents that will regulate growth and increase body weight. Aside from the
utilization of these compounds for alleviating human deficiencies, these manufac-
turers conceive of potentially large markets in the veterinary field to increase
livestock size and weight to meet the world's anticipated food needs. Since we
had already included growth hormone and somatomedin as some of the initial candi-
dates for consideration in this task, they suggested there would be strong commer-
cial interest in other growth factors including somatostatin, somatomammotropin,
and possibly hypothalamic influencing factors.
Improved vaccines to provide immunity against specific diseases was also suggested
by several companies,, Vaccines, in general, have two major problems. Their rela-
tive impurity usually causes side reactions in approximately 10% of the recipients.
They are difficult to put into solutions of sufficient concentration to permit
4
injections of acceptable volumes of the material without precipitation. Electro-
phoretic processing in space may be the method of choice to increase the purity of
the vaccine material and thus reduce the total amount of protein needed for each
injection. In the livestock industry it is desirable to give each animal only one
injection containing many different vaccines. The present technology (concentra-
tion of total proteins in a given quantity of fluid or development of polyvalent
single protein antigens) will only allow three vaccines to be combined in one
injection. Increasing the number of vaccines to 5 or 8 per injection is highly
desirable.
An additional area of interest for the companies we contacted was the stability
of crystallization procedures in space. The production of one pharmaceutical
compound requires its crystallization as the final step before packaging. A
change in its crystalline configuration results in different pharmaceutical
activity. (One company has experienced three such crystalline changes in one of
	
A} ;
its major product lines.) Since the procedure does not revert back to the
initial structure, production must be halted and FDA approval sought for the new
crystal configuration. Because the approval cycle can take years, any process
stability in space may cause them to use a space bioprocessing method rather than
ground operations.
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4.4
	
CONCLUSIONS AND RECOMMENDATIONS
We have explored a number of natural pharmaceutical products from a technical and
a marketing viewpoint to serve as potential candidates for a space bioprocessing
venture.	 This group of products was presented to the pharmaceutical 	 industry as
well as the medical and pharmacy academic community. 	 With their concurrence, the
list was narrowed down to twelve products: 	 alpha-l-antitrypsin, antihemophilic
factor, epidermal 	 growth factor, erythropoietin, granulocyte stimulating factor,
beta cells, human gamma globulins,
	
interferon, urokinase, transfer factor,
U somatomedin and growth hormone. 	 Literature reviews of each of these products
showed that technical
	
information was voluminous but of little direct value to
j sizing a processing system. 	 Pieces of information were missing that would require
technical assumptions, based on laboratory and bioengineering experience, in order
a
to proceed with production system analysis.
All of the twelve biological products reviewed could exercise the proposed system
in part or in its entirety thus supporting the concept of a true multiproduct
;,. system.
	
Knowledge of the cell sources for erythropoietin, epidermal growth factor,
growth hormone, interferon and alpha-antitrypsin production and an awareness that
these cells and hormones can be separated by electrophoretic techniques, all
support the concept of a full bioprocessing production system. 	 Antihemophilic
factor VIII and specific immune globulins are blood proteins with no defined site
of production in a living organism.	 They, therefore, would only be able to exer-
' ise the space bioprocessings P te	 t o se	 .	 Ic	 p 	 sys m ^n	 h	 partition mode	 stets of Langerhans
fI1 ' (beta cells) and urokinase producing cells can be grown in tissue culture and also
separated electrophoretically. 	 Because the mobilities of these cells in an elec-
trical field are lower than proteins, the separation chamber may have to be modi-
fied slightly in design or operational 	 function.	 All twelve products could benefit
through space bioprocessing by improvements in purity and throughput.
Based on economic and technical 	 information, this task developed a value index of
i^ each product with respect to their humanitarian value and applicability to the
concept of production through space bioprocessing.
	 This index ranked the twelve
products in descending order of importance:
	 transfer factor, erythropoietin, beta
t. cells, alpha-antitrypsin, epidermal 	 growth factor, interferon, immunoglobulins,
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growth hormone, antihemophilic factor, urokinase, somatomedin, granulocyte stimu-
lating factor. In addition to this numerical evaluation, two additional subjective
criteria were applied to each product, i.e. - would the product exercise the con-
ceptual bioprocessing system in one or more modes of operation and could compari-
son data be attained between earth and space processing. This total evaluation
resulted in a recommendation that erythropoietin, Islets of Langerhans (beta
cells), antihemophilic factor, alpha antitrypsin, epidermal growth factor and
interferon be used to exercise the model space bioprocessi,g system.
A preliminary marketing analysis of the six model products indicated that they
would all be viable commercial candidates. Four of the products, erythropoietin
and Islets of Langerhans (beta cells), alpha antitrypsin and epidermal growth
factor would have minimal competition from earth based commercial sources. Space
processed antihemophilic factor was projected as attaining thirty percent of the
product market by 1986 as a result of its increased process yield and higher
level of purity. Interferon would p-,°obably attain the majority of the market
because of simplicity of production and quantity throughput in comparison to
current ground based techniques. A risk assessment of obtaining these market
objectives after pilot plant demonstration showed a minimum seventy percent
chance of success. The widespread beneficial effect of these biological products
on the average American would develop a new regard for space and an interest
in its commercialization.
Discussions with a number of pharmaceutical companies resulted in a list of
several other biologically active products for eventual consideration. These
included: thymic factors, specific immunoglobulins, somatostatin, somatomammotro-
pin and polyvalent vaccines. It is recommended that these products be explored in
depth as a point of future communication and interest with the pharmaceutical
companies.
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5.0 INTRODUCTION
The purpose of this tas ► , is to assess the requirements for a multiproduct produc-
tion facility to produce the selected products. Important considerations in this
regard are the production rates relative to the needs defined in the Product
Requirements and Analysis task and the capabilities projected for Shuttle and
associated supporting hardware. These considerations along with the requirements
for good manufacturing practices imposed by the Food and D rug Administration were
used to formulate the process protocols for the selected products. These protocols
and requirements will provide the basis for future conceptual design of a multi-
product pharmaceutical production facility. Such design studies performed in
cooperation with ethical drug companies will provide information vital to future
space manufacturing investment decisions by private industry.
5.1 BACKGROUND AND APPROACH
The rationale for this investigation of space processing of pharmaceuticals is
that the microgravity environment of space may provide advantages to the production
and purification of biological materials with attendant humanitarian benefits.
Experiments conducted in space have already demonstrated the advantages of using
static (14) and free flow (15) electrophoresis to separate biological materials in
a microgravity environment. Cells separated during static electrophoresis showed
increased production of urokinase and erythropoietin when subsequently subcultured
in Earth based laboratories (16). Other studies, directed toward determining the
a	 effects of microgravity on a biological system, demonstrated increased cell density
in cultures of the bacterium Salmonella typhimurium growing In space compared to
ground control experiments. This increased density was attributed to improved
transport of nutrients to, and waste materials from, the growing cell (17).
Another report indicates that increased cellular growth rate and increased cell
density may be obtained in space as a result of growing cells on carriers suspended
due to lack of gravity (18).
Our approach to establishing process requirements is to evaluate current ground
processes if any, assess how to best utilize space advantages through new or
modified processes, and to define the process protocols on which the requirements
will be based. The process protocols will reflect those existing Food and Drug
Administration (FDA) requirements that will probably be applicable to the space
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processing of pharmaceuticals. The key element of the process evaluation is to
define mass flow balances for the space processes at production rates that satisfy
the targeted market shares defined in the section on Product Requirements and Anal-
ysis. A multiproduct facility can then be defined to satisfy the combined require-
ments and product mix trade-offs can then be made in favor of those products which
benefit most from space processing. In addition, establishing the scale of the
process allows meaningful evaluation of man interface requirements. The results of
the tradeoff studies will be a multiproduct process system description, and the
protocol for the process.
5.2 ANALYSIS AND RESULTS
This section presents the results of the analysis defining the requirements for a
multiproduct pharmaceutical production facility. Basic to this facility analysis
is the selection of production methods described in Section 5.2.1, a consideration
of applicable FDA requirements (Section 5.2.2), and the process evaluation (Section
5.2.3). The resulting multiproduct process system is described in Section 5.3.
Any of the six candidate products selected in Section four could be processed in
the multiproduct facility in one of its three operational configurations, i.e.,
a) separation of protein alone, b) culture and separation of cells alone, and
c) separation and culture of cells followed by separation of the protein products
of those cells. Each of the products would use essentially the same facility com-
ponents with only minor instrument setting changes for the particular product
being processed. The three operational configurations are illustrated by in-depth
process system requirements analysis for a product in each category. The three
products employed in the requirements analyses are erythropoietin, antihemophilic
factor, and pancreatic beta cells.
5.2.1 Production Methods
A biological production facility requires at a minimum the capability of separating
pharmaceutical products from naturally occurring mixtures of cells and/or proteins.
In addition, the production of such a system could be enhanced if it included the
capability of culturing desired tissue strains. Such a system is shown schematic-
ally in Figure 5.2-1. Also included in the system is the assay capability required
to ascertain that the desired products are produced. As shown in the figure, this
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system has different entry points dependent oil
	
raw material and the iinal
product. For example, if the desired product is beta cells, it is possible to
separate them directly from pancreatic tissue; however, production rates could be
increased if these cells were subsequently cultured and separated from the culture
media by a second cell electrophoretic procedure. For other applications, proteins
are the desired products rather than cells. In these cases protein mixtures can be
processed as in the case of blood serum or reconstituted lyophilized protein mix-
ture. The separation of Antihemophilic Factor VIII from blood plasma or cryopre-
cipitate is an example of the direct separation of proteins. In other cases,
protein production requires that specific cells which are high producers be sepa-
rated and subsequently cultured to obtain usable yields of the final product.
An example of this is the production of erythropoietin by kidney cells.
It is obvious that two processes at a minimum are required to demonstrate multi-
product capability, biological material separation and tissue culture. Possible
methods of biological material separation are presented in Figure 5.2-2. The
method most often used to separate proteins on the ground is precipitation, because
of its inherent throughput advantage. ilowever, it should be noted that except for
throughput, the method of choice in terms of resolution, yield, and simplicity is
electrophoresis. Therefore, when the throughput advantage for continuous flow
space electrophoresis over ground electrophoresis (which is calculated to be at
least two orders of magnitude) is considered, it becomes the method of choice.
This choice is further reinforced when the separation of cells for culturing is
considered, because space electrophoresis could have definite advantages in
obtaining the required resolution.
In determining the method of tissue culture the method of choice is less clear.
There are two possible methods, growth in monolayer and growth in suspension. In
general, primary cells from the body grow only in monolayer fonn attached to a
surface, so products like beta cell culture would require this method. It is
possible that cells which are high producers of desirable protein products may
present themselves as transformed cells which can be grown in suspension cultures.
If cells can be grown in suspension, then growth is enhanced and the system can be
simplified. Because of the uncertainties of advances possible in cell culture,
conservative cell culture ground rules were based on densities obtainable either
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in monolayer on the surfaces of beads or in suspension. This approach eliminated
sensitivity of the analysis to cell culture modes.
5.2.2 Lplicable FDA Requirements
All of the candidate products evaluated in this study were either natural body
substances or the products of natural body substances. Therefore, with the aid of
a participating pharmaceutical company, contact was made with the Bureau of Bio-
logics of the Food and Drug Administration to start exploratory discussions of the
space bioprocessing concept, the candidate substances considered for production,
and the applicable governing regulations. This agency was very cooperative and
appreciative of being brought into our program at the conceptual stages. It gave
them an understanding of what the goalsof space bioprocessing were and our
approach to achieving those goals. This awareness of the program then enabled them
to provide meaningful guidance to our systems design and thus be in compliance with
their good manufacturing practices. This guidance will be continued through meet-
ings with Bureau of Biologics representatives from they divisions they consider
pertinent to this concept. It has been made clear that these representatives
could see no insurmountable problems with regard to space bioprocessing as
outlined by us.
In determining a basis for applicability of FDA requirements to producing pharma-
ceuticals in space, many considerations emerge. Of primary importance was the
category of the particular product. According to the requirements, products are
classified as either biologic or drug. Furthermore, current good manufacturing
practices, which are pertinent to the determination of applicable requirements,
exist for both biological and drug products. [fence', it was necessary to either
classify the three candidate space products into the biological/drug categories or
select and analyze a specific current good manufacturing practice that would
represent the applicable manufacturing practices or regulations for all three
categories of the candidate products. The latter approach was adopted since the
former required assistance from the FDA, in the form of their opinion, and had not
been received at the time of this writing. The regulation analyzed was Current
Good Manufacturing Practice for Finished Pharmaceuticals (see Appendix B) which
was assumed to encompass all or most of the specific requirements found in the
other regulations and current good manufacturing practices. This particular
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regulation was judged most representative of the FDA regulations and would formu-
late a good basis for system definition constraints.
Categorization of the three selected candidate products into the biological/drug
scheme was somewhat confused by the definition of a biological product. Biological
W	 products include any virus, serum, toxin, anti-toxin or analogous product. A virus
is a minute living organism causing an infectious disease. A serum is a product
a	 obtained from blood by removing clotting components and cells. A toxin is a pro-
duct containing a poisonous substance which can induce an immune response when
injected in nonfatal doses. An anti-toxin is the immune response substance which
counteracts the toxin. Only one of the three candidate products fits these defini-
tions
	
antihemophilic factor is a blood component. The remaining two products,
beta cells and erythropoietin do not fall into these classifications and thus
cannot be classified as biological products at this time.
Additional considerations in determining applicability of requirements included
those factors bearing on traditional space vehicle design and operation. Among
others, weight conservation, cost optimization, reliability, weightlessness, mini-
r	 mal man interface, data volume and requirements, crew number and skill levels were
 y
	 the criteria used. Discussion of automated continuous processing arose often,
which seems to indicate some degrek. of importance for incorporating this feature.
Besides minimizing man interface and increasing reliability, automated continuous
processing would also facilitate realization of FDA requirements by eliminating
the human element.
The applicable portions of the regulations from current Good Manufacturing Prac-
tices for Finished Pharmaceuticals are tabulated in Figure 5.2-3. Appendix B
contains a reprint of the complete regulation. Each regulation or portion is
classified as "applicable," "applicable with interpretation" and "applicable as
modified.	 The entries "subject to interpretation" include an interpretation
posed for FDA consideration. Proposed modifications are further described in
Figure 5.2-4 and are concerned with anomalies and discrepancies due to unique
applications of the requirements to a space processing system.
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APPLICABLE FDA REQUIREMENTS
BASED ON PART 211 - CURRENT GOGJ MANUFACTURING PRACTICE
FOR FINISHED PHARMACEUTICALS - FROM 1977 TITLE 21 CODE
OF FEDERAL REGULATIONS
REGULATION	 GENERAL SUBJECT SUMMARIZED VERSION RATIONALE/IMPACT APPLICABILITY
SUB-PART	 PARAGRAPH
A	 211.10	 PERSONNEL	 (a) PERSONNEL RESPONSIBLE FOR OH-ORBIT PERSONNEL MAY HAVE MOD
DIRECTING THE MANUFACTURE SPACECRAFT OPERATIONS DUTIES
AND CONTROL OF THE DRUG AS PRIMARY RESPONSIBILITY,
SMALL BE ADEQUATE IN EDU- BUT EFFICIENT UTILIZATION OF
CATION, TRAINING i EXPCR- PERSONNEL NAY REQUIRE THEIR
IENCE.	 ALL PERSONNEL SHALL USAGE IN DRUG PROCESSING,
HAVE CAPABILITIES COMMEN- THESE PEOPLE MAY NOT HAVE
SURATE WITH THEIR ASSIGNED PRIMARY TRAINING iN DRUG PRO-
FUNCTIONS AND ADEQUATE CESSING BUT WiLL COORDINATE
UNDERSTANDING OF OPERA- WITH RESPONSiBLE GROUND
TION RATIONALE, PERSONNEL,
(b) EXCLUDE FROM CONTACT CREW i ALL GROUND OPERATIONS APP
WiTH DRUG PRODUCTS, PERSONNEL CONTACTING DRUG
THOSE PERSONS WITH ILL- WILL HAVE TG BE SCREENED.
NESS OR OPEN LESIONS TO SIMILAR CONTAMINATION OF ALL
AVOID CONTAMINATION. CONTACTED EQUIPMENT AND COM-
PONENTS WILL NEED TO BE PRE-
VENTED,	 IF ILLNESS ON REMOTE,
ENCLOSED, SPACECRAFT BREAKS
OUT, OPERATIONS WILL HAVE TO
CEASE AND FACILITIES MAY HAVE
BE STERILIZED,
B	 211.20	 CONSTRUCTION i BUILDINGS i FACILITIES SPECIFIC REQUIREMENTS FOR MOD
MAINTENANCE OF SHALL BE MAINTAINED BUILDINGS WHERE DRUG PRODUCTS
FACILITIES i CLEAN AND ORDERLY AND ARE PROCESSED,	 AS STATED.
EQUIPMENT SHALL PROVIDE ADEQUATE DOES NOT INCLUDE OTHER ENCLO-
SPACE FOR STORAGE, HANDL- SURES AS WILL BE THE CASE FOR
ING, PROCESSING, LABORA- A SPACE VEHICLE.
TORY OPERATIONS, PACKAG-
ING EQUIPMENT i MATERIALS.
PROVIDE ADEQUATE FACIL-
ITIES TO MINIMIZE CONTAM-
INATION BY EXTRANEOUS
ADULTERANTS. INCLUDING
CROSS CONTAMINATION
BETWEEN PRODUCTS AND FOR
SUITABLE STORAGE CONDi-
TIONS.
B	 211.30	 EQUIPMENT PROCESSING EQUIPMENT SHALL STIPULATES SPECIAL DESIGN MOD
BE MAINTAINED CLEAN i REQUIREMENTS FOR PROCESSING
ORDERLY AND SHALL BE OF EQUIPMENT.
SUITABLE DESIGN, SIZE AND
CONSTRUCTION TO FACILI-
TATE CLEANING, MAINTEN-
ANCE AND OPERATION.
(a) CONTACTED SURFACES SHALT
NOT BE REACTIVE, ADDITIVE,
OR ABSORPTIVE 50 AS TO
ALTER DRUGS.
(b) LUBRICANTS, COOLANTS, ETC,
CANNOT CONTACT DRUG PRO-
DUCTS.
(c) CONSTRUCTION A iNSTALLA-
TION ALLOW AOJUSTMENT,
DISASSEMBLY, CLEANING, i
MAINTENANCE.
(d) BE SUITABLE FOR ANY TEST-
iNG, MEASURING, MIXING,
WEIGHING, OR OTHER PRO-
CESSING OR OTHER STORAGE
OPERATIONS.
APP - PROBABLY APPLICABLE
INT - POSSIBLE APPLICABLE - SUBJECT TO INTERPRETATION
MOD - APPLICABLE AS MODIFIED - SEE SEPARATE CHART
Page i of 3
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C	 211.42 COMPONENTS
C	 211.55 PRODUCT CON-
TAINERS &
THEIR COMPON-
ENTS
(ACE
REGULATION
SUB-PART
	
PARAGRAPH	 GENERAL SUBJECT SUMMARIZED VERSION
RATIONALE/IMPACT
C	 211.40	 PRODUCTION AND CON-	 (a) EACH SIGNIFICANT STEP SHALL DEFINES MONITORING & RECORD-
TROL PROCEDURES BE PERFORMED BY A COMPET- ING REQUIREMENTS DURING
ENT/RESPONSIBLE PERSON AND PROCESSING WHICH WILL NEED
CHECKED BY A SECOND PERSON, TO BE ADDRESSED IN THE
IF AUTOMATICALLY CONTROL- SPACE PROCESSING SYSTEM
LED, THEN CHECKED BY A DESIGN, REMOTE OPERATION
PERSON,	 A WRITTEN RECORD A MONITORING WOULD REQUIRE
SHALL BE RECORDED IMMEDI- GROUND CHECKING AND RECORD-
ATELY FOLLOWING COMPLETION ING.
OF SUCH STEPS.
(h) ALL CONTAINERS, LINES & THIS CAN BE INTERPRETED TO
EQUIPMENT SHALL BE 1DENT1- APPLY TO CONTINUOUS PRO-
FIED INDICA T ING CONTENTS CESSING SYSTEMS & WOULD
L STAGE OF PROCESSING OF FACILITATE CLEANING, MAIN-
THE BATCH. TENANCE & GQER'T10N.
(t) TO MINIMIZE CONTAMINATION/ PERIODIC CLEANING & REFUR-
PREVENT MIXUPS, EQUIPMENT BISHMENT IS 'REQUIRED.
A CONTAINERS SHALL BE
- CLEANED AT SUITABLE INTER-
VALS.
(d) APPROPRIATE PRECAUTIONS REQUIRES PRECAUTIONS &
TAKEN TO MINIMIZE MICRO- PROCEUDRE5 FOR PREVEN-
BIOLOGICAL CONTAMINATION. TION OF CONTAMINATION
i (e) APPROPRIATE PROCEDURES REQUIRES PRFCAUTIONS &
TAKEN TO MINIMIZE CROSS- PROCEDURES FOR PREVEN-
CONTAMINATION BETWEEN DRUGS. TION OF CONTAMINATION
(f) TO ASSURE UNIFORMITY & REQUIRES 1N-PROCESS CONTROLS
INTEGRITY OF PRODUCTS,
THERE :HALL BE ADEQUATE
WHICH MAY DICTATE DIFFER-
ENT IMPLEMENTATION STRAT-
IN-PROCESS CONTROLS DONE EGIES FOR REMOTELY OPERATED
AT APPROPRIATE INTERVALS. EQUIPMENT.
a
(J) PROHIBITS USE OF ASBESTOS- SPECIFIC DESIGN CONSTRAINT.
CONTAINING OR OTHER FIBER
RELEASING FILTERS UNLESS
NECESSARY AND BACKED BY
A NONFIBER RELEASING
!I
f
FIBER.
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APPLICABILITY
MOD
INT B
APP
APP
APP
MOD
APP
ALL COMPONENTS SHALL BE
	 REQUIRES SPECIAL HANDLING,
STORED & HANDLED IN A SAFE, SAMPLING & TESTING FOR ALL
SANITARY AND ORDERLY
	 DRUG CONSTITUENTS BEFORE
MANNER, COMPONENTS SHALL
	 PROCESSING, THESE REQUIRE-
BE WITHHELD FROM USE UNTIL MENTS WILL AFFECT GROUND
IDENTIFIED, SAMPLED, AND
	 OPERATIONS PLANNING. LIMITED
TESTED FOR CONFORMANCE	 NUMBER OF COMPONENTS WILL
WITH SPECIFICATIONS. COM-
	 BE ON HAND DUE TO SPACE AND
PONENTS SHALL BE ROTATED 	 WEIGHT LIMITATIONS.
IN STOCK, AND GUARDED
AGAINST CONTAMINATION.
APPROPRIATE RECORDS AND
INVENTORIES OF EACH COM-
PONENT SHALL BE MAINTAINED.
RESERVE SAMPLES SHALL DE
BE MAINTAINED FOR SPECIFIED
PERIODS.
SUITABLE SPECIFICATIONS,
	 SPECIFIC CONTAINER REQUIRE-
METHODS, & PROCEDURES
	 MENTS.
SHALL BE USED TO ASSURE
CONTAINER, CLOSURES & PARTS
ARE SUITABLE FOR INTENDED
USE. CONTAINERS SHALL NOT
BE REACTIVE, ADDITIVE, OR
ABSORBTIVE SO TO ALTER THE
DRUG PRODUCTS,
MOD
APP
APP - PROBABLY APPLICABLE
INT - POSSIBLE APPLICABLE - SUBJECT TO INTERPRETATION
MOD - APPLICABLE AS MODIFIED - SEE SEPARATE CHART
u
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FIGURE 5.2-3 (Con-Inued)
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REGULATION
SUB-PART
	
PARAGRAPH
	
GENERAL SUBJECT SUMMARIZED VERSION RATIONALE/IMPACT
C	 211.58	 LABORATORY CONTROLS SPECIFICATIONS, STANDARDS, SPACE PROCESSING HARDWARE,
AND TEST PROCEDURES TO OPERATIONS AND PLANNING
ASSURE THAT COMPONENTS. WILL NEED TO ADDRESS THIS
IN-PROCESSED DRUGS, AND REQUIREMENT.	 IN-PROCESS
FINISHED PRODUCTS CONFORM SAMPLING AND TESTING MIGHT
TO APPROPRIATE STANDARDS. BE A FORMIDABLE TASK FOR
ESTABLISH ADEQUATE RECORDS AN AUTOMATIC REMOTE PRO-
AND PROCEDURES FOR IN- CESSING SYSTEM,
PROCESS SAMPLING AND
TESTING.
C	 211.62
	
EXPIRATION DATING PRODUCTS LIABLE TO DETER- LONG TERM BULK STORAGE
IATION MUST MEET APPRO- MAY CAUSE PRODUCT DETER-
PRIATE STANDARDS AT TIME IORATION.
	
STORAGE CON-
OF USE BY EXPIRATION TAINERS WILL BE LABLED
DATING RELATED TO STA- WITH REGARD TO BULK
BILITY TESTING OF PRO- PROCESSING DATE.
DUCT.
v
1
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APPLICABILITY
APP
APP
INT
INT
INT
ONLY THOSE DRUGS THAT HAVE
MET ESTABLISHED STANDARDS
AND SPECIFICATIONS CAN BE
DISTRIBUTED, MIX-UPS
BETWEEN DRUGS SHOULD BE
PREVENTED DURING PACKAG-
ING/LABELING.
A MASTER PRODUCTION AND
CONTROL RECORD FOR EACH
PRODUCT SHALL BE PREPARED
INCLUDING PRODUCT NAME,
INGREDIENTS, WEIGHTS,
ACTUAL AND THEORETICAL
YIELDS, INSTRUCTIONS, PRO-
CEDURES, SPECIFICATIONS,
NOTATIONS, PRECAUTIONS,
ETC.
A PATCH PRODUCTION AND
CONTROL RECORD FOR EACH
PRODUCT SHALL BE PREPARED
INCLUDING: A'RECORD OF
EACH SIGNIFICANT STEP,
COGNIZANT PERSONS SIGNING
PROCEDURES (OR CHECKING
OPERATIONS), M1JOR EQUIP-
MENT, COMPONENTS AND PRO-
DUCTS USED, IN-PROCESS i
LABORATORY RESULTS, DATES
OF PROCESSING, ETC.
THIS REQUIREMENT WILL HAVE
LIMITED APPLICABILITY SINCE
FINAL PACKAGING AND DISTRI-
BUTION WILL OCCUR AFTER
SPACE OPERATIONS. THE SPACE
PRODUCED PRODUCTS ((IN BULK
UNITS) WILL 2E ADEQUATELY
PACKAGED AND LABELED AND
HAVE MET STANDARDS.
DATA F ROM REMOTE MONITORING
DEVICES AND CONTROL PROCED-
URES FROM MISSION DOCUMENTS
WILL SUFFICE TO FULFILL THIS
REQlre;aMENT PROVIDED THESE
DATA AND PROCEDURES INCLUDE
APPROPRIATE INFORMATION PER
THIS REQUIREMENT. "WEIGHTS"
IMPLIES PREMEASUREO GROUND
WEIGHTS.
THIS REQUIREMENT IS APPLIC-
ABLE AND EACH RECORD SHALL
BE MAINTAINED FOR EACH
MISSION WHERE BATCHES CAN
BE EQUATED TO HARVEST OR
RE-STOCKING PERIODS.
D	 211.80 PACKAGING AND
LABELING
E	 211.101 RECORDS 6 REPORTS
1
APP - PROBABLY APPLICABLE
INT - POSSIBLE APPLICABLE - SUBJECT TO INTERPRETATION
MOD - APPLICABLE AS MODIFIED - SEE SEPARATE CHART
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(f) "PROVIDE FOR SAFE AND
SANITARY DISPOSAL OF
SEWAGE, TRASH AND OTHER
REFUSE WITHIN AND FROM
THE BUILDINGS AND
IMMEDIATE PREMISES."
I
P	 211.30'	 EQUIPMENT
	
ADDITION
n r
I
i
B 211.20 CONSTRUCTION A
MAINTENANCE OF
FACILITIES AND
EQUIPMENT
"BUILDINGS SHALL BE
MAINTAINED . . . .
AND LOCATION . . . . ."
ri«
(c) "BE CONSTRUCTED AND
INSTALLED TO FACIL-
ITATE ADJUSTMENT, DIS-
ASSEMBLY, CLEANING R
MAINTENANCE TO ASSURE
THE RELIABILITY......
7
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SUGGESTED MODIFICATIONS AN) ADDITIONS TO
CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS
BASED ON PART 211 - CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS
(TITLE 12 CHAPTER 1 1977 CODE OF FEDERAL REGUALTIONS)
EXISTING REGULATION
SUB PART PARAGRAPH GENERAL SUBJECT	
CRITICAL PHRASE/SENTENCE	 RECOMMENDATION	 REASON
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-	 A	 211.10	 GENERAL PROVISIONS,	 (a) "THE PERSONNEL RESPON-
PERSONNEL
	
	
SIBLE FORDIRECTING THE
MANUFACTURE AND CONTROL
OF THE DRUG .,., "ALL
PERSONNEL SHALL HAVE
CAPABILITIES COMMENSUR-
ATE WITH THEIR ASSIGNED
FUNCTIONS, ..,."
ADD SENTENCE "FOR	 PARAGRAPH NEEDS TO
RMTE— P C
`
k€ ISf6V1^	 ADDRESS THE RESPON-
MIT6FfATTE-AE^1+^CFICAI	 S101LITIES OF PRO-
OR —ELECTRON—IC— CESSING DIRECTION/
l ESSI G SYSTEMS 	 OPERATIONS DURING
IHE COGNIZANT OFLRA .-	 AN IN ORBIT PROGRAM
TING PENSONREMOTELY CONTROLLED/
HAVL	
NE
ELLDIRECTED.
WITH E	 S BLE
L
ADD "AND FACILITIES"	 TO ALLOW MANUFACTURE
AFTER-"b-GTL^ G	 ND AND CONTROL OF DRUG
REMOVE "AND LOCATION"	 PROCESSING IN ENCLO-
SURES OTHER THAN
BUILDINGS (e.g. SPACE
OPERATIONS VEHICLE)
CHANGE (f)" ... FROM	 WASTE HANDLING IN
THE BUILDINGS, FACIL-	 SPACE OPERATION
ITTIEES AND/OR IM ICEMTE NECESSITATES ONBOARD
PREMMES." 	 STORAGE AND PRECLUDES
ADD SENTENCE "IN LIEU	 IMMEDIATE REMOVAL
OF REFUSE REMOVVL '— TILL END OF MISSION
Tlt VE S1
	
GE	 OR REVISIT.
L	 USE
D
PERMISSIBLE."
ADD SENTENCE "WHERE	 REMEDIAL MAINTENANCE
RELIABILITY OF"EdU-CP-	 OF SEMI-AUTOMATIC
1R N^ ^I6T-I.GH Tti- PROCESSING SYSTEM
DUFDANT E	 k WOULD BE LIMITED TO
OR CONTROLS ARE FERMIS- MINOR REPAIRS DURING
ALE""
	
SPACE OPERATIONS WHILE
1N-ORBIT REPAIRS OF AN
AUTOMATIC SYSTEM WOULD
BE ENTIRELY PRECLUDED.
WEIGHT CONSERVATION
AND EFFICIENCY CON-
SIDERATIONS DICTATE
OPTIMUM UTILIZATION
OF MATERIALS IN SPACE
OPERATION,
C 211.40	 PRODUCTION AND CON-
	 (a) "EACH SIGNIFICANT STEP	 ADD SENTENCE "WHEN REMOTE
	 ONSITE, IMMEDIATE
TROL PRCEDURES
	 IN THE PROCESS ...
	 SHALL	 AUTOMATIC CONTINU U	 MONITORING OF REMOTE
BE PERFORMFO	 . AND
	 CE	 N	 Y	 EMS E USED.- AUTOMATIC PROCESSING
CHECKED ... ; OR, IF SUCH 	 PROPER PEUTRWRI-MUL—L MAY NOT BE POSSIBLE.
STEPS IN THE PROCESSING	 BE CHECKED NUOUS	 ON ORBIT MAN-INTER-
ARE CONTROLLED BY PRE-MONI
	 RING A 10	 E	 E	 FERENCE SHOULD BE
CISION AUTOMATIC, MECHAN-
	 3URVEILLANCF OFhTAfTNENT
	 MINIMIZED.
ICAL, OR ELECTRONIC EQUIP-
	 5TEP5 ANDS	 KEY
MENT, THEIR PROPER PER- SU	 C ENT
FORMANCE IS ADEQUATELY
	 D	 U S
CHECKED BY ONE, OR MORE,
COMPONENT AND RESPON-
SIBLE INDIVIDUALS.
SUCH IDENTIFICATIONS
SHALL BE RECORDED IMMEDI-
ATELY FOLLOWING THE COM-
PLETION OF SUCH STEPS."
Page 1 of 2
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RECOMMENDATION
(a) "CACH CONTAINER OF COM-
	 REMOVE "VISUALLY" AND	 TO EXPAND INTENT TO
PONENT SHALL BE EXAMINED	 ", INCLUDING EXAMINATION
	
COVER OPERATION IN
VISUALLY FOR DAMAGE OR 	 FOR BREAKAGE Of SEALS," 	 SPACE SYSTEM WHERE
CONTAMINATION PRIOR TO
	 ON-SITE INSPECTION
USE, INCLUDING EXAMINA-
	
IMMEDIATELY PRIOR TO
TION FOR BREAKAGE OF	 PROCESSING MAY BE
SEALS, WHEN INDICATED." 	 POSSIBLE.
(f) "(1) APPROVED COMPONENTS 	 CHANGE. (f) (1) 	 BY	 TO PERMIT RE-USE OF
SHALL BE HANDLED AND
	
OTHER DRUGS OR COMPON-	 COMPONENTS IN A
STORED TO GUARD AGAINST
	
ENTS UNLESS SUCH COM-	 CONTINUOUS PROCESSING
CONTAMINATING OR BEING 	 PONLNT IS ADDITIONALLY 	 SYSTEM. THIS WILL
CONTAMINATED BY OTHER	 USEFLL'E'CaUfETTE IN A -
	CONTRIBUTE TG OPTIM-
DRUGS OR COMPONENTS."	 CONTINUOUS SYSTEM 4b	 IZATION OF WEIGHT
CAN l3L'NGCYC'LED', RE=-	 CONSEPVATION.
(f)	 "(2) APPROVED COMPON- CHANGES	 (f)	 (2)	 ....	 THE TO REMOVE RESTRICTION
ENTS SHALL BE ROTATED OLDEST STOCK IS USED THAT DOES NOT APPLY IN
IN SUCH A MANNER THAT FIRST, UNIESS SUCH ROTA- CONTINUOUS PROCESSING
THE OLDEST STOCK IS TION	 15M R C ICAL	 'N SYSTEMS.	 NOT POSSIBLE
USED FIRST.
_
RE-C	 CU A IIG ^NTINU IN WEIGHTLESS HOMO-
)SPROCESS N
	 SYSTEM,"_ GENEOUS MIXTURE, FOR
EXAMPLE.
(9)	 "(3) AN
	 INDIVIDUAL CHANGES (9) (3) "_DRUG TO f'"91FY REGULATION
INVENTORY AND RECORD MANUFACTURED OR PROCESSED FOR CONTINUOUS
FOR EACH COMPONENT OR,	 IN THE CASE OF AUTO- INVENTORY	 IN A CON-
USED IN EACH BATCH OF MA IC CONTINUOUS RECORD TINUOUS PROCESSING
DRUG MANUFACTURED OR OF E CH COMPONENT AND SYSTEM,
PROCESSED." RATE DURING PROCESSING,"
C	 211.42
	 COMPONENTS
Page 2 of 2
p:
I
Y
FIGURE 5.2-4 (Conti iq uod )
a
I
EXISTING REGULATION GENERAL SUBJECT
SUB PART PARAGRAPH
211.42	 COMPONENTS
CRITICAL PHRASE/SENTENCE
(f) "TO ASSURE THE UNIFORMITY
AND INTEGRITY OF PRODUCTS,
THERE SHALL BE ADEQUATE
IN-PROCESS CONTROLS, SUCH
AS CHECK WEIGHTS .......
THE HOMOGENEITY OF SUSPEN-
SIONS, AND THE CLARITY OF
SOLUTIONS. IN-PROCESS
SAMPLING SHALL BE DONE AT
APPROPRIATE INTERVALS
USING SUITABLE EQUIPMENT."
REASON
PERIODIC IN-PROCESS
SAMPLING BY MANUAL
PROCEDURES MAY BE
PRECLUDED BY REMOTE
NATURE OF SYSTEM.
WEIGHTLESS CONDITIONS
EFFECTIVELY CONTROL
HOMOGENEITY OF SOLU-
TIONS IN SUSPENSION
UNLESS SOME ORGANIC
DECOMPOSITION IS
OCCURRING. IN WEIGHT-
LESS CONDITIONS,
PREWEIGHED MATERIAL
WILL BE ADDED TO
DEFINITE VOLUMES
AND CAN BE CHECKED
BY CHEMICAL ANALYSIS,
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Modifications were recommended in several areas. Where the operators and super-
visors were required to have sufficient experience and traini ng, a qualifyingq	 P	 9	 q	
statement was added to permit Spacecraft crew operation and ground supervision.
a	
The requirments on facilities and equipment needed special consideration in order
to handle waste in a space system, to allow recycling systems and to permit remote
operation and monitoring of automatic processing systems. Weighing in space poses
r	 technical problems and thus, reference to any weighing operation had to be replaced
with adequate substitutes. None of the FDA regulations were deemed major impedi-
ments to implementation of a space processing program.
In general, this regulation is organized into five subdivisions: general provi-
sions, construction and maintenance of facilities and equipment, product quality
control, packaging and labeling, and records and reports. The general provisions
regulation allows use of automatic equipment and specifies certain personnel
^. requirements for those persons involved in drug processing. The section headed
construction and maintenance of facilities and equipment lists requirements for
buildings and equipment. The product quality control section regulates quality
n	 procedures, requirements for components (constituents), specifications for con-
tainers, and laboratory controls, including in-process controls. The packaging and
labeling section enumerates controls for packaging and labeling drug products and
in-process components. The records and reports subdivision stipulates requirements
,.	
for all production, control and distribution records.
The implications contained in these regulations are, by nature, subject to inter-
pretation and conjecture. Since compliance to regulation includes meeting the
intent as contained in these implications, sufficient understanding of these is
important. The overriding consideration of the regulations is product safety as
assured by adequate cleanliness, orderliness, and documentation before, during and
after processing. A main overtone in the regulations dictates the desirable
approach to processing drugs: dedicated and proper hardware, informed and trained
operators, sufficient controls and monitors to act as checks and balances, appro-
priate documentation to ensure product conformance to established standards and
traceability of distributed drugs, and orderly handling of products and components.
Since the philosophies in the aerospace world are contiguous to this approach,
compliance to drug regulations should not be insurmountable.
;. f
r
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5.2.3 Process Evaluation
Evaluating the processes for the space production of the three selected pharmaceu-
tical products requires definition of mass flow rates and capacities for the equip-
ment required for the process. These mass balances are defined for three cases;
1) accomplishing the entire production cycle in space, 2) accomplishing the entire
production cycle on the ground, and 3) the use of a combination of space and ground
production that could be more advantageous than either of the previous alterna-
tives. In order to make a meaningful comparison, consistent, reasonable ground
rules and assumptions wer(^ estahiished. These are described in the following para-
graph. The mass balances for the production of erythropoietin, beta cells, and
Antihemophilic Factor VIII are presented in subsequent paragraphs. Man interface
requirements are discussed in Section 5.3. It is important to the optimization of
a space production system for demonstration that the tradeoffs presented in the
comparison of space-only production cycles, ground production cycles and space/
ground combinations are used to re-evaluate the product production rates esta-
blished in the Product Requirements and Analysis section. The results of this
overall evaluation were used as the basis for the definition of the Multi-Product
Process System described in Section 5.4 of this report.
Ground Rules and Assumptions
Ground rules and assumptions are required to make comparative evaluations of pro-
cessing pharmaceutical products in space. Assumptions are required in the areas of
tissue culture, electrophoretic separation, transportation of raw materials, cell
handling, and recycle capability. Because of the variability of biological sys-
tems, rational and t!?r.,ervative assumptions were made with respect 'to the tissue
culture requirements, applicable either to suspension culture or monolayer culture
on beads. These ground rules are summarized in Table 5.2-1. These assumptions
are: that cells can be 'inoculated at a concentration of 4.4 x 10 5 cells/ml.
The nutrient required at this concentration is .019 g/ml/day. The doubling time
of cells was assumed to be 35 hours. The concentration of cells during production
was assumed to be 3 x 10 6
 cells/ml. For those production cycles which require
the culture medium, the medium was assumed to be 0.7% by weight solid protein.
This culture medium corresponds to nutrient that is 10% fetal calf serum by
volume. In growing cells as a product, it was assumed that primary cells grcwn
to maximum density can be removed at a rate of one-half their concentration per
-	 5-14
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TABLE 5.2-1')
PROCESS EVALUATION GROUNDRULES
o	 CELL CULTURE
- INOCULATE AT 4.4 x 10 5 CELLS/ML
- CULTURE TO 3 x 106 CELLS/ML
- NUTRIENT REPLACEMENT 0.019 GM/ML-DRY
- MEDIA 0.7% PROTEIN (FETAL CALF SERUM)
- DOUBLING TIME 35 HOURS
- ERYTHROPOIETIN PRODUCTION RATE 9.5 x 10
-6
 UNIT/CELL-DAY
K^
o	 ELECTROPHORESIS
- CELLS	 1
GROUND - 1 ML/HR AT 1 x 106 CELLS/ML
r
w= SPACE	 - 1 ML/HR AT 1 x 108 CELLS/ML
COLLECTED BANDWIDTH - 50% FOR CULTURE INOCULUMS
90% AFTER CULTURE
- PROTEINS
4,- GROUND - 18 ML/HR AT 0.1/ PROTEIN
SPACE	 - 36 ML/HR AT 10.0% PROTEIN
,.
o	 GENERAL
- TRANSPORTATION COST $700/KG
- 1 KG TANKAGE/KG SUPPLIES
- 0.6 KG PLASTIC BAGS/KG CRYOPRECIPITATE
- FREEZE/THAW CELL VIABILITY L0 	 0%
- 10% LOSS FOR WATER RECLAMATION
r
- 360 DAY PRODUCTION CYCLE
a
o	 MARKET GOALS	 w
- ERYTHROPOIETIN 30% (1.3 x 109 UNITS)
- BETA CELLS 20% (1.9 x 10 11	CELLS)
- ANTIHEMOPHILIC FACTOR 30% (1.5 x 10 8 UNITS)
:w
^ 3 `	 i	
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doubling period for 21 days before restarting the culture. In growing cells that
generate protein as a product, it was assumed that the cells would have four pro-
duction periods, each of which would be 14 days, for a total of 56 days per cycle.
Ground rules made with respect to electrophoresis chamber performance are summa-
rized in Table 5.2-1. The sample flowrate for protein separation was assumed to
be 36 ml/hr at a resolution quality of 0.3 x 10 -4
 cm2/volt-sec. If it is found
in future work that this resolution quality is not sufficient, then the number of
chambers and the electrical power requirements changes will be inversely propor-
tional to the change in resolution quality. Sample flowrates for cell separation
were assumed to be 1 ml/hr. Allowable concentration of protein samples is ass^lmed
to be 10% (weight/volume) for space separation and 0.1% concentration for ground
separation at comparable resolution. The corresponding cell concentrations were
assumed to be 1 x 108
 cells/ml for space separation and a reduction to 1 x 106
cells/ml for ground separation at comparable resolution. The 10 6 cells/ml ground
limitation is the expected maximum concentration level that will allow sample
streaming and subsequent separation in a one-g environment. Cells, however, can
be readily concentrated to 108/ml without clumping and this concentration level
is expected to be the microgravity limit. The higher concentration estimated for
both cells and proteins is due to elimination of gravity effects on both buffer
flow and sample flow. In addition, it is expected that for proteins in particular,
higher allowable centerline temperature rise would allow doubling unit thickness
with a corresponding increase in throughput. In separation of cells for initial
culture the yield was reduced to 50% so that a corresponding increase in purity
could be obtained assuming a normal distribution of cells over the outlet tubes.
After culture, in subsequent electrophoresis, a wider fraction corresponding to a
90% yield was taken because of a predominance of the desired cell type.
These and other miscellaneous assumptions are presented in Table 5.2-1 including
those regarding transportation. Shuttle capacity was assumed to be 29,400 kg and
one kilogram of tankage was assumed for each kilogram of supplies, with the excep-
tion of the lightweight plastic bags for cryoprecipitate which have a mass ratio
of 0.6 kg/kg. The cell viability loss from the freeze/thaw cycle was assumed to
be 60% based on ASTP experience. Finally, in reclamation of water for space pro-
duction a 107. loss is assumed.
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ERYTHROPOIETIN MASS BALANCE.
R
Space - The mass balance for the production of erythropoietin (ESF) in space is
'
	
	
as shown in Figure 5.2-5. To satisfy 30% of the market for erythropoietin, 2.1 x
109 erythropoietin units are required per year. The number of high yield cells
required to produce this amount can be estimated based on ASTP MA-011 data (16).
r	 The highest yield fraction and subsequent subculture was 14-2 which produced 5g	 Y	 q	 p
units/nil after being on production media for 35 days. This subculture was grown
in a 25 cm  T-fla.K in 10 nil of medium. What is not known, however, is the period
of time that was actually required to reach 5 units/ml erythropoietin concentration
since intermediate data were not taken. Assuming that erythropoietin production
by the cells is inhibited by the concentration in the medium, then production
possibly could have taken only one day or as many as the entire thirty-five. For
purposes of sizing the system it was assumed that production required seven days.
With this assumption and an assumed cell density, equivalent to 3 x 10 4 cells/cm2
in monolayer on beads, we can estimate the erythropoietin production rate per cell
per day to be:
k	
5 Units/ml x 10 ml x Flask x	 cm 2	
= 9.52 x 106 Units
7 Days 	 Flask
	 25 cm 
	
3 x 104
 cells	 Cell-Day
and for 2.1 x 109 units we need 2.2 x 10 14 cell-days. Because cells must first
be cultured before production, production will not be continuous. It is assumed
that primary cells can be cultured, put on production for 14 days, and then most
of them discarded and the culture restarted. The cells would be restarted three
times, that is for a total of four production periods. Each restart from about
10% of the former population would require about 7 days to reach production. The
primary cell growth period would be 20 days however, because of the small inoculum
1	 obtained by cell electrophoresis. The resulting cycle is shown in Figure 5.2=6.
As shown, the entire production cycle is 97 days. One year would have 3 complete
cycles plus a partial cycle including 2 of the 14 day production periods, or a
`	 total of 196 production days. Therefore, the daily number of cells required is:
2.2 x 1014
 cell days =12
196 Production Days	 1.12 x 10	 cells
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At a cell density of 3 x 106 cells/nil the culture volume required is 375 which
would be divided into 3 tanks to provide a continuous electrophoresis. Initially,
these tasks would require 20 days to reach 3 x 106
 cells/nil of which 3 days is
for startup, therefore for a 35 hour doubling time the initia' inoculni is:
17 x 24 In 2
- ^--^—)
^ 1.123x 10
12 
)e	 = 1.16 x 108 cells
As the initial inoculuin should be at approximately 4 x 10  cells/nil, the initial
culture volume should be about 290 nil and provisions would have to be made for the
main culture tank and a 6 liter startup tank to have a volume variation of 20:1.
Since only about 7.6% of kidney cells are high producers of erythropoietin and 60%
are lost in the initial freeze/thaw cycle, 10% are lost in storage at 4°C, and
initial cell electrophoresis has a yield of 50%, the number of kidney cells
required is:
8
0.076 O.-4T
1. 1 6 	 1 0
0.9 0.5) = 8.48 x 10 9 Cells/Cycle
At 1 x 10 8
 cells/ml the electrophoresis time required is 84.8 hours or about 4
days. Now since there are 360/97 inocula required per tank per year, the total
kidney cells required for the initial electrophoretic separation are:
8.48 x 10 9
 x 360 x 3 = 9.4 x 1010 cells
And the yearly output of erythropoietin producing cells by the cell electrophore-
sis unit to inoculate the culture tanks is:
1.16 x 108 x 
36607 
x 3 = 1.29 x 10 9 cells
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The culture medium and the protein must be removed from the tank at the concentra-
tion limit so that the erythropoietin concentration in the medium is maintained at
5 units/ml. Since two out of three culture tanks will be in production at any
one time there will be 213 x 1.12 x 10 12 cells producing erythropoietin and the
production rate will be:
2	 12	 6 units	 6 units
^-	 x 1.12 x 10 cells x 9.52 x 10" cell-day- — 	 = 7.108 x 10
_cTa _y
N x
t^ At 5 units/ml the required flow is 1422 liters/day. This medium flow has about
0.7% by weight protein solids, most of which is the protein of the fetal calf
serum used as nutrient. Therefore, to concentrate this medium to 10% protein by
mass, the concentration outflow needs to be:
0.7% x 1422 liters = 100 liters
10%	 day	 day
Since each electrophoresis chamber is assumed to have a throughput of 36 ml/hr
the number of electrophoresis chambers required is:
l00 liters x hr-chamber x daY
-
 - 115 chambersday	 66 liter - 24 tr -
,; r
The water recycled directly to the culture. is 1422 kg/day minus 100 kg/day or 1322
l	 kg/day. Of the 100 kg/day undergoing electrophoresis, there is 10 kg/day lost
and 80 kg/day of water recovered. About 10 kg of solids contain erythropoietin,
3i
most of which is waste. To support the level of tissue culture required it is
estimated that 8160 kg of nutrients, 6 kg of oxygen, and 4750 kg of H 2
 are
required, for a total of 12,900 kg of supplies and a like amount of tankage.
.	
Together these masses constitute about 0.88 of a Shuttle payload capability.
ti
w:
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Ground - The mass balance for the ground production of erythropoietin (ESF) is as
shown in Figure 5.2-7.
	
The mass balance is for the production of 2.1 x 10 9 ESF
units per year, satisfying 30% of the potential market. 	 This amount requires the
same 2.2 x 1014 cell-days of production calculated for the space mass balance.
The production cycle derived for space operations would also be used for ground
production.	 The principal difference between ground and space production is in
the throughput for cell
	
and protein electrophoresis.
	
For space electrophoresis
of cells the input stream can be concentrated to about 1 x 108 cells/ml, which
is somewhat below actual 	 limits of physical
	
packing for typical 	 cell	 sizes.	 The j
limiting concentration for cell electrophoresis on the ground is approximately
two orders of magnitude lower or 1 x 10 6 cells/ml, for comparable separation
quality.	 Another difference between the ground and space mass balance is that
the 60% loss estimated for freezing and thawing of cells can be eliminated.
Therefore the total	 number of kidney cells required per cycle is not the 8.48 x
109
 cells required for space production, but 40% of that number or 3.4 x 109
cells.	 For the same cell electrophoresis time used during space production (84.8 .'
hours), the number of comparable electrophoresis chambers required at a volumetric
throughput of 1 ml/hour is:
1	 l	 3.4x109cells
1	 ml	 x 84.8 hr
	 x	 1 x 10b cells	 = 40 chambers
hr-unit
	 ml
This says that forty times as many chambers are required to obtain the same output
of viable cells on the ground.
An even larger increase in the number of electrophoresis units occurs in the sepa-
ration of erythropoietin from production media. For the space production case the
medium, which contained about 0.7% protein solids by weight corresponding to 10%
fetal calf serum by volume, was concentrated to 10% protein by weight. For ground
electrophoresis the practical limit for protein concentration is about 0.1% by
weight, therefore, the medium must undergo a 7:1 dilution before electrophoresis.
Just as for the production in space, the required outflow of medium to limit the
concentration to 5 units/ml is 1422 liters/day. For ground production then the
electrophoresis input rate including the 7:1 dilution is:
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0.7% x 1422 Liters - 9954 Liters
T-T^	 may	 Day
Since the protein throughput of the space electrophoresis chamber was estimated to
be 36 ml/hr and the space chamber was double the thickness of the ground chamber,
the corresponding ground chamber throughput would be 18 ml/hr. At 18 ml/hr the
required number of electrophoresis units would be:
9954 Liters x	 Hr	
x Da
	
- 23042 Chambers
	
Fa - 0:018 Liter
	 -
Similarly, to support the required level of tissue culture, the same amount of
nutrients are required for tissue culture, however water reclaimation is not
necessary because of ready availability.
Space/Ground - A combination of space/ground production of erythropoietin is
illustrated by the mass balance shown in Figure 5.2-8. Because the principal
advantage of microgravity is the increased cell and protein electrophoresis
throughput, and tissue culture in space requires transportation of nutrients, it
is expected to be more desirable than either all-space or all-ground production.
As illustrated by the figure, the transportation involved causes production to be
a serial process consisting of cell electrophoresis in space, cell culture and
production medium lyophilization on the ground, and protein eiectrophresis in
space. Mission duration for the space proteins were selected to be representative
of possible Shuttle on orbit operations, with a seven day period of cell electro-
phoresis and a longer, 30 day, period for protein electrophoresis, to minimize the
number of chambers required.
The time remaining for tissue culture is 328 days and it was assumed that three
tissue culture tanks would be used to obtain approximately constant input to the
lyophilizer, with two tanks on production most of the time. Because initial
startup would be staggered at 7 day intervals, the last-tank-started cycle would
have 328 days minus 14 days or 314 days. Therefore, in all cases, there would be
3 complete 97 day production cycles. The remaining 23 days could then be appor-
tioned for the ground logistics associated with the two Shuttle flights. Since
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this cell production cycle has only 168 days, c (mipared to 196 days for all space
production, size of the culture tanks will have to be increased accordingly. As
for space production 2.2 x 10 14 cell-days of production are required and the
number of cells per tank is:
2.2 x 1014
 cell days 
= 1.3 x 10 12 cells168 production days
And at a cell density of 3 x 106 cells/ml the culture volume required is 433
liters, which divided into 3 tanks is 144 liters per tank. Initially these tanks
would require 20 days to reach 3 x 106 cells/ml of which 3 days is for startup,
therefore for a 35 hour doubling time the initial inoculum is:
12
X17 x 24
)
1n 2
-r-( 1-- 3	 ^-3 1^ ) e
	
= 1.34 x 108
 cells
As the initial inoculum should be at approximately 4 x 10  cells/ml, the initial
culture volume should be about 335 nil and provisions would have to be made for a
main culture tank and a 7 liter startup tank with a volume variation capability of
about 20:1. Since only 7.6% of kidney cells are high producers of erythropoietin
and there are two freeze/thaw cycles with a loss of about 60% each, in addition to
10% storage loss at 4°C, the number of kidney cells required including a 50% high
resolution electrophoresis yield is:
1.34 x 108	10 cel ls(.076)(0.4)(0.4)(0-9)(0.5) - 2.45 x 10	 cycles
At 1 x 108 cells/ml and l ml/hr the chamber time required is 245 hours, which
exceeds the desired 7 day mission. Therefore about 1.46 units are required to
compress the time to 7 days. In addition, there are 3 production cycles per tank
and 3 tanks. Therefore, the total number of cell electrophoresis chambers
required is:
1.46 Chambers x 3 Cycles x 3 Tanks = 14 ChambersCycle	 Year
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The effect of reducing the number of days available for product electrophoresis
due to the serial nature of space/ground production is to increase the number of
chambers required. Space production required 115 chambers operating for 284
production days or 32660 chamber-days. To do the same amount of separation in 30
days, the number of chambers would be:
32660 Chamber Da y _
s - 1089 Chambers
Days
_, r
The amount of nutrients required for ground tissue culture is the same as for
space culture, except that water is not reclaimed.
Comparison - Comparison of space production, ground production, and the space/
ground combination is presented in Figure 5.2-9. The basis for comparison is
ground production which would require 23,042 electrophoresis chambers to produce
;f
µ
	
	 enough erythropoietin for 100 of the potential market. For space production, only
115 chambers would be required, but 26,300 kg of supplies and tankage would have
to be transported. At a cost of $100/kg, the transportation cost would be $18.7M.
The elimination of 22,927 chambers, with all the complexity, power consumption,
and buffer loss makes all space production a better choice. However, the best
choice is probably the space/ground combination, in which 974 more chambers are
required with the same buffer loss and power consumption, but the added complexity
of tissue culture in space is eliminated. In this case transportation of nutrients
is eliminated in favor of lyophilized protein reducing transportation cost to
$8.2M for 11,300 kg of supplies and tankage. That the space/ground combination is
the best choice is even more clear, if the electrophoresis operation is made to be
continuous over a multi-year period. Then the number of electrophoresis chambers
required would be substantially reduced and be comparable to the space production
r
case.
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AHF (CRYOPRECIPITATE) MASS BALANCE
Cryoprecipitate is a serum product obtained by freezing whole serum and collecting
the precipitate which fails to redissolve when the serum is allowed to thaw ato.4 C. One pint of serum yields about 2 to 3 ml of material termed cryoprecipitate.
This 2 to 3 nil contains approximately 125 units of AFH VIII activity (about 50
units/ml), and about 550 mg of total protein solids in addition to AHF. A typical
analysis of this variable product shows these solids consist of Fibrinogen (31.8%),
Albumin (6.8%), alpha globulin (0.9%), beta globulin (30.5%), gamma globulin
(20.9%) and unidentified material (10%).
Separation of factor VIII from the other impurities consists of dissolving the
cryoprecipitate in an appropriate buffer and processing it through a continuous
free-flow electrophoresis unit. The concentration of protein solids can be
greater during space electrophoresis due to the microgravity environment. For the
purpose of comparing a ground vs space separation we have chosen 0.1% protein con-
centration limit for ground separation and 10% concentration for space separation.
Two cases are described, one in which cryoprecipitate is separated on the ground to
yield 18 grams of AHF and the other to yield the same amount by processing in
space. Both processes are based on a period of 360 days. By-products are also
considered as they make up the bulk of the starting material. The starting
material is 3000 kg of cryoprecipitate in both cases.
Space Process - The cryoprecipitate space process is shown in Figure 5.2-10.
Frozen cryoprecipitate is flown to the facility via Shuttle where it is thawed,
diluted 1:1 with buffer and electrophoretically separated at a rate of 36 nil/hour.
The 3000 kg of product can be processed at a rate of .300 ,0 k9/360 days or 8.33 kg
per day. With 8.33 kg buffer added per day this requires processing 16.7 kg day
through the electrophoresis separation or at 36 ml/.hour the number of electropho-
resis chambers is:
^j	 16.7kg/day x l kgml x 360 day
Electrophoresis Chambers =
	
	
= 19.3
24 hr36 ml/hr x day x 360 day
<.
Y
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1
or about 20 electrophoresis chambers designed to operate at 36 wl/hr sample
throughput. During this process the cryoprecipitate is separated into 6 individual
fractions containing factor VIII, Fibrinogen, Albumin, Alpha globulin, Beta globu-
lin, and Gamma globulin. These materials are passed through a membrane concentra-
tor where most of the water is reclaimed for processing.
For this process, since cryoprecipitate is diluted 1:1 with buffer, a total of 3000
kg of buffer is required to process 3000 kg of cryoprecipitate. A portion of this
can be claimed from the cyroprecipitate since it contains 78% water. Thus, 3000
x 0.78 or 2340 kg can be reclaimed. Assuming a 10% loss of water during reclama-
tion, a total of 2340 minus 234 or 2106 kg is reclaimed. Thus, 3000 minus 2106 or
894 kg of water are required to be shipped and held in reserve for processing. At
a process rate of 16.7 kg/day, we lose 1.5 kg/day of water and reclaim 13.3 kg/day,
which is returned to the reservoir for further usage. The concentration materials
are then lyophilized and returned to earth. During the lyophilization process,
final traces of moisture are removed and this water is returned to the reservoir
for reuse. This process requires the transport of 3000 kg cryoprecipitate, 894 kg
H2O, 894 kg tankage and 1800 kg of cryoprecipitate containers, or 6588 kg total
transport weight. At $700/kg this equals a transportation cost of $700 x 6588 =
$4.6M.
The amount of 18 grams of AHF VIII obtained will supply 30% of the total market
for this product. The selling price of 11¢/AHF unit provides an AHF value of
$16.57F. By-product values were determined from current catalog prices for
research grade materials. By-product quantities were determined from the results
of a single MDAC experiment. If these by-products were upgraded to injectables,
the value would be substantially increased.
Ground - There are two major differences between separation of cryoprecipitate
products on the ground as opposed to space processing. One of these is the size of
the ground electrophoresis compared to that of the space chamber. The ground
chamber is 112 the thickness of the space unit and thus has a throughput of 1/2
that obtained in space. We are assuming that a 10% sample concentration can be
processed in space compared to a 0.1% concentration on the ground. The process
for the ground separation is shown in Figure 5.2-11.
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As with space processing, 3000 kg of cryoprecipitate is used as the starting mate-
I!	 rial. However, instead of diluting the sample at a ratio of 3000 kg cryoprecipi-
tate to 3000 kg of water, which results in a protein concentration of about 10%
separation, the dilution ratio is 3000 kg cryoprecipitate to 600,000 kg of water
to give a concentration of about 0.1% protein for ground separation.
The number of electrophoresis chambers required to process this volume is:
600,000 Liters
	 1	 1
0.018 Liters/Hr x -^ x	 3877.3 Chambers
or about 3878 electrophoresis chambers.
As i t
h
e process ing , t	 cryoprec ipit ated	 o6	 fractionsn h s pace 	 he 	 is separate int 	major fra ^ ns
{	 of which the 18 gram yield of cryoprecipitate supplies 30% of the total market.
8y-product values are also as defined in the space process.
Comparison - Ground production of 18 grams of OF would require 3878 electrophore-
sis chambers. For space production 20 chambers would be required, but 6588 kg of
}	 supplies and tankage would have to be transported, At a cost of $700/kg, the
transportation cost would be $4.6M. The elimination of 3858 chambers, with all
u`	
the complexity, power consumption and buffer loss may make space a better choice
for AHF purification. An important driver may be the necessity for high purity OF
since higher purity can be obtained in space than on the ground. This considera-
tion was not made in the analysis but should be considered in future efforts. Fig-
ure 5.2-12 illustrates the comparison.
it
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BETA CELL PURIFICATION FROM PANCREAS HOMOGENATE
Three cases are treated for Beta Cell purification. They are 1) space culture and
space electrophoresis, 2) ground culture and space electrophoresis, and 3) ground
culture and ground electrophoresis. Each process is to require a one year (360
day) period.
In all cases a pancreas is minced, and the cells titered and suspended in a suit-
able buffer at the appropriate concentration for each process. Cell inoculum is
about 4.4 x 10 5 cell per ml of growth medium and the cell population, when pro-
duction cycles begin, is assumed to be about 3.0 x 10 6 cells/ml.
In each case cells undergo a lag period of about 3 days followed by logarithmic
growth, at which time the cell population doubles every 35 hours. 	 Once in the
production phase, cells are harvested by removing 50% of the culture fluid every
35 hours and replacing the fluid with fresh nutrients and returned medium.
Nutrients are replaced at a rate of 0.02 gm/ml/day. All cell cycles consist of a
7 day growth cycle and 21 days of production. At the end of the production cycle,
F	 the culture vessel is voided to about the original inoculum volume and those
remaining cells are used as a fresh inoculum to start a new culture.
c
In case #l, a total of 12.8 such cycles is used, for (12.8 x 21) = 269 production
days. For case #2, 12 cycles of (12 x 21) = 252 production days are required.
'a
Sample flow rates used in the electrophoresis unit are assumed to be the same for
earth and space, 1 ml/hour; cell concentration used for the electrophoretic process
is l x 108
 /ml in space and l x 106 /ml on the ground. The higher concentration
separable in space is the gain due to the microgravity environment.
Beta cells will undergo two electrophoresis steps regardless of the particular
process. Cell yields from the first electrophoresis are assumed to be 50% and
that from the final electrophoresis is assumed 90%.
' Cell loss due to freezing and thawing is considered to be 60%, and water lost
during the process is assumed to be 10%. The cost of space transportation is
computed at $700 per kilogram.
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pace Culture and Space Electrophoresis - For space culture of Beta cells, the
pancreas cells are suspended in buffer at a concentration of about 1.0 x 108 cells/
ml of buffer, frozen and transported to the space facility via Shuttle. This pro-
cess is shown in Figure 5.2-13 where 6.8 x 10 9 cells are processed through the
separator. On thawing, only 40%, or 2.72 x 10 9 cells remain viable. This suspen-
sion of both live and dead cells are processed through the electrophoresis unit at
the rate of 1 ml/hour requiring:
68 n!1	
= 2.83 Days1 nil/hr x 24 hr/day
or about 3 days process time.
Only 7.5% of the total pancreas cells are Beta cells and only 507. are recovered
by this first electrophoretic process. Therefore the yield of cells after the
first electrophoresis process will be
2.72 x 10 9 Viable Cells x 0.075 Beta Cells x 0.5 Loss =
1.02 x 108
 Purified Beta Cells
This amount of cells is inoculated into 231 ml of tissue culture medium in a vessel
with a maximum capacity of 1900 ml at a concentration of 4.4 x 10 5 cells/ml.	 In
7 days, growth will have occurred through the lag and logarithmic phases and a cell
concentration of about 1.5 x 10 6 cells/ml will have been obtained. During this
period the culture volume will have been increased periodically to the production
volume of 1900 ml. In another 35 hours the cells will again double, to 3.0 x 106
cells/nil, at which time 50% of the cells can be harvested every 35 hours and the
volume replaced with fresh nutrients and returned medium. This culture cycle is
shown in Figure 5.3-14.
Thus,
1900 nil x 0.5 Volume Removed x (3 x 10 6
 cells/ml)
2.85 x 109 cells/35 hour, or
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2.85 x 109
 x 24 = 19.5 x 109 Cells/Day
in a volume of
1900 x 7 x 0.5 = 651 nil/day
These cells are concentrated to 1 x 10 8 cells/ml for electrophoresis, resulting
in a volume of:
1.9 x 109 
= 19.5 ml/day
1 x 108
to be processed through the electrophoresis unit. A total of 1.95 x 10 9 x 269
production days = 5.2 x 10 11 cells must be processed per year. At a process rate
of 1 ml/hour per electrophoresis chamber, a single chamber will process these
cells in:
5.2 x 10 11 cells	
= 269 Days
19.5 ml/day x 1 x 108
 cells/ml
or 12.8 (7-21 day) cycles. The number of electrophoresis chambers required for
space electrophoresis is,
5.2 x 10 11
 cells	 1	 1	 1	 _
1 x 108
 cells/ml x 1 ml/hr/chamber 
x 
269 day x 24 hr/day 0.8
thus, a single unit can process all the required cells.
A 10% loss of cells is incurred during electrophoresis and an additional 60% loss
is incurred during the freezing process for their return to earth; thus the net
yield of cells is
5.2 x 1011 x 40 x 9 0 = 1.88 x 1011 Cells
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at a rate of 3 x 10 5 cells per dose this represents about 630,000 doses or about
20% or the market.
During this cell harvesting and concentration procedure a portion of water is lost
and a portion is returned. Removal of cells at the rate of 50% of the latest 1900
ml, or 950 ml every 35 hours equates to,
950 ml x F = 651 ml/day
Of this volume 19.5 ml per day are lost since they are run through the electropho-
resis unit. An additional 1M or 65 ml are not returnable due to unavoidable
losses, leaving 562 ml/day to be returned to the tissue culture vessel. This
medium is then mixed with fresh nutrients and returned therein.
In addition to water and nutrients, other materials required for maintaining the
culture system include oxygen and carbon dioxide and sodium hydroxide for pH
control. During the entire culture period the following amounts of materials are
estimated to be required: Nutrients, (11.6 kg); oxygen, (2.53 kg); carbon dioxide
(2.7 kg) and sodium hydroxide, (0.27 kg).
Each day 651 ml of water is removed from the tissue culture vessel of which only
562 can be returned; thus (651-562) =-amount per day which must be returned. This
equals (651-562) x 269 = 23,941 ml or 23,.9 kg. Initial charging of the system will
require an additional 7.2 kg. This water, nutrient and additional culture mate-
rials constitute a total weight of 11.6 + 2.53 + 2.7 + 0.27 + 23.9 + 7.2 = 48.2 kg
at a cost of $700/kg, and assuming a 1/1 ratio for tankage the transportation costs
equal $700 (48.2 x 2) = $67,480.
Ground Culture/Ground Electrophoresis - Ground culture and electrophoresis of Beta
cells requires a starting concentration of 2.3 x 10 9 cells in 2300 ml of buffer.
The 'cell concentration, (1 x 10 6 cells/ml) is two orders of magnitude lower than
that processed in space due to the gravity effects. This concentrate is electro-
phoresed at a rate of 1 ml/hr. Assuming a 24 day Shuttle process time would
require:
°z
.	 r
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2.36x IO	
x 1 ml/hr/chamber X	 day X 
2^ - 3.9 Chambers
1 x 10 cells/ml
Using four chambers, this can be accomplished in 24 days.
Of the 2.3 x 109 cells electrophoresed, 7.5% or 1.7 x 108 are Beta cells and 50%
or 8.8 x 10 7 are recovered after the first electrophoresis. These are used to
inoculate 200 ml of c0 ture fluid contained in as 800 ml tank. The cells will
attain a concentration of about 1.5 x 10 6 cells/ml on day 6, and after 35 more
hours will attain a concentration of 3.0 x 10 6 cells/ml at which time the produc-
tion cycle begins. At this point 50% of the total volume, or about 3.0 x 106
cells/ml x 400 ml = 1.2 x 10 9 cells every 35 hours. This equates to 1.2 x 10 9 x
24/35 or about 8.2 x 10 8 cells/day.
For 12 (7-21 day) cycles this provides 252 days x 8.2 x 10 8 cells/day = 2.1 x 1011
total cells for separation by electrophoresis. These cells are adjusted to a con-
centration of 1 x 10 6 cells/ml. The number of chambers required to separate
these cells is,
2.06 x 10 11	 1	 1	 I
1 x 106	 x 1 ml/hr/chamber x 336 days x 24 hr/day = 26.04
or 27 chambers to process the cells. During this process 10% of the cell are lost
resulting in a net yield of 2.06 x 10 11 x .9 = 1.85 x 10 11 cells. At a rate of
3 x 105 cells per dose this equals 630,000 doses or about 20% of the market. This
evaluation is shown in Figure 5.2-15.
Ground Culture and.Space Electrophoresis - Pancreas cells are suspended at a con-
centration of 3.6 x 10 10 cells in 360 ml of buffer, frozen and transported to
space via the Shuttle. The process is shown in Figure 5.2-16. On thawing, 40% or
1.44 x 1010 cells/360 ml remain viable. This suspension of both dead and live
cells are processed through the electrophoresis unit at a rate of 1 ml/hour,
requiring:
360 ml
	
= 15 Days
1 ml/hr x 24 hr/day
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Using 3 electrophoresis chambers this process is completed in 5 days. Only 7.5%
of the 1.44 x 10 10
 cells are Beta cells and only 50% recovery is anticipated from
this first electrophoresis process. Therefore, the yield of cells after the first
electrophoresis will be:
1.44 x 10 10 Viable Cells x 0.075 Beta Cells x 0.5 Loss =
5.4 x 108
 Beta Cells
another 60% is lost when the cells are frozen for transport to the ground and
rethawed; thus:
5.4 x 108
 Cells x 4-00 = 2.2 x 108 Cell Yield
This 2.2 x 108
 cells is used to inoculate 500 ml of tissue culture medium in a
vessel with maximum capacity of 5094 ml at a concentration of 4.4 x 10 5
 cells/ml.
In 6 days, growth will have occurred through the lag and logarithmic phases and a
cell concentration of about 1.7 x 10 6
 cells per ml will have been attained.
During this period the culture volume will be increased periodically to the
production volume, 5094 ml.
In another 35 hours the cells will again double, to 3.0 x 10 6
 cells per ml, at
which time 50% of the cells can be harvested every 35 hours and the volume ;-eplaced
with fresh nutrients in returned medium.
Thus :
5094 ml x 0.5 Volume Removed x (3 x 106
 cells/ml)
7.64 x 109
 cells/35 fir period
or
x 7.64 x 10 9 = 5.24 x 109
 cells/day
as
in a volume of 24/35 x 5094 x 0.5 	 1746 ml/day.
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These cells are concentrated to 1.0 x 10 8 cells/ml or a volume of 52.4 ml/day,
frozen and transported to space for electrophoresis.
A total of 5.24 x 10 9
 x 252 production days = 1.32 x 1012 cells which must be
processed each year. To process this number requires:
' 1.32 x 10
12
 cells	 1	 1	 1
1 x 108
 cell:.'ml x 
1 ml/hr/chamber x 24 hr/day x 18 days = 30.6
Thus, 31 chambers are required to process the 1.32 x 10 12 cells. Sixty percent of
the cells lose their viability during the freeze/thaw cycle and an additional 10%
-	 are lost during electrophoresis. The yield from electrophoresis is thus:
Yield = 1.32 x 10 12 x 0.4 x 0.9 = 4.75 x 1011
 Cells
These cells are frozen and transported to earth for transplantation. During this
process an additional 600 loss is incurred due to freezing, leaving a net yield of
4.75 x 1011 x 0.4 = 1.9 x 10 11 total cells. At a rate of 3 x 10 5
 cells/dose this
represents about 630,000 doses or about 20% of the market.
Transportation costs for this ground/space combination include the original
pancreas, and taking up the ground-processed cells. These weights, respectively,
are .36 kg and 132 kg or about 132.36 kg total. With tankage, a total of 265 kg
r	 is required and at $700/kg: 700 x 265 or $185,500 total transportation cost.
The cost for nutrients for the ground culturing is about $3,489 for a total of
about $189,000.
Comparison - The least expensive process is the all ground process in which 4 cham-
bers are required and no transportation costs are incurred. However, it is not
likely that cells separated on the ground will be as pure as those separated in the
space environment since better resolution can be obtained in the microgravity.
r'.
4
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If purity is a requirement, then the ground/space process seems more advantageous
since the space environment will be utilized to obtain higher purity. The costs
of transportation may be negligible when compared to the benefits obtained from
being able to process high purity cells. A disadvantage of the ground/space pro-
cess is the number of chambers, 31, which must be used. The higher number is
required since the space electrophoresis must be conducted in a shorter period of
time, 18 days, than the ground process. This is required to provide only a single
space transportation of the cells instead of several Shuttle launches spread
throughout the year. With these considerations, even wif-, the added transportation
costs it appears beneficial to employ a total space proce:;;, thus eliminating all
but one chamber and yet providing high purity cells for use on the ground. Figure
5.2-17 illustrates the comparison.
Summary Evaluation
A comparison of space production with alternative ground production or combinations
is shown in Figure 5.2-17. For antihemophilic factor separations from cryoprecipi-
tate, the advantages of space separation are obvious. For a transportation cost
differential of $3.47M, the complexity and cost of 3878 chambers is reduced to that
of 20 chambers in space. This cost is a?so a relatively small fraction of the $257M
value of the separated products. For beta cells, the product value is much higher
at $1007M, based on equivalent insulin injections; however, the amount of product
and the scale of the process is smaller. Again, there is a large reduction in
electrophoresis chambers required favoring space processing. For ESF production
the small amount of product in the culture media required both large scale cell
culture and electrophoresis. The large scale favors ground culture; however, the
large number of chambers (23,042) required for ground separation favors a space
separation/ground culture combination. Erythropoietin process requirements make
it much less desirable as a product for the multiproduct system than either beta
cells or antihemophilic factor.
5.3 MULTIPRODUCT PROCESS SYSTEM DESCRIPTION
System Requirements - The basic requirement for the multiproduct process system
is the ability to produce the three selected candidate products: erythropoietin,
beta cells, and antihemophilic factor VIII. The system mass flows required to
produce the desired market shares for each product were presented in Section 5.2.3.
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Based on the space transportation requirements and a comparison with ground opera-
tions, it was determined that, generally, cell and protein separations should be
space operations. Whether tissue culture should be a space operation was found to
be dependent on the product. If the product is the cells being cultured, as in the
case of beta cells, then the reasonable transportation requirements make it advan-
tageous to culture in space, because the cell separations to get the starting
nocula and to separate the products are best done in space. If the product is
small amounts of protein from the cells in the culture media, as in the case of
erythropoietin, then the excessive transportation requirements make ground culture
followed by space electrophoresis of reconstituted, lyophilized media more advan-
tageous. However, because of the excessive separation requirements along with many
technical unknowns, erythropoietin is not included in the requirements for a multi-
product processing system at this time. The resulting system capabilities are
heavily biased toward electrophoretic separatiDn, but include tissue culture capa-
bility to the extent required for the culturing of cells as products, or limited
investigation of protein production from tissue culture.
System Description - A schematic of the system is shown in Figure 5.3-1. Produc-
tion of beta cells by tissue culture takes place in a 2 liter culture vessel.
The culture is supplied with the required oxygen and carbon dioxide based on
partial pressures sensed by the controllers. Medium pH is controlled by the addi-
tion of sodium hydroxide. Nutrients are stored dry in appropriate proportions for
growth and production media and are mixed and supplied as required. To start the
culture, the desired cells are separated by electrophoresis and maintained at low
temperature (_<4%) in a startup tank until the initial inoculum is collected. The
inoculum is then introduced into a small amount of growth medium in the culture
tank, maintained at approximately 37% and the volume of medium gradually increased
as the cells multiply. When the cells have reached the desired concentration, the
cells and medium are passed through a membrane concentrator. By returning most of
the medium and none of the cells to the culture, the concentrator increases cell
concentration to about 108
 cells per ml to maximize the cell throughput of the
electrophoresis chamber. At this point it may be necessary to perform counter
current ion exchange to remove nutrient salts from the cell sample to ensure proper
electrophoresis unit performance. Temperature of the fluid is maintained at < 4°C.
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After separation, the output fraction is analyzed to ascertain that the desired
cells were obtained and these cells are then frozen at a controlled rate and
placed in a freezer at <-20°C for storage. Cell growth and separation can only
continue for a few weeks and then the culture must be restarted. To restart the
culture most of the cells and culture medium are removed along with the accumulated
waste, and fresh nutrient medium is added. Then after the cells have multiplied
to the desired concentration they once again can be separated.
Protein separation is accomplished in 20 electrophoresis chambers with a through-
put of 36 ml/hr, each. One important aspect of this space operation is that
buffer reclamation is required to maintain the space operating advantage. To
reclaim the buffer, the cell or protein waste is filtered out and the fluid is
passed through ion exchange and organic columns. The clarified fluid is then
tested for conductivity and used along with makeup water to make the required
buffer. The buffering components are stored dry and are added in buffer mixing
tanks. The desired output fractions are then concentrated by removal of excess
buffer and the fractions are lyophilized (freeze dried) for storage at < 20°C.
System Protocols - Each of the three selected products exercise the system in a
different mode, i.e. - AHF as a protein electrophoretic separation system, beta
cells as a tissue culture and cell electrophoretic system and erythropoietin as a
tissue culture, cell and protein electrophoresis system. The specific protocols
for space production of the three products will be found in Appendix C. Each
protocol defines in general terms the preflight and inflight operations required.
to produce the products.
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6.0 INTRODUCTION
During this study a number of lessons have been learned about obtaining and foster-
ing commercial producer participation in studies of space processing. These
should be given due consideration in formulating plans for future studies of this 	 F
nature. They are presented here in brief, and MDAC-St. Louis recommends that they
l
be adopted as elements in the NASA model for exploring other market sectors con- 	 ,.
R
sidered for the commercialization of space.
6.1 INVOLVING PRODUCER COMPANIES
L . The key to involving industry in space processing is to establish a fully business-
like footing for their participation. In most cases, the producer industry is
relatively unfamiliar with the space environment, operations in space and the
requirements and techniques of designing and integrating systems hardware to be
flown in space missions. Dealing directly with NASA would involve them in a new
form of governmental interface to which they are not accustomed.
The "Buffer Team"
In this situation, a "buffer" organization is needed to serve as the interface
'.	 between NASA and the segment of industry NASA desires to interest. Aerospace
companies are in a particularly good position to serve in this buffer capacity.
By establishing a buffer team between itself and the industry with which it
desires to build participatory agreements, NASA can establish the businessman-to-
businessman relationship so essential to nuturing commercial enterprise in space.
By this approach, NASA was free to stand aside while, in the present instance,
MDAC-St. Louis engaged and fostered the interest of pharmaceutical firms on a
Pstrictly business basis. MDAC demonstrated its own willingness to commit to space
processing, thereby encouraging pharmaceutical concerns to make proportionate
commitments to their potential future mutual benefit. As this approach applies in
the pharmaceutical field, so it should apply in many other industries.
The aerospace company chosen for the buffer team should have established a compe-
tence in dealing with the particular process NASA wishes to advance as a candidate
for production operations in space. Moreover, the company should have made a
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significant commitment on its own, in terms of funds and manpower, to the develop-
ment of that process before NASA chooses that firm to serve as the buffer team.
Only if the aerospace company has made a real management commitment to the particu-
lar process and products of interest, can it convince candidate participating
producer firms of the potential for timely returns on their investments.
The buffer team should also include an independent business analysis firm special-
izing in the particular industry to be approached. Most aerospace companies do
not possess the personnel and experience, in a marketing area other than their
own, to identify good prospective cooperating firms or perform the business
analysis required in preparing to contact them. The right business analysis firm
(such as price Waterhouse Company vis-a-vis pharmaceuticals) not only knows the
industries of interest, but is familiar with the particular environment in which
the producers operate. It has access to business documentation resources beyond
the aerospace horizon; and, most importantly, such a firm will know key management
and technical personnel of these companies plus the correct business basis on
which to approach them.
By choosing an aerospace company with a business commitment to both a particular
process and class of products for space production and then linking to that
company a First class business analysis firm specializing in business relations
among producers and marketers of the products of interest, NASA will create the
strongest possible team to establish a business basis on which producer industries
may be induced to participate in space processing development.
Candidate Company Selection
The producer firms identified by the buffer team should be subjected to a pene-
trating business analysis by the business consultant member of the team. This
analysis should include such factors as: the firm's annual sales and growth; the
size of the company; the new products it has marketed; the tenure of the firm's
senior officers; the surplus funds available for investment; the size of the
firm's R&D budget; and the identifiable constraints on the firm's growth. I n
addition, there will be factors requiring evaluation which are peculiar to the
specific class of industry being approached.
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Choosing the companies to be contacted will involve weighing a variety of these
factors. Here too, the business consultant member of the team will be of particu-
lar assistance. During the assessment of each candidate firm a number of weighting
	
}	 considerations have evolved. Companies demonstrating a relatively stable rate of
growth will seek out new methods to retain it. Both small and large companies are
more willing to take risks than medium size companies, because the former must be
more agressive to succeed and the latter have more capital for expansion. The
number of new products ,laced on the market and the size of a company's R&D budget
are indications of its creativity and commitment to innovation. In the area of
personnel, the position tenure of senior officers is also a measure of innovative-
	
T	 ness; if these officials are changed frequently they will be less likely to make
affirmative decisions involving risks of long range returns. As a final example,
	
T	 case must be taken to identify any constraints to growth for each company. In
some instances we have found that company research was directed toward only one
specific product or that a specific product was absorbing most of the development
	
-	 budget. Growth potential, based on a company's willingness to look at new ideas
or risk investment in new processes, is minimized in such cases.
Prepresentation Preparations
	
A	 Once the companies to be contacted have been chosen, the contacts should begin
with an introductory letter transmitted at the corporate level. Corporate involve-
ment in the first contact is essential to assure that the producer company will
recognize the established commitment of the "buffer" company (e.g., MDAC-St. Louis)
to space processing and will respond by poviding'a management level audience. In
	
T	 follow-up telephone calls, arrangements should be made for a formal presentation
at the producer's own facility. The audience will be more at ease on their "home
ground", and it will give them the option of bringing in additional company person-
nel as the need arises during the presentation. Plenty of time should be allowed
1	 for the company being visited to complete a pre-meeting investigation of the
"presenting company" to determine the presentor's technical and business interests,
level of commitment and degree of competence.
Having made contact with the producer companies and established a degree of
rapport with their business or technical management, the presenting company should
tailor each presentation to the interests of the key people in each producer
	
.:	 company, i.e., the corporate decision makers and senior technical personnel.
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Presentation Team
A number of personnel and technical characteristics are highly desirable for the
presentation team. Personnel making the presentation should be thoroughly famil-
iarized with the segment of industry they will be visiting; at least one member of
the team should have credible experience in that producer industry. All members
of the team should be prepared to speak the vocabulary distinct to that industrial
field of endeavor.
The presentation team should be a systems team that is capable of addressing all
aspects of space processing to the audience's satisfaction. Not only must they be
knowledgeable in the area of products and processes, but also familiar with space
flight systems and how day to day activities in space are carried out. They must
be thoroughly prepared, as well, to discuss resource requirements, costs and
manpower, and schedules. Inclusion of a life sciences specialist in the team is
highly desirable so that questions on man's contributions and requirements in
space can be answered.
Presentation Approach
The presentation approach should reflect the businessman-to-businessman relation-
ship desired between the buffer team and the manufacturing firm. MDAC-St. Louis'
experience in this study illustrates this. Pharmaceutical firms, for example, are
reluctant to become involved with government R&D funding; they desire to avoid any
potential compromise of their patent right which might arise through such an
involvement. Moreover, in a high risk venture such as commercial space processing,
they desire a "buffer" industry that is familiar with space systems and operations
as well as drug company operation. They are unfamiliar with the space environment
and usually do not claim the engineering talent and diversity sufficient to make
space experimentation worthwhile on their own. Finally, they would prefer not to
add to their existing government interfaces.
Since the aerospace industry possesses the requisite engineering talent and the
experience of working within the NASA administrative framework, they can serve
very well in this "buffer" capacity. By the same reasoning, the aerospace industry
is usually not familiar with the government regulatory agencies for the participat-
ing industry, e.g., the Food and Drug Administration for the pharmaceutical
industry. In this situation, the presentation approach should reflect that a
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r.,	 joint working arrangement between the visited company and the aerospace industry 	 k
would be mutually beneficial using the strengths of each partner to achieve new
goals.
During the presentation, the question is invariably asked of the precentor, "Why
should we manufacturers be interested in space processing?" Placing a good reason
for their interest early in the presentation can forestall the inquiry. The
reason can easily be developed identifying the visited company with a candidate
F'	 product that has the potential of being produced in space and that also complements
their already existing product line. We have found it is also essential to indi-
cate very early in our presentations that the products discussed are of the very
^' r
low volume-very high value type. Many of the proprietary pharmaceutical companies
think in terms of large volume-low cost products which are not applicable in the
space operations we visualize.
f^
The presentation should deal with current reality and what can be accomplished
within short term goals. It's focus should avoid the subject of long-range, large
scale space facilities. Most companies do not plan more than three to five years
in advance because of the rapid change in technology and the press of competition.
{	 The pharmaceutical companies seem to be one of the few exceptions to this rule iny
,n
that they plan between five and fifteen years in advance. This long lead time is
occasioned by the lengthy (3-11 years) regulatory approval cycle of a new product
that their competitors must also go through.
ti
One of the most important considerations is the attitude of the presentation. It
should avoid talking down to the audience. Minute detail should be dropped if the
audience is familiar with the product or process. The presentation must reflect
the fact that the audience has the expertise in the field, and we as visitors are
seeking help through their participation. The presentation team can show their
depth of knowledge of the industry by answering technical questions posed by the
audience.
The presentation approach must recognize the realities of business life. It must
reflect that industry is profit rather than knowledge oriented; research must
ultimately lead to increased corporate profit. By selecting products of particular
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interest to that company and presenting relevant market and business forecasts, a
profit potential can be demonstrated in a way to engage both the technical and
management attention of the audience. Using a conservative approach in the presen-
tation, especially with technical and business values familiar to the audience,
will give individuals an excellent chance to contribute to the discussions and to
realize that their experience and participation would greatly enhance the program.
The presentation should demonstrate the personal commitment of the speakers and
their company to the program. It must convey the attitude: "We are deeply
involved and would like you to join us" rather than "You tell us what we can do
for you in space." If the presentation features working hardware, mathematical
analyses and models, as well as preliminary product data with their related market
and risk analyses, the audience will feel that the presenters have a strong
corporate investment in the concept, both financially and in terms of minhours of
effort.
Brochures of the presentation material should be left with the key men of the
audience. This brochure should contain all the visual aids plus an explanation of
each. It will serve as a memory aid for internal company discussions. In addi-
tion, a point of contact for both the presenting team and the company visited
should be identified for follow-up telephone calls requesting help or clarification
on either side.
Post Presentation Period
Results of the presentations will develop relatively slowly. The companies
visited will take time to digest what is presented and investigate the claims made.
Experience in this study has shown that this phase will take about three months.
If results of the initial investigation are favorable, the company will present
	 r
the concept to their corporate management. This second phase usually will take
two more months. The formal development of participating documentation (e.g.,
protocols, agreements, etc.) and approval of budgets will ordinarily consume an
additional six to twelve months. All during this time, routine contact between
the two companies should be maintained with pertinent management and technological
data exchange by both sides as required.
ti
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During this period, it ,s extremely important not to exploit the manufacturing
company names or the products they have under consideration. Most industries are
very competitive and mai-ntain strict confidentiality regarding the potential
products or processes they are investigating. If such information became generally
known without the consent of the candidate participant, cooperation would probably
be terminated. The privacy of a manufacturing company considering participation
must be respected until the firm decides to announce publicly, for itself, its
intent to participate it the exploration of space applications.
6.2 LABORATORY SUPPORT
Interlaboratory testing protocols take time to assemble and be approved by the
management of both companies. It is imperative that responsible personnel be
involved in working up the agreements. Detail must be ,provided with regard to
both the specificity of the test and the level of sensitivity for that test.
While both companies may be testing for the same end product, if each investigates
the presence of a different characteristic of that product (or the same character-
istic at different sensitivity levels) one of the laboratories may report negative
analytical results even though the end product is present. At least two different
analytical tests must be used to cross check if any compromise of the product
integrity may be suspected.
W,'
When working with the bioprocessing of pharmaceutical products it is necessary to
have the support of a broad based biological laboratory and its inclusive person-
nel. If a particular test is not within the analytical program of the laboratory,
it will usually take about four months to obtain the requisite chemicals and
instruments, become familiar with the test and develop the repeatability and
accuracy required. By establishing, from the beginning, a diversified laboratory
and staff capability, the time and effort to incorporate new procedures can be
eliminated or drastically reduced.	 Y
ILogistics is a very critical factor when dealing with biological products. They
must be protected from the environment at all times with only very short temporal
excursions beyond those limits permitted. While the most detailed logistics plans
may be proposed on paper, the human element is involved in its execution. The
larger the corporation and the further the distance between companies, the greater
,
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the chance for mishandcifig -the environment critical product during shipping,
transportation and receiving. The experiences gained in this study will serve
well for developing and executing product logistics support activities between a
participating company and the space launching facilities.
The continuous flow electrophoresis system used as the heart of the space-
bioprocessing system is a very powerful analytical instrument. Its resolving capa-
bilities, in many instances, are greater than that observed by zone electrophore-
sis. Commercially prepared and certified pure protein samples present a single
band pattern in zone electrophoresis. When these same purified samples were used
to calibrate the continuous flow electrophoresis instrument or identify the loca-
tion of that protein in a mixture of proteins being separated under the same condi-
tions a ,- that for the zone electrophoresis system, it was not uncommon to find
more than one separation peak for the material. These smaller, secondary peaks
observed may be trace impurities or they may represent dissociation products of
the calibrating material. This latter hypothesis is unlikely, however, because
when the ma i , peak is collected, lyophilized, resuspended, and again electropho-
retically processed, the secondary peaks do not appear.
A data base concerning a potentially profitable candidate product must be developed
upon which a technology interchange can be established between the interfacing
company and the candidate producing company. MQAC-St. Louis established such a
technology interchange with the participating pharmaceutical companies. This in
turn, we believe, has enhanced the level of interest of these companies in the
potential offered by processing pharmaceuticals in space.
While mutually exploring candidate products with a potential space process, new
product derivatives may be found that can be exploited jointly. The electropho-
retic separation of AHF VIII from cryoprecipitate is an example. Although molecu-
lar dissociation of AHF III occurs, the clotting properties are still intact.
Since the classic hemophilic patient lacks only the clotting moiety, its dissocia-
tion is not a deterent to further investigation of this product. Both participat-
ing pharmaceutical companies expressed interest in a purified clotting moiety as a
possible product.
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Preliminary tests revealed that the use of cryoprecipitate as a product source
I	 will require development of special handling procedures to assure day to day
uniformity of sample. This does not pose a critical technological obstacle.
Starting with human plasma as a product source, it may be possible to obtain all
1 the important blood fractions of medical importance in purified form in a single
continuous process. Gamma globulins, used to protect against bacterial and viral
discases, are slow moving materials whereas albumin, used as a plasma expander is
very fast moving. These materials are Currently obtained commercially by precipi-
tation methods requiring the use of unwanted materials in the separation process.
t	 In such procedures important components, such as AHF VIII, other clotting factors,
alpha antitrypsin, etc., may be neglected, lost or denatured by the process. A
#	 process in which all blood components can be 'isolated in a single step is of
r	
significant interest to both participating companies from the standpoint of
economics as well as expansion of their product line.
6.3 PRODUCT REQUIREMENTS AND ANALYSIS
1
	
	
Many potential products can be proposed for space processing by reviewing the
literature and discussing the subject with professionals in the field of interest.
p
Care must be exercised, however, when selecting the products. Many of the sugges-
tions may be of interest scientifically for their own sake but will have little
chu4,ce of being rapidly adopted by the workers in that field if they offer no
substantial improvement over existing materials. Industrial manufacturers have
marketing staffs and diversification groups that are continuously looking for new
products. Their main criteria, however, is can the company make a profit from it
in a relatively short period of time. If the companies do not see a significant
return on their investment in research and development of a product they will
ignore that product.
When products are attractive from a marketing standpoint, technical information is
then gathered to assess the capability of producing the product and the extent of
the competition to be expected. Literature reviews, both technical and marketing,
on each of the products will generally show that the information is voluminous but
of little direct value to sizing a processing system. Pieces of information are
4 usually missing that would require technical assumptions based on laboratory and
1
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Production experience in order to proceed with a production system analysis. What
may be relatively easy to do in a laboratory on a small scale may be fraught with
problems when the process is magnified to meet commercial needs.
Judgments must be made concerning the potential of product competition from other
technologies during the period of investment recovery. Most pharmaceutical
companies contacted about space processing brought up the possible competition
from the recombinant DNA approach to protein synthesis using bacteria. Their own
study and analysis of that concept led them to understand that that process still
has a long way to go to become practical. While the recombinant DNA process may
be able to make the products on a large scale in the distant future, they would
still need a process like the continuous flow electrophoresis system to isolate
the product in sufficient purity to make that process commercially feasible.
Thus, two possibly competitive processes may actually be complementary.
A hardware system that is capable of producing a variety of products with only
minor operational changes, e.g., instrument settings, chemical substrates, and
flow rates, would offer significant operational, logistics and cost advantages to
a producer. All of the twelve biological products reviewed in this study could
exercise the proposed system in part or in its entirety thus supporting the concept
of a true multiproduct system. Knowledge of the cell sources for erythropoietin,
epidermal growth factor, growth hormone, interferon and alpha-antitrypsin produc-
tion and an awareness that these cells and ho mones can be separated by electropho-
retic techniques, all supported the concept of a full bioprocessing production
system. Antihemophilic factor VIII and specific immune globulins are blood
proteins with as yet no defined site of production in a living organism. They,
therefore, would only be able to exercise the space bioprocessing system in the
separation mode. Beta cells and urokinase producing cells can be grown in tissue
culture and also separated elect;.^ophoretically. Because the mobilities of these
cells in an electrical field are lower than proteins, the separation chamber may
have to be modified slightly in design or operational function. All twelve
products could benefit through space bioprocessing by improvements in purity and
throughput. Additional analyses, such as that done by mass balancing would be
required to show their economic feasibility,
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Based on economic and technical information, this study developed a value index of
each product with respect to the % r humanitarian value and applicability to the
concept of production through space bioprocessi,ng.
In addition to this numerical evaluation, at the current state of knowledge two
additional subjective criteria must be applied to each product, i.e., would the
product exercise the conceptual bioprocessing system in one or more modes of
operation and could comparison data be attained between earth and space processing.
a	 The comparison data must be available, cr arrived at by analysis, to show the
potential of space processing to prospective producers.
Development of market data on products important to candidate participating firms
is a key to securing their interest. A search of the literature, supplemented by
consultations with clinical authorities will provide the information necessary to
develop a picture of the current market open for the model products. Reasonable
assumptions, based on the guidance of clinical research teams, will yield useful
market projections for advanced clinical uses. Finally, appropriate business risk
analyses should be employed to assess the market risks for processes and products
as they move from initial R&D commitment through ground and flight experimentation
to achieve successful flight production demonstrations. By offering these prelimi-
nary analyses to prospective participators, much useful data can be obtained
during the presentation itself. Most important, the potential participating firms
will be assured that the presentor has a business understanding and an investment
attitude appropriate for cooperative endeavors for their mutual benefit.
Discussions with a number of pharmaceutical companies resulted in a list of
several other biologically active products for eventual consideration. These
included: thymic factors, specific immunoglobulins, somatostatin, somatomammotro-
pin and polyvalent vaccines. It is recommended that these products be explored in
depth as a point of future communication and interest with the pharmaceutical
companies.
6.4 PROCESS SYSTEM REQUIREMENTS
While this study was done to assess the commercial feasibility of manufacturing
pharmaceutical products in space, it serves as a model for those who wish to
consider other pr,, :-s7,,es or products in the same environment. The use of the mass
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balances concept forces a delineation of what must be accomplished in the process
for each product in a stepwise fashion. The calculated quantities of materials at
each step will quickly determine if the process is feasible with current technol-
ogy, where the areas of information must be obtained to fill in the gaps, and
anticipated recurring transportation costs to haul the material to and from spacs:.
While it does not define the total cost of the system, it does give the prospective
manufacturer and NASA a general idea of the size, power and weight of the process-
ing equipment as well as the extent and type of storage requirements. The length
of the missions will be defined to determine economic feasibility. This will
have to be interwoven with the NASA program and schedules to determine if, and
when, a vehicle capability will be available to support such a manufacturing
facility. Legal regulatory considerations will also have to be defined.
After a relatively thorough review of the current commercial and laboratory
methods for producing the final twelve candidate products, a conceptual design of
a space bioprocessing system was verified. It could be used as a multiproduct
process system with only minor instrument settings and fluids composition changes
when different products enter into the system. A comparison of space production
with alternative ground production, or combinations of the two locations was
performed on three candidate products using the concept of mass balancing.
Based on the space transportation requirements and a comparison with ground opera-
tions, it was determined that, generally, cell and protein separations should be
space operations. Whether tissue culture should be a space operation was found to
be dependent on the product. If the product is the cells 'being cultured, as in
the case of beta cells, then the reasonable transportation requirements make it
`
	
	 advantageous to culture in space, because the cell separations to get the starting
inoculums and to separate the products are best done in space. If the product is
small amounts of protein from the cells in the culture media, as in the case of
erythropoietin, then the excessive transportation requirements make ground culture
followed by space electrophresis of reconstituted, lyophilized media more advanta-
geous. Erythropoietin shows an excessive requirement for orbital separation
systems along with many technical unknowns. However, it was included in the
requirements for a multiproduct processing system at this time in order to provide.
a typical capability for applied research on marginal materials of this type. The
resulting system capabilities are heavily biased toward electrophoretic separation,
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but include tissue culture capability to the extent required for the culturing of
cells as products, or limited investigation of protein production from tissue
culture.
The use of mass flow balances for each candidate product were very helpful in
clarifying the sizing, continuous support, and transportation requirements for the
system. They were particularly useful in highlighting areas where new techniques
are required. For example, it is essential that a major portion of the fluid
materials required to operate the system in space be reclaimed. The cost of
transporting these fluids, if not recycled, would eliminate the profit potential
of the bioprocessing system. Moreover, the continuous loss of the fluid to the
space environment surrounding the structure containing the bioprocessing system
would preclude the possibility of other NASA activities external to that structure.
Reclamation of these fluids is not now feasible and is a study area requiring
immediate and concentrated investigation.
Another pertinent observation was that commercial production of a particular,
candidate product was only feasible by bioprocessing in space rather than by using
z a ground based facility. The cost of the large quantities of buffers to process
erythropoietin in commercial quantities on the ground by electrophoretic techniques
would be more than the annual expected sales of the product. More over, the total
annual requirements for that buffer's constituents would be greater than that
currently being manufactured world wide.
All of the candidate products evaluated in this study were natural body substances.
Therefore, with the aid of a participating pharmaceutical company, contact was made
with the Bureau of Biologics of the Food and Drug Administration to start explora-
tory discussions of the space bioprocessing concept, the candidate substances
considered for production, and the applicable governing regulations. This agency
was very cooperative and appreciative of being brought into our program at the
conceptual stages. It gave them an understanding of what the goals of space
bioprocessing were and our approach to achieving those goals. This awareness of
the program then enabled them to provide meaningful guidance to our systems design
and thus be in compliance with their good manufacturing practices. It has been
made clear that these representatives could see no insurmountable problems with
regard to space bioprocessing as outlined by us.
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TEST PROTOCOL
ANTIHEMOPHILIC FACTOR
12 December 1977
E	
PREPARATION AND HANDLING OF ANTIHEMOPHILIC FACTOR VIIIe
SAMPLES FOR TESTING BY
(PARTICIPATING PHARMACEUTICAL COMPANY)
r
Purpose and Contents
The purpose of this protocol is to establish the basic guidelines for prepara-
tion, handling, and assaying samples which have been processed through the
McDonnell Douglas Astronautics Company - St. Louis (MDAC-St. Louis) electrophore
sis unit and sent to (participating company) for testing.
x2. The contents of the protocol 	 are arranged as follows;
1.	 Introduction
2.	 Electrophoretic Process
{ 3.	 Preliminary Assay at MDAC-St. Louis
4.	 Assay of Samples at	 (participating company)
5.	 Sample Volume and Characteristics
6.	 Sample Disposal
7.	 Test Periodicity
8.	 Data Management
9.	 Technical
	
Contact
1.0	 INTRODUCTION
1
McDonnell Douglas Astronautics Company - St. Louis
	 (MDAC -St. Louis)	 has requested
the aid of (participating company) to conduct assays on material	 processed
through an electrophoresis chamber.	 The samples will consist of biological
materials contained either in cryoprecipitate or the commercially available
Hemophil	 preparation, a more purified form of Factor VIII.
Samples will be sent to (participating company) frozen on dry ice per their
specific requirements and will be accompanied by a sample history sheet providing
any preliminary data acquired by MDAC-St. Louis personnel. After the assays are
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completed, the samples will be disposed of at the discretion of the (participat-
ing company) personnel.
Data acquired from these tests will become the property of MDAC-St. Louis and will
be shared with (participating company) and managed as described in Section B.
The 'ength of this arrangement is open. However, for planning purposes, a period
of six months is anticipated for preliminary screening, after which time a more
detailed arrangement may be in order. During this six month period, it is
anticipated that one set of samples every two weeks will provide sufficient
turnaround time to be able to apply acquired data to the conduct of the next
sample acquisition.
2.0 E LECTROPHORETIC PROCESS
The electrophoretic process will consist of passing samples through a carrier
buffer in the electrophoretic chamber in such a manner that laminar flow is
attained. Under these cond i tions, when voltage is applied across the unit the
materials in the sample will migrate to the anode or cathode depending upon their
net charge. As they separate they can be collected in separate test tubes at the
exit portion of the chamber. The collected samples can be assayed immediately
and the remainder quick frozen at -70'°C for future use.
During the electrophoresis process, sample temperature is maintained at 4-10°C.
From the time sample is prepared for assay until the separate fractions are
frozen will be about 30-40 minutes.
3.0 PRELIMINARY ASSAY AT MDAC-ST. LOUIS
All samples will be screened by MDAC-St. Louis personnel before shipment to (par-
ticipating company). Upon collection of samples, 1.0 ml will be removed and
assayed for Factor VIII by the coagulation test described in Appendix A, para-
graph 1, and for total protein by a modified Lowry procedure described in Appen-
dix A, paragraph 2. The remainder of the sample (about 4.5 ml) will be quick
frozen in dry ice-acetone and then stored at -70°C until shipped to (participating
company).
mz
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4.0 ASSAY OF SAMPLLS AT (PARTICIPATING COMPANY)
Tests conducted by (participating company) personnel will depend on the number of
samples sent. However, one or more of the following will be conducted, depending
upon available personnel, time constraints, etc.
A. One-stage Factor VIII assay utilizing Factor VIII deficient
plasma.
H. One-stage factor VIII assay utilizing Factor VIII deficient plasma
(barium ch,oride absorption).
C. Two-stage Factor VIII assay.
D. Fibrin split products.
E. Chromogenic assays for thrombin and plasmin.
F. Hepatitis B surface antigen.
G. Factor VIII antigen - Laurell method.
These assays will be conducted by procedures normally employed by (participating
company). For the purposes of these preliminary tests, it is not necessary
for their test methods to be disclosed.
5.0 SAMPLE VOLUMES AND CHARACTERISTICS
The volume of each sample sent to (participating company) for assay purposes will
consist of about 4 to 5 ml. Each electrophoresis run will consist initially of
about folir tubes of zero time materials and as many as 14-16 tubes of processed
or separated material. As described above, MDAC-St. Louis will provide the
results of in-house assays for each tube with respect to AHF VIII clotting
activity and protein concentration.
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Once established that various activities are found in particular tubes, then it
will not be necessary to perform all tests on all tubes. For example, we know
that Factor VIII will be contained in only about four of the 14-16 tubes, but we
do not know about the location of other materials such as the hepatitis antigen,
proteolytic enzymes, etc. Thus, once established where the various activities
occur, only the fractions of interest would be sent for assay. As such data
become available, the number of "runs" and samples can be more clearly defined.
REPORT MOC E2104
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All samples will be safe for transport by common carrier and no particular safety
procedures will be required by either laboratory. The only cautions that will
prevail are those normally imposed for handling human serum cryoprecipitate or
partially purified human plasma Antihemophilic Factor VIII.
6.0 SAMPLE DISPOSAL
All samples obtained by (participating company) will be assayed and discarded at
their discretion. MDAC-St. Louis has no requirement for their return. Addition-
ally, if so desired (participatiung company) personnel may subject the samples to
additional testing not discussed specifically in this protocol. MDAC-St. Louis
will be informed of such additional testing or usage.
7.0 TEST PERIODICITY
It is anticipated that data obtained from testing will result in the increase in
knowledge of the potential of the electrophoresis process to separate biological
products. Therefore, the results of each run should have some bearing on the
nature of future experiments. A tern-around time for data reporting of two weeks
would result in a process run and subsequent samples about every two weeks.
Initially, then, the protocol will call fora sample run to be sent to (partici-
pating company) every two weeks. In order to use their data for the next run,
MDAC-St. Louis should have test results within the next 7-10 days.
8.0 DATA MANAGEMENT
All data will become the property of MDAC-St. Louis, and can be used at their
discretion for inclusion in contract reports, in-house documents and Independent
Research and Development (IRAD) reports. This will include a free exchange of
data with (participating company).
At the discretion of (participating company) their affliation may or may not be
used in these reports. The nature of this affiliation can be detailed prior to
any handling of data in reports which are sent to third parties.
Any open literature publications which may result as a result of these tests would
include personnel of (participating company) at their discretion.
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9.0 TECHNICAL CONTACT
All questions regarding the test protocol, laboratory procedures, shipping of
samples, etc., should be directed to:
Dr. J. W. Lanham
McDonnell Douglas Astronautics Company
P.O. Box 516, Dept E423, Bldg 65
St. Louis, MO'63166
(314) 232-7923
1
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Test Protocol
Appendix A
1. Assay of Antihemophilic Factor VIII
Reagents	 a. Glyoxaline Buffer -
3.4 gm Imidazole in 250 ml distilled water.
186.0 nil 0.1 in HU added to above
5.85 gin NaCl added to above
Bring volume to 950 ml
pH to 7.35
Bring volume to 1000 ml
b. Platelin plus Activator - DADE #84218-1
c. Factor VIII deficient plasma - DADE #6234-8
d. 0.025M CaCl2
e. Factor VIII Reference Standard - WHO Referen,-:! II -
DATA #64224-10
Procedure	 a. Into 13 x 100 ml tubes add the following:
0.1 ml Reagent b.
0.1 ml Sample to be tested
0.1 nil Reagent a.
0.1 ml Reagent c.
b. Incubate at 37°C for 10 minutes
c. Add 0.1 nil Reagent d.
d. Begin timing immediately and measure time until clot forms.
The time required for clot formation is compared to the
time required when 0.1 ml of a Factor VIII Reference
Standard containing 0.25 to 1.0 unit/ml is used in place of
0.1 ml of sample.
Results are recorded as percent of AHF VIII in normal serum.
2. Protein Assay
Reagents	 a. 1.5 ml of 1.0117 Potassium Tartrate in 150 ml of 2% Na2CO3.
While stirring add 1.5 ml of 1'/10 CuSO4 (or 1.5'10 CuSO4 • 5 H20).
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b. Folin Reagent - Sigma Chemical Company #F-9252 - Dilute 1:1
with distilled water.
c. One N NaOH.
Procedure	 a. Add 1 ml of sample to be tested to test tube.
b. Add 0.5 ml Reagent c.
c. Add 5.0 ml Reagent a. Incubate 10 minutes at room
temperature.
d. Add 0.5 ml Reagent b. Let stand 30 minutes at room
temperature.
e. Read in spectrophotometer at 700 nm.
f. Standard curve is prepared using 1.0 ml aliquots of known
protein content from 0 to 320/Ag/ml.
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MATERIALS
1.
2.
3.
4.
5.
C.
7.
PROCEDURE
1.
2.
3.
4.
5.
G.
7.
I3.
9.
Y
Buffer	 - 9.769 Sodium Barbital
2.479 Barbituric Acid	
Dissolve in one liter of distilled
5.789 TRIS
	
water and dilute up to 2L.
Agarose	 - Purified Powder
Dissolve 0.19 in 10 ml of above buffer'
Antiserum	 Behring Factor VIII Antisera
55°C Water Bath
LKB Immunoelectrophoresis Apparatus
Balance Plate
Cooling Pl ate
Anti-Condensation Cover
8.4 x 9.4 cm Glass Plates
CoolaaaSSie-Blue R-250 Stain
Neal: 20 ml of above buffer to 100°C.
Dissolve 0.29 of Agarose Power to yield 1!^ Agarose solution. Neat
until Solution boilS.
Prepare Factor VIII standards usincg a stock concentration of 5 rag
per 1111 of buffer and dilute serially.
Pour 10 ml of 1;a Agarose solution into 10 ml test tube and place in 55°C
11,,0 bath Until temperature of Solution decreases to 55°.
Dilute Factor~ VIII Antisera and buffer 1/1.5 to yield 5.671 antibody
concentration.
Add 560X of diluted antibody to 10 ml of 1" Agarose solution.
Neat balance p':ate and place glass plates on to warm tip.
Carefully pour tube of Agarose solution containing Factor VIII antibody
onto plate until all edges are covered.
Allow 15 minutes to cool.
Punch appropriate number of holes in agar to ,yield 3	 or 10	 vol rune
holes using gel puncher and template.
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10. Spot samples and standards to be tested.
11. Place dates on cooling date.p	 91
Soak paper wicks (5 layers thick) for 15 to 30 minutes. Cover edges
of both sides of plate(s).
12. Cover with anticondensation lid.
13. Turn voltage on to yield 6.5 mAmps per plate.
14. Check voltage across gel; should be 2-5 V/cm.
15. Run for 18 hours.
STAINING PROCEDURE
1. Remove plate(s). Place absorbent paper on top. Cover with 1 kg jar
to press gel to fine film.
2. Wash plate in 0.15 M NaCl solution - 15 minutes.
3. Press as in Step 1. - 15 minutes.
4. Repeat steps 2 and 3.
5. Wash in distilled 1.1 20 - 15 minutes.
G. Press.
7. Dry in 50% oven for 20 minutes.
8. Stain in Coomassie-131ue R-250 - 20 minutes.
9. Destain in three solutions of acetic acid destaining solution.
10. Dry in 50°C oven.
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REAGENTS AND EQUIPMENT
1. Ames Prothrombin Heating Plate (Model #4500) 37°C
2. Ames Prothrombin Reaction Chamber (#4510)
3. Dade Normal Human Serum Lyophilized
4. Dade AHF Deficient Serum Lyophilized
5. 0.025M Calcium Chloride (made in H20)
6. Glyoxaline Buffer - 3.4 gm Imidazole in 250 ml H2O
- 186 ml O.1N HCl
- 5.85 gm NaCl
- bring to one liter with H 2O and pH to 7.35
- Keep at 4°C.
7. Normal Human Serum Standards
Dilute in H2O - 1:10, 1:20, 1:40, 1:80 and 1:160. Keep all samples
in ice. Once serum is reconstituted, it is only good for approximately
two hours.
8. Dade Cephaloplastin Activator
PROCEDURE
1. Preheat plate and reaction chamber to 37°C.
2. For standards or unknown add:
Large side of chamber: 50A activator
50 X standard dilution or sample
50 A AHF deficient serum
50,k buffer
Small side of chamber: 50 N 0.025M CaCl2
3. Let incubate at 37°C for exactly 10 minutes.
4. Mix two sides together and time with a stopwatch until clot is formed
(performed at room temperature).
5. Stop if greater than two minutes.
1/10 dilution = 100% activity
1, 1 dilution = 50% activity
1 0 dilation = 25% activity
1/80 dilution = 12.5° activity
6. Graph on two-cycle semilog paper.
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APPENDIX A-2
TEST PROTOCOL-PANCREATIC ENDOCRINE CELLS
GROWTH HORMONE
GRANULOCYTE STIMULATING FACTOR
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^ 	 Test Protocol
2 August 1978
r	 Preparation and Handling of Biological Samples
for Testing by (Participating Company)
Purpose and Contents
The purpose of this protocol	 is to establish the basic guidelines for prepara-
tion, handling and assay of samples which have been processed through the
McDonnell Douglas Astronautics Company - St. Louis	 (MDAC-St. Louis) electro-
phoresis unit and sent to (participating laboratory) for testing.
'
The contents of the protocol are arranged as follows:
1. Introduction
2. Electrophoresis process
3. Preliminary assay at MDAC-St. Louis
1. Assay at	 (participating company).
f
x^
5. Sample volume and characteristics
6. Sample Disposal
7. Data management
8. Technical
	
contact MDAC-St. Louis
1.0 INTRODUCTION
MDAC-St. Louis is initiating an interlaboratory test program with (participating
I +
	
	 laboratory) to conduct tests which will aid in the selection of products as
candidates for space bioprocessing. This test protocol will serve as a basic
guideline for these tests and -is amenable to changes and updates where necessary.
Present materials being considered are pancreatic beta cells, pituitary cells
'	 producing growth hormone, and cells producing granulocyte stimulating factor.
p Since living cells are the primary product, special handling is required not only
during processing and assay, but during transport of the samples from one labora-
tory to another.
Where human cells are required and cannot readily be purchased by MDAC-St. Louis,
	
r	 (participating company) will attempt to provide the necessary organs for study.
 A-15
g
	
! K£	 MCOONNELL. O08JOLAS ASTAWONAUrOCS COMPANY:T. LCW#s 0/V#0 j0 f
(	 REPORT MOC E2104
`Now, ^^;!^
	
VOLUME II
X SPACE	 9 NOVEMBER 1976
MANUFACTURING
Preliminary in-house data will be supplied to (participating company) along with
samples to be tested.
All data resulting from this participation can only be used with the consent and
discretion of the other participant. If the information is released, the use of
corporate names witn the data is excluded unless additional consent is provided.
The length of this testing program is open. For preliminary purposes this test
protocol will assume a one year relationship after which time progress will
dictate follow-on tests.
2.0 ELECTROPHORETIC PROCESS
The electrophoretic process will consist of passing samples through a carrier
buffer in the electrophoretic chamber in such a manner that laminar flow is
attained. Under these conditions, when voltage is applied across the unit the
materials in the sample will migrate to the anode or cathode depending upon their
net charge. As they separate they can be collected in separar? test tubes at the
exit portion of the chamber. The collected samples will be assayed for cell
counts, viabiity, hormone release and culture, and sent to the participating
company for analysis and/or further testing. In general, temperatures in the
electrophoresis chamber will be maintained between 4°C and 10°C. Processed
samples will be shipped either on dry ice, refrigerated or at room temperatures,
depending on the cell types and their specific requirements.
3.0 PRELIMINARY ASSAY AT MDAC-ST. LOUIS
Basically, MDAC-St. Louis personnel-will conduct tests to determine the following:
(1) ability to separate cells from debris and from one another, (2) viability of
processed cells, (3) hormone produced by processed cells, and (4) ability to
culture processed cells. Procedures used for these assays are described in
Appendix A of this protocol.
Currently our in house capabilities include culture of the routine cell types
such as primary kidney cells, suspensions of transformed cells, and lymphocytes.
Insulin, glucagon and growth hormone assays are being developed and culture
techniques for the specific cells are being investigated. Our tentative schedule
R
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calls for completion of an 'insulin and glucagon assay procedure by early 1979,
e growth hormone and granulocyte stimulating factor during the second quarter of
that year and state of the art culture capabilities by mid 1979.
4.0 ASSAYS OF SAMPLES AT (PARTICIPATING COMPANY)
j	 Not Complete. Will be determined after (participating company) has reviewed
protocol and final agreement is established as to the products to be tested.
N
3
5.0 SAMPLE VOLUMES AND CHARACTERISTICS
Sample volumes will be determined during processing. Since most processed
samples will be cellular, they may be supplied as slurries or pellets. If the
original volumes are maintained, as may be required for some samples, the volumes
will be 4 to 8 ml. The number of samples to be tested by (participating company)
will vary depending on the separation of products and the product(s) of interest
in the separated sample. For example, if the sample separates over only a few
tubes then only a few samples need to be assayed. However, if the sample
separates over several tubes, then many samples will require testing from that
particular process..
6.0 SAMPLE DISPOSAL
4	
Samples sent to the participating company will be disposed of at their discretion
after testing is completed. Additional tests may be conducted by the participa-
ting laboratory if they desire. However, MDAC-St. Louis will be informed of the
nature of any additional tests and will have access to the results.
7.0 DATA MANAGEMENT
All data will become the property of MDAC-St. Louis, and can be used at their
l	 discretion for inclusion in contract reports, in-house documents and Independent
Research and Development (IRAD) reports. This will include a free exchange of
data with (participating company).
At the discretion of (participating company) their affliation may or may not be
used in these reports. The nature of this affiliation can be detailed prior to
any handling of data in reports which are sent to third parties.
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Any open literature publications which may result as a result of these tests would
include personnel of (participating company) at their discretion.
8.0 TECHNICAL CONTACT - MDAC-ST. LOUIS
All questions regarding the test protocol, laboratory procedures, shipping of
samples, etc., should be directed to:
Dr. J. W. Lanham
McDonnell Douglas Astronautics Company
P.O. Box 516, Dept E423, Bldg 65
St. Louis, Missouri 63166
(314) 232-7923
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PANCREATIC ENDOCRINE CELL SEPARATION PROCEDURE
A. Pancreas minced.
B. Treat with collagenase.
C. Assay islet hormone production.
{ D. Trypsinize to obtain alpha and beta cells.
E. Stain and count cells.
F. Process through electrophoresis unit.
G. Assay products for cell	 count, hormones.
PANCREATIC ENDOCRINE CELL SEPARATION
PANCREAS
1) MINCE
2) COLLAGE.NASE
3) CENTRIFUGE
4	
ISLETS
a
f'
TRYPSIN IZE
f^ ASSAY
— CELLS A. INSULINLa	
CELLS B. GLUCAGON
C. GASTRIN
FIDENTWICATION
	
ELECTROPHORESIS
CHAMBER
A) STAIN
B) COUNT
COLLECTION 1) g — CELLS — INSULIN
TUBES GLUCAGON2) a —CELLS {—GASTRIN
r
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INSULIN ASSAY PROCEDURE
A. Insulin culture fluid complexed with anti-insulin serum.
B. I125 insulin added - competition for anti-insulin serum.
C. Ethanol extraction.
D. I 125 insulin - anti insulin complex counted in gamma counter.
INSULIN ASSAY PROCEDURE
ISLET CULTURE FLUID
OR
Q—CELL CULTURE FLUID
+ ASSAY
REAGENTS
A.
SECRETED INSULIN
AIS'
INCUBATE @ 370 FOR 30 MIN.
B.
AIS —SECRETED INSULIN COMPLEXFORMATION
1	
INCUBATE WITH 1 125 — INSULIN
ROOM TEMPERATURE FOR 30 MIN
C. O	 EXCESS AIS •- 1125 INSULIN
AIS —SECRETED INSULIN
INCUBATE WITH 95% ETHANOL
FOR 30 MIN @ ROOM TEMPERATURE
CENTRIFUGE FOR 10 MIN @ 800 g
D.d=b
--SUPERNATANT DISCARDED
AIS — INSULIN COMPLEX
GAMMA COUNTER	 MICROUNITS OF INSULIN PRODUCED
*AIS =GUINEA PIG ANTI-INSULIN SERUM
A-20
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GLUCAGON ASSAY PROCEDURE
A. Glucagon culture fluid and I 125 _ glucagon - anti glucagon complexes formed.
11. Precipitating antibody added.
C. Complex formed.
1'). I 125 - glucagon complex counted in gamma counter.
GLUCAGON ASSAY PROCEDURE
a - CELL
CULTURE FLUID
+ ASSAY
REAGENTS
A.
BUFFER
GLUCAGON ..
 1 125 GLUCAGON
RABBIT AGS'
1
INCUBATE @ 40 FOR 96 HRS
B.
AGS-GLUCAGON
	 COMPLEX
AGS-1 t2 GLUCAGON FORMATION
ADD EXCESS RABBIT? GLOBULIN
+ ANTI-RABBIT SERUM
PRECIPITATING ANTI,BODY
INCUBATE @ 40 FOR 48 HRS
C,	 CENTRIFUGE 0 2800 RMP FOR 20 MIN
SUPERNATANT DISCARDED
COMPLEX
GAMMA COUNTER ,
- RABBIT ANTI-GLUCAGON SERUM
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INSULIN AND GLUCAGON ASSAY REFERENCES
1. Diabetes, 17:537, 1968.
2. Diabetes, 18:660, 1969.
3. Diabetes, 20:33, 191.
4. Endocrinology, 81:226, 1967.
5. Handbook of Physiology/Vol. I'- The Endocrine Pancreas, Williams & Williams,
Baltimore, 1572.
6. Am. Zool., 13:613, 1973.
7. Glucagon Molecular Physiology, Clinical and Therapeutic Implication,
P. J. Lefebvre and R. H. Unger, Pergamon, Oxford, 1972.
8. Br. Med. Bull., 30:18, 1974.
9. Biochem. J., 89:114, 1963.
10. BBA, 251:363, 1971.
11. ACTA Endocrinol, 54:527, 1967.
12. Handbook of Radioimmunoassay, G. E. Abraham (eu.), Marcel Dekker, Inc., NY,
1977.
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PANCREATIC ENDOCRINE CELL CULTURE
A. Pancreas Distended and Minced (1)
B. Collagenase Digestion (2)
C. Ficoll Gradient (2)
D.	 Islets
	
i
	
a. Culture (3, 4, 5) and Viability Testing (6, 7, 8, 9, 10)
b. Electrophoresis and Viability Testing
E. Islet Trypsin Digestion (11)
a. Alpha and [seta cells isolation (12)
b. Alpha cells isolation (13)
F.	 Cells
a. Culture (3, 4, 5, 12) and Viability Testing (6, 7, 8, 9, 10)
b. Electrophoresis and Viability Testing
(Numbers in parenthesis indicate references for each procedure.)
PANCREATIC ENDOCRINE CELL CULTURE
PANCREAS
• COLLAGENASE
• FICOLL GRADIENT
ISLETS	 TRYPSIN DIGESTION
a + 0 CELLS F-- a CELLS
CULTURE ^j	 (CULTURE	 /CULTURE i
VIABILITY TESTING: 1) IMMUNOFLUORESENCE
2) INSULIN RELEASE
3) GLUCAGON RELEASE
4) DIFFERENTIAL STAIN
	
if	 5) H3
 THYMIDINE INCORPORATION
S
f^
ELECTROPHORESIS CHAMBER
I_
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1. Diabetes, 16:35, 167.
2. Transplantation, 16:686, 1972.
3. Endocrinology, 90 .:239, 1972.
4. Endocrinology, 96:637, 1975.
5. Tissue and Cell, 1(4):747,1975:
6. Endocrinology, 99(3):684, 1976.
7. Diabetes, 21 (Suppl 2):546, 1972.
8. American Journal of Clinical Pathology, 20:656, 1950.
9. Diabetologia, 12:115, 1976.
10. Diabetes, 22:687, 1973.
11. Proc. of Society of Exp. Biol and Med, 149 :402, 1975.
12. Endocrinology, 84:203, 1969.
13. Pancreatic Beta Cell Culture, Workshop Conferences, HOESCHTJVol 5,
'Exerpta Medica, Amsterdam, Oxford, 1977.
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PRIMARY PITUITARY CELL SEPARATION AND CULTURE
A. Pituitary - Minced 	 (1)
B. Trypsin Digestion (2)
C. Neuraminidase Digestion
b D. Wash and Centrifuge
E. Cell	 Suspension
a.	 Culture
	
(3),
	 or
b.	 Electrophoresis
F. Viability Testing
a.	 Growth Hormone Release (4, 	 5, 6,
	 7)
b.	 Immunofluorescence (9)
c.	 Differential	 Stain	 (8,	 9)
(Numbers in parenthesis
	 indicate references for each procedure.)
PRIMARY PITUITARY CELL CULTURE
r,
PITUITARY
• MINCE
• TRYPSIN DIGESTION
• NEURAMINIDASE DIGESTION
-` • WASH
CELLS
E h
COLUMN ELECTROPHORESIS CL, 	 URE !' -J
(	 y r	 VIABILITY TESTING
• GROWTH HORMONE RELEASE
„. • IMMUNO FLUORESENCE
• DIFFERENTIAL STAIN
I `	 A-25
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PRIMARY PITUITARY CELL CULTURE REFERENCES
1. The Anterior Pituitary, Ultrastructure in Biological Systems/Vol. 7,
A. Tixier-Vidal and M. G. Farquhar, Academic Press, NY 1975.
2. Journal Cell Biology, 59:276, 1973.
3. Journal of Clinical Endocrinology and Metabolism, 45:73, 1977.
4. Metabolism, 13:1135, 1964.
5. Biochem. Journal, 89:114, 1963.
6. Journal of Lab. Clin. Med., ,,Q, 1973, 1967.
7. Methods of Hormone Radioimmurwassay, B. M. Jaffe and H. R. Behrman, Academic
Press, NY 1974.
8. Manual of Histologic Staining Methods of the Armed Forces Institute of
Pathology, 3rd edition, L. G. Lune, American Registry of Pathology, 1968.
9. Selected Histochemical and Histopathological Methods, S. W. Thompson,
Charles C. Thomas, Illinois, 1966.
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GROWTH HORMONE ASSAY PROCEDURE
A.	 Growth hormone culture fluid and I 125 growth hormone - antigrowth hormone
4
complex formed.
B.	 Precipitating antibody added.	 i
C.	 Complex formed.
l I 5D.	 12 ' - growtfi hormone complex counted in gamma counter.
GROWTH HORMONE ASSAY PROCEDURE
{l
PITUITARY CULTURE
FLUID
;ra
A.
d
Y
SECRETED GROWTH HORMONE
d
B.
" ADD 1 125 - LABELED —GROWTH HORMONE
ADO RABBIT ANTI — GROWTH HORMONE
I(, 24 HOUR ROOM TEMP. INCUBATION
C.
`ADD GOAT ANTI-RABBIT IMMUNOGLOBULIN
18 HOUR ROOM TEMPERATURE INCUBATION
CENTRIFUGE
D.
SUPERNATANT DISCARDED
d	 , GROWTH HORMONE — ANTIBODY COMPLEX
GAMMA COUNTER
	 NANOGRAMS PRODUCED
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&	 GROWTH HORMONE ASSAY REFERENCES
1. Biochem. J., 89:114, 1963.
2. Metabolism, 13:1135, 1964.
3. J. Lab. Clin. Med., 70:973, 1967.
4. Methods of Hormone Radioimmunoassay, B. M. Jaffe and H. R. Behrman,
Academic Press, NY, 1974.
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PRIMARY KIDNEY CELL CULTURE
A. Kidney - Minced and Washed (1)
u,
B. Trypsin Digestion
C. Filter Cell Suspension
D. Wash and Centrifuge - twice in a buffer
" E. Determine Cell
	
Viability	 (2)
a.	 Culture	 (1)	 and
b.	 Electrophoresis
F. Determine viability
(Numbers in parenthesis	 indicate references for each procedure.)
^	 F
 it	 I
PRIMARY KIDNEY CELL CULTURE
u
KIDNEY
• MINCEf
{^ • WASH
u • TRYPSIN DIGESTION
• FILTER
rj	 ' • WASH TWICE
CELL SUSPENSION
VIABILITY DETERMINATION
CULTURE
I ELECTROPHORESIS CHAMBER
T^
3^
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PRIMARY KIDNEY CELL CULTURE REFERENCES
1. Tissue Culture: Methods and Applications, Academic Press, NY, 1973.
P. E. Kruse, Jr., and M. K. Patterson, Sr.
2. Experimental Cell Research, 11:297, 1956.
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GRANULOCYTE COLONY STIMULATING FACTOR (CSF)
SEPARATION
t
L ; I.	 Kidney Cells
A.	 Cell	 Suspension	 (1)
R.	 Liability Test	 (2)
a.	 Culture (1) - Electrophoresis and/or CSF Assy (3, 4, 5), or
b.	 Electrophoresis - Culture and/or CSF Assay
II.	 Lymphocytes
A.	 Electrophoresis - Culture and CSF Assay, or
l
Culture	 (1)
R.	 Culture Lymphocytes
C.	 Add Cytochalsin R	 (6)
D.	 Dialysis CSF Media
E.	 Electrophoresis - Culture and CSF Assay
i^y 	,
III.	 Urine
v A.	 Electrophoresis,	 or
R.	 Purification of CSF 	 (4)
a.	 Dialysis
b.	 Add Calcium Phosphate
c.	 Centrifuge and Save Pellet
d.	 Resuspend Pellet and Centrifuge
e.	 Save Supernatant
f.	 CSF Assay
k'
IV.	 Serum - Electrophoresis
r_.i (Numbers	 in parenthesis	 'indicate references for each procedure.)
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e
GRANULOCYTE COLONY STIMULATING FACTOR (CSF) SEPARATION
TISSUE CULTURE BIOLOGICAL !	 p
• KIDNEY CELLS FLUIDS
LYMPHOCYTES •URINE
I
•SERUM
7
VARIOUS TREATMENTS
r
KIDNEY CELLS LYMPHOCYTES URINE	 SERUM
VIABILITY TEST
---
i'
__	 — "
CULTURE l^.
DIALYSIS
1
t
—
CALCIUM
PHOSPHATE
CULTURE /,^ CYTOCHALSIN B
VIABILITY CENTRIFUGE
TEST
- — SAVE
I T
PELLET
RESUSPEND a	 .
VIABILITY DIALYSIS
TEST SAVE
SUPERNATANT,
ELECTROPHORESIS CHAMBER n
k ASSAY FOR CSF v
w
ii
;'
^x
xc3c
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n GRANULOCYTE COLONY STIMULATING FACTOR (GSF) SEPARATION REFERENCES
1. Tissue Culture: Methods and Applications, Academic Press, NY, 1973.
P. E. Kruse, Jr.	 and M. K. Patterson, Jr.
2. Experimental Cell Research, 11:297	 (1656).
3. J.	 Cell	 Phys.	 76:89,	 1970.
4. J.	 Lab Clin Med,	 79(4):657, 1972.
5. Selected Histochemical
	
and Histopathological	 Methods, S.	 W. Thompson (ed.),
ti Charles C. Thomas Company, Illinois,	 1966.
a
6. Cell	 Immun. 36:388, 1979.
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GRANULOCYTE COLONY STIMULATING FACTOR (CSF) ASSAY
a,
CSF SAMPLE
• ADD MOUSE BONE MARROW — AGAR CULTURE MEDIA
• LET GEL
+^ x
8
	
u	 1
M	 1-^
ICII
	
V	
,' 1
INCUBATE 7 DAYS AT 370C
10%CO 2 IN AIR
j
t
T COLONIES
	_ p 	 t
i	
r,E
W.^
»Ij
1
STAIN FOR IDENTIFICATION
	 f
COLONIES/105 MARROW CELLS
w
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GRANULOCYTE COLONY STIMULATING FACTOR ASSAY REFERENCES
1. J.	 Cell Physiology, 76:89, 1970.
2. J.	 Lab. Clin.
	
Med.,	 79(4):657, 1972.
3. Selected Histochemical	 and Histopatholoyical	 Methods, S.	 W. Thompson	 (ed.),
Charles C. Thomas Company, Illinois,	 1966.
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PART 311--CURRENT GOOD MANU-
FACTURING PRACTICE FOR FIN-
ISHED PHARMACEUTICALS
Subpart A--General Provisions
Sec,
211.1 Finished pharmaceuticals; manufac•
turing practice.
211.10 Personnel.
Subpart A--Construction and Maintenance of
Facilities and Equipment
211.20 Buildings.
211,30 Equipment,
Subpart C—Product Quality Control
211.40 Production and control procedures.
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1049-1050 as amended, 1055 . 1056 as amend•
ed l21 U.S.C. 351, 3711.
SouecE: 40 FIR 14025, Mar. 27, 1975, unless
otherwise noted,
Subpart A—Gen9ral Provisions
§ 211.1 Finished pharmaceuticals; manu-
facturing practice.
(a) The criteria in §§ 211.20-211.115,
inclusive, shall apply in determining
whether the methods used In, or the
facilities or controls used for, the man-
ufacture, processing, packing, or hold-
ing of a drug conform to or are operat-
ed or administered in conformity with
current good manufacturing practice
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	 § 211.20
to assure that a drug meets the re-
quirements of the act as to safety and
has the identity and strength and
meets the quality and purity charac-
teristics which it purports or is repre-
sented to possess as required by sec-
tion 501 ( a) (2) (B) of the act.
(b) The regulations in this part
permit the use of precision automatic,
mechanical, or electronic equipment in
the production and control of drugs
when adequate inspection and check-
inY procedures are used to assure
proper performance.
8211.10 Personnel,
(a) The personnel responsible for di-
recting the manufacture and control
of the dru g shall be adequate in
number and background of education,
training, and experience, or combing.
tion thereof, to assure that the drug
has the safety, identity, strength,
quality, and purity that it purports to
possess. All personnel shall have capa.
bilities commensurate with their as-
signed functions, a thorough under-
standing of the manufacturing or con
trot operations they perform, the nec-
essary training or experience, and ade-
quate information concerning the
reason for application of pertinent
Provisions of this part to their respec-
tive functions,
(b) Any person shown at any time
(either by medical examination or su-
pervisory observation) to have an ap-
parent illness or open lesions that may
adversely affect the safety or quality
of drugs shall be excluded from direct
contact with drug products until the
condition is corrected. All employees
shall be instructed to report to super-
visory personnel any conditions that
may have such an adverse effect on
drug products.
Subpart d---Construction and Mainte-
nonce of Facilities and Equipment
1211.20 Huildinwi.
Buildings shall be maintained in a
clean and orderly manner and shall be
of suitable size, construction, and loca-
tion to facilitate adequate cleaning,
maintenance, and proper operations in
the manufacturing, processing, pack-
Ing, labeling, or holding of a drug. The
buildings shall:
(a) Provide adequate space for:
(1) Orderly placement of equipment
and materials to minimize any risk of
mixups between different dru gs, drug
components, in-process materials,
packaging materials, or labeling, and
to minimize the possibility of contami-
nation.
(2) The receipt, storage, and with-
holdin g from use of components pend-
ing sampling, identification, and test-
Ing prior to release by the materials
approval unit for manufacturing or
Packaging.
(3) The holding of rejected compo-
nents prior to disposition to preclude
the possibility of their use in manufac-
turing or packaging procedures :or
which they are unsuitable.
(4) The stora ge of components, con-
tainers, packaging materials, and la-
beling.
(5) Any manufacturing and process-
ing operations performed,
(6) Any packaging or labeling oper-
ations.
(1) Storage of finished products,
(8) Control and production- laborato-
ry operations,
(b) Provide adequate lighting, venti-
lation, and screening and, when neces-
sary for the intended production or
control purposes, provide facilities for
adequate air-pressure, microbiological,
dust, humidity, and temperature con-
trols to;
(1) Minimize contamination of prod-
ucts by extraneous adulterants, includ.
ing cross-contamination of one prod-
uct by dust or particles of ingredients
arising from the manufacture, storage,
or handling of another product,
(2) Minimize dissemination of micro-
organisms from one area to another,
(3) Provide suitable storage condi-
tions for drug components, in-process
materials, andfinished dru gs in con-
formance with stability information as
derived under § 211,60,
(c) Provide: adequate locker facilities
and hot and cold water washin g facili-
ties, including soap or del rrgent, air
drier or single service towels, and clean
toilet facilities near working areas,
(d) Provide an adequate supply of
potable water (§ 1250.82 of this chap-
ter) under continuous positive pres-
sure in a plumbing system free of de-
fects that could cause or contribute to
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1211.30
contamination of any drug. Drains
shall be of adequate size and, where
connected directly to a sewer, shall be
equipped with traps to prevent back-si-
phonage.
(e) .Provide suitable housing and
space for the care of all laboratory
animals.
(f) Provide for safe and sanitary dis-
posal of sewage, trash, and' other
refuse within and from the buildings
and immediate premises.
1211.30 Equipment.
Equipment used for the manufac-
ture, processing, packing, labeling,
holding, testing, or control of drugs
shall be maintained in a clean and or-
derly manner and shall be of suitable
design, size, construction, and location
to facilitate cleaning, maintenance,
and operation for its intended pur-
pose. The equipment shall:
(a) Be so constructed that all sur-
faces that come into contact with a
drug product shall not be reactive, ad-
ditive, or absorptive so as to alter the
safety, identity, strength, quality, or
purity of the drug or its components
beyond the official or other estab-
lished requirements.
(b) Be so constructed that any sub-
stances required for operation of the
equipment, such as, lubricants or cool-
ants, do not contact drug products so
as to alter the safety, identity,
strength, quality, or purity of the drug
or its components beyond the official
or other established requirements,
(c) Be constructed and installed to
facilitate adjustment, disassembly
cleaning and maintenance to assure
the reliability of control procedures
uniformity of production and exclu-
sion from the dru gs of contaminants
from previous and current operations
that might affect the safety, identity,
strength, quality, or purity of the drug
or its components beyond the official
or other established requirements.
(d) Be of suitable type, size, and ac-
curacy for any testing„ measuring,
mixing, weighing, or other processing
or storage operations,
Title 21—Food and Drugs
Subpart C—Product Quality Control
§ 211.40 Production and control Croce.
durea,
Production and control procedures
shall include all rea..onable precau-
tions, including the following, to
assure that the drugs produced have
the safety, Identity, stren gth, quality,
and purity they purport to possi,ss:
(a) Each significant step in the pro-
cess, such as the selection, weighing,
and measuring of components, the ad-
dition of ingredients during the pro-
cess, weighing and measuring durin.-
various stages of the processing, and
the determination of the finished
yield, shall be performed by a compe-
tent and responsible individual acid
checked by a second competent and re-
sponsible individual; or if such ste ps in
the processing are controlled by preci-
sion automatic, mechanical, or elec-
tronic equipmv y)t, their proper perfor-
mance is adequately checked by one or
more competent and responsible indi-
viduals. The written record of the sig-
nificant steps in the process shall be
identified by the individual perform-
ing these tests and by the individual
charged with checking these steps.
Such identifications shall be recorded
Immediately following the completion
of such steps,
(b) All containers, lines, and equip-
ment used durin g the production of a
batch of a drug shall be properly iden-
tified at all times to accuratel y and
completely indicate their contents
and, when necessary, the stage of pro-
cessing of the batch.
(c) To minimize contamination and
prevent mixups, equipment, utensils,
and containers shall be thoroughly
and appropriately cleaned and proner-
ly stored and have previous batch
identification removed or obliterated
between batches or at suitable inter-
vals in continuous production oper-
ations.
(d) Appropriate precautions shall be
taken to minimize microbiolovical and
Other contamination in the production
of drugs purporting to be sterile or
which by virtue of their intended use
should be free from objectionable mi-
croorganisms.
(e) Appropriate procedures shall be
established to minimize the hazard of
1 —_'^- I	 as
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cross-contamination of any drugs
while being manufactured or stored.
(f) To assure the uniformity and in-
tegrity of products, there shall be ade-
quate in-process controls, such as
check ;tig the weights and disintegra-
tion times of tablets, the adequacy of
mixing, the homogeneity of suspen-
Mons, and the clarity of solutions. In-
process sampling shall be done at ap-
propriate intervals using suitable
equipnxent.
(g) Representative samples of all
dosage form drugs shall be tested to
determine their conformance with the
specifications for the product before
distribution,
(h) Procedures shall be instituted
whereby review and approval of all
production and control records, includ-
ing packaging and labeling, shall be
made prior to the release  or distribu-
tion of a batch. A thorough investiga-
tion of any unexplained discrepancy
or the failure of a batch to meet. any
of its specifications shall be undertak-
en whether or not, the batch has al-
ready been distributed. This Investiga-
tion shall be undertaken by it compe-
tent and responsible individual and
shall extend to other batches of the
same drug and other drugs that may
have been associated with the specific
failure. A written record of the investi-
gation shall be made and shall include
the conclusions and followup.
(1) Returned goods shall be identi-
fied as such and held. If the conditions
under which returned goods have been
held stored, or shipped prior to or
during their return, or the condition
of the product, its container, carton,
or labeling as a result of storage or
shipping, cast doubt on the safety,
identity, strength, quality, or purity bf
the drug, the returned goods shall be
destroyed or subjected to adequate ex-
amination or testing to assure that the
material meets all appropriate stan-
dards or specifications before being re-
turned to stock for warehouse distri-
bution or repacking. If the product is
neither destroyed nor returned to
stock, it may be reprocessed provided
the final product meets all its stan-
dards and specifications, Records of
returned goods shall be maintained
and shall indicate the quatitity re-
turned, date, and actual disposition of
the product. If the reason for returned
goods implicates associated batches,
an appropriate Investigation shall be
made in accordance with the require-
ments of paragraph ( h) of this section.
(j) Use of asbestos -containing or
other fiber-releasing filters: (1) Filters
used in the manufacture, processin g or
packaging of components of drug
products for parenteral injection in
humans shall not re !ease fibers into
such products, No asbestos-containing
or other fiber -releasing filter may be
used in the manufacture, processing,
or packaging of such products unless it
is not possible to manufacture that
drug product or component without
tile use of such a filter, Filtration, as
needed, shall be through a non-fiber-
releasing filter. For the purposes of
this regulation a non-fiber-releasing
filter is defined as a non-w5bestos filter
that, after any appropriate pretreat-
ment such as washing or flushing, will
not continue to release fibers into the
drug product or component that is
bein g filtered. A fiber is defined a9 any
particle with length at least three
times greater than its width.
(2) If use of a fiber-releasing filter is
required, an additional non-fiber-re-
leasing filter of maximum pore size of
0.22 microns (0.45 microns it' the man-
ufacturing conditions so dictate) shall
subsequently be used to reduce the
content of any asbestos-form particles
In the drug product or component. Use
of an asbestos-containing filter with or
without subsequent use of a specific
non-fiber-releasing filter Is permissible
only upon submission of proof to the
appropriate bureau of the Food and
Drug Administration that use of a
non-fiber-releasing filter will, or is
likely to,. compromise the safety or ef-
fectiveness of the drug.
(3) Substitution for a fiber-releasing
filter shall be achieved on or before
September 14, 1976. If such substitu-
tion is not achieved on or before
March 14, 1976, the manufacturer of
the drug product for parenteral injec-
tion who requires the additional 6
months to develop new manufacturing
procedures so as to utilize non-fiber-re-
leasing filters in place of fiber-releas-
ing filters shall submit monthly re-
ports to the appropriate bureau of the
Food and Drug Administration indi.
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eating progress in substituting the new
filters. Such a substitution shall be
shown to have been effected without
loss of the safety or effectiveness of
the drug.
[40 FR 14025, Aar. 27, 1975, as amended at
41 FR 16933, A p r, 23, 19761
4 211 .42 ComponentN.
All components and other materials
used in the manufacture, processing,
and packagin g of drua products, and
materials necessary for building and
equipment maintenance, upon receipt
shall be stored and handled In a safe.
salutary, and orderly manner, Ade.
quate measures shall be taken to pre-
vent mixups and cross-contantinat ion
affecting drugs and dru g; products.
Components shall be withheld from
use until they have been identified.
sampled, and tested for conformance
with established specifications and are
released by a materials a pproval unit,
Control of components shall include
the following:
(a) Each container of component
shall be examined visually for damage
or contamination prior to use, includ-
Ing examination for breakage of seals
when indicated.	 ,
(b) An adequate number of samples
shall be taken from a representative
number of component containers from
each lot and shall be subjected to one
or more tests to establish the specific
Identity.
(c) Representative samples of com-
ponents liable to contaminat an with
filth, Insect infestation, or other ex-
traneous contaminants shall be appro-
priately examined.
(d) Representative samples of all
components intended for use as active
ingredients shall be tested to deter-
mine their strength in order to assure
conformance with appropriate specifi-
cations.
(e) Representative samples of com-
ponents liable to microbiological con-
tamination shall be subjected to mi-
crobiological tests prior to use.. Such
components shall not contain microor.
ganisms that are objectionable in view
of their Intended use;
(f) Approved components shall be
appropriately identified and retested
as necessary to assure that they con-
form to appropriate specifications of
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Identity, strength, quality, and purity
at time of use, This requires the fol-
lowing:
(1) Approved components shalt he
handled and stored to Guard against
contantinat.in g or being contaminated
by other drugs or components.
(2) Approved components shall be
rotated In such a manner that the
oldest stock is used first,
(3) Rejected compon ents shall be
identified and held to preclude their
use in manufacturing or processing
procedures for which they are unsuit-
able.
(g) Appropriate records shall be
maintained, including the following:
(1) The identity and quantity of the
component, the name of the supplier,
the supplier's lot number, and the
date of receipt.
(2) Examinations and tests per-
formed and rejected components and
their disposition.
(3) An individual inventory and
record for each component used in
each batch of drug manufactured or
processed,
(h) An appropriately identified re-
serve sample of all active ingredients
consisting of at least twice the quanti-
ty necessary for all required tests,
except those for sterility and determi•
nation of the presence of pyrogens,
shall be retained for at least 2 years
after distribution of the last dru g lot
incorporating the component has been
completed or 1 year after the expira-
tion date of this last drug lot, whichev-
er Is longer,
§ 211.55 Product containers and their
component».
Suitable specifications, te,"t methods,
cleaning p rocedures, and when indicat-
ed, sterilization procedures shall be
used to ,assure that containers, clo-
sures, and other component parts of
dru g packages are suitable for their in-
tended use. Containers for parenteral
drugs, drug products or drag compo-
nents shall be cleansed with water
which has been filtered through a
non-fiber-releasing filter equivalent to
that indicated in 5211.40(j) (2). Prod-
uct containers and their components
shall not be reactive, additive, or ab-
sorptive so as to alter the safety, iden-
tity, strength, quality, or purity of the
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drug or its components beyond the of-
ficial or established requirements and
shall provide adequate protection
against external factors that can cause
deterioration or contamination of the
drug.
(Sea. 501, 502, 701, 52 8tat, 1040-1051,
1055-1059, as amended: (21 U.S.C. 351, 352,
371))
1211.58 Laboratory controls.
Laboratory controls shall Include
the establishment of scientifically
sound and appropriate specifications,
standards, and test procedures to
assure that components, in-processed
drugs, and finished products conform
to appropriate standards of identity,
strength, quality, and purity, Labora-
tory controls shall include:
(a) The establishment of master re-
cords containing appropriate specifica-
tions for the acceptance of each lot of
drug components, product containers,
and their components used in drug
production and packaging and a de-
scription of the sampling and testing
procedures used for them. Said sam-
ples shall be representative and ade-
quately identified. Such records shall
also provide for appropriate retesting
of drug components, product contain-
ers, and their components subject to
deterioration.(b) A reserve sample of all active in-
gredients as required by g 211.42(h),(c) The establishment of master re-
cords, when needed, containing specifi-
cations and a description of sampling
and testing procedures for in-process
drug preparations. Such samples shall
be adequately representative and
properly identified.(d) The establishment of master re-
cords containing a description of sam-
pling procedures and appropriate
specifications for finished drug prod-
ucts. Such samples shall be adequately
representative and properl y identified.(e) Adequate provisions for checking
the identity and strength of drug
products for all active ingredients and
for assuring:(1) Sterility of dru gs purported to be
sterile and freedom from objectionable
microorganisms for those drugs which
should be so by virtue of their intend-
ed use.
(2) The absence of pyrogens for
those drugs purporting to be pyrogen-
free,(3) Minimal contamination of oph-
thalmic ointments by foreign particles
and harsh or abrasive substances.
(4) That the drug release pattern of
sustained release products is tested by
laboratory methods to assure confor-
mance to the release specifications.
(f) Adequate provision for auditing
the reliability, accuracy, precision, and
performance of laboratory test proce-
dures and laboratory instruments
used.(g) A properly identified reserve
sample of the finished product (stored
in the same immediate container-clo-
sure system in which the drug is mar-
keted) consisting of at least twice the
quantity necessary to perform all the
required tests, except those for steril-
ity and determination of the absence
of pyrogens, and stored under condi-
tions consistent with product labeling
shall be retained for at least 2 years
after the drug distribution has been
completed or at least 1 year after the
drug's expiration date, whichever is
longer.(h) Provision for retaining complete
records of all laboratory data relating
to each batch or lot of drug to which
they apply. Such records shall be re-
tained for at least 2 years after distri-
bution has been completed or 1 year
after the drug's expirltion date,
whichever is longer.(1) Provision that animals shall be
maintained and controlled in a
manner that assures suitability for
their intended use. They shall be iden-
tified and appropriate records main-
tained to determine the history of use.(j) Provision that firms which manu-
facture nonpenicillin products (includ-
ing certifiable antibiotic products) on
the same premises or use the same
equipment as that used for manufac-
turing penicillin products, or that op-
erate under any circumstances that .
may reasonably be regarded as con-
ducive to contamination of other
drugs by penicillin, shall test such
nonpenicillin products to determine
whether any have become cross-con-
taminated by penicillin. Such products
shall not be marketed if intended for
use in man and the product is con-
B-8
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¢ 211.60
taminated with an amount of penicil-
lin equivalent to 0.05 unit or more of
penicillin G per maximum single dose
recommended in the labeling of a drug
intended for parenteral administra-
tion, or an amount of penicillin equiv-
alent to 0 .5 unit or more of penicillin
0 per maximum single dose recom-
mended in the labeling of a drug in-
tended for oral use.
1211.60 Stability.
There shall be assurance of the sta-
bility of finished drug products. This
stability shall be:
(a) Determined by reliable, meaning-
ful, and specific test methods.
(b) Determined on products in the
same container -closure systems in
which they are marketed.
(c) Determined on any dry drug
product that is to be reconstituted at
the time of dispensing ( as directed in
its labeling), as well as on the reconsti-
tuted product,
(d) Recorded and maintained in such
manner that the stability data may be
utilized in establishing product expira-
tion dates.
1211.62 Expiration dating.
To assure that drug products liable
to deterioration meet appropriate
standards of identity, strength, qual-
ity, and purity at the time of use, the
label of all such drugs shall have suit-
able expiration dates which relate to
stability tests performed on the prod-
uct,
(a) Expiration dates appearing on
the drug labeling shall be justified by
readily available data from :stability
studies such as described in § 211,60.
(b) Expiration dates shall be related
to appropriate storage conditions
stated on the labeling wherever the
expiration, date appears,
(c) When the drug is marketed in
the dry state for use in preparin g
 a
liquid product, the labeling shall bear
expiration information for the recon-
stituted product as well as an expira-
tion date for the dry
 product.
Title 21—Food and Drugs
Subpart D—Packaging and Labeling
§ 211,80 Packaging and labeling.
Packaging and labeling operations
shall be adequately controlled; To
assure that only thos, drug products
that have met the standards and speci-
fications established in their master
production and control records snall
be distributed; to prevent mixups be-
tween drugs durin g filling, packaging,
and labeling operations; to assure that
correct labels and labeling are em-
ployed for the drug: and to identify
the finished product with a lot or con-
trol number that permits determina-
tion of the history of the manufacture
and control of the batch. An hour,
day, or shift code is appropriate as a
lot or control number for dr(:g prod-
ucts manufactured or processed in
continuous production equipment.
Packaging and labeling operations
shall:
(a) Be separated (physically or spa-
tially) from operations on other drugs
In a manner adequate to avoid mixups
and minimize Bross-contamination,
Two or more packaging or labelme op-
erations having drugs, containers, or
labeling similar in appearance sh-all
not be in process simultaneously on
adjacent or nearby lines unless these
operations are separated either phys-
ically or spatially.
(b) Provide for an inspection of the
facilities prior to use to assure that all
drugs and previously used packaging
and labeling materials have. been re-
moved.
(c) Include the following labeling
controls:
(1) The holding of labels and pack-
age labeling upon receipt pending
review and p roofin g against an ap-
proved final ropv by a competent. and
responsible individual to assure that
they are accurate regardim Acnrity,
content, and conformity with the ap-
proved copy before release to inven-
tory.
(2) The maintenance and storage of
each type of label and pack i,,(, label-
ing representing different products,
strength, dosage forms, or quantlL.Y of
contents in such a manner as to pre•
vent mixups and provide proper identi-
fication.
^U
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(3) A suitable system for assuring
that only current labels and package
labeling are retained and that stocks
of obsolete labels and package labeling
are destroyed.
(4) Restriction of access to labels
and package labeling to authorized
personnel,
(5) Avoidance of gang printing of cut
labels, cartons, or Inserts when the
labels, cartons, or inserts are for dif-
ferent products or different strengths
of the same products or are of the
same size and have identical or similar
format and/or color schemes. If gang
printing is employed, packaging and
labeling operations shall provide for
added control procedures, These
added controls should consider sheet
layout, stacking , cutting, and handling
during and after printing.
(d) Provide strict control of the
package labeling issued for use with
the drug. Such issue shall be carefully
checked by a competent and responsi-
ble person for identity and conformity
to the labeling specified in the batch
production record. Said record shall
identify the labeling and the quanti-
ties issued and used and shall reason-
ably reconcile any discrepancy be-
tween the quantity of drug finished
and the quantities of labeling issued.
All excess package labeling bearing lot
or control numbers shall be destroyed.
In event of any significant unex-
plained discrepancy, an investigation
should be carried out according to
I 211.40(h).
(e) Provide for adequate examina-
tion or laboratory testing of represen-
tative samples of finished products
after packaging and labeling to safe-
guard against any errors in the finish
ing operations and to prevent distribu-
tion of any batch until all specified
tests have been met.
Subpart E—Records and Reports
f 211.101 Master production and control
records; batch production and control
records:
(a) To assure uniformity from batch
to batch, a master production and con•
trol record for each drug product and
each batch size of drug product shall
be prepared, dated, and si gned or ini-
tialed by a competent and responsible
individual and shall be Independently
checked, reconciled, dated, and signed
or initialed by a second competent and
responsible Individual, The master
production and control record shall In-
clude:
(1) The name of the product, de-
scription of the dosage form, and a
specimen or copy of each label and all
other labelin g associated with the
retail or bulk unit, including copies of
such labeling signed or Initialed and
dated by the person or persons respon-
sible for approval of such labeling.
(2) The name and weight or measure
of each active ingredient per dosage
unit or per unit of weight or measure
of the finished drug, and a statement
of the total weight or measure of any
dosage unit.
(3) A complete list of ingredients
designated by names or codes suffi-
ciently specific to indicate any special
quality characteristic; an accurate
statement of the weight or measure of
each ingredient regardless of whether
It appears in the finished product,
except that reasonable variations may
be permitted 4In the amount of compo-
nents necessary in the preparation in
dosage form provided that provisions
for such variations are included in the
master production and control record:
an appropriate statement concerning
any calculated .excess of an ingredient:
an appropriate statement of theoreti-
cal weight or measure at various
stages of processing and a statement
of the theoretical yield.
(4) A description of the containers,
closures, and packaging and finishing
materials.
(5) Manufacturing and control
Instructions, procedures, specifica-
tions, special notations, and precau-
tions to be followed.
(b) The batch production and con-
trol record shall be prepared for each
batch of drug produced and shall in-
clude complete information relatin g to
the production and control of each.
batch. These records shall be retained
for at least 2 years after the batch dis-
tribution is complete or at least 1 year
after the batch expiration date, which-
ever is longer. These records shall
identify the specific labeling and lot or
control numbers used on the batch
and shall be readily available during
B-10
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such retention period. The batch
record shall include:
(1) An accurate reproduction of the
appropriate master formula record
checked, dated, and signed or initialed
by a competent and responsible indi-
vidual,
(2) A record of each significant step
in the manufacturing, processing,
packaging, labelin g , testing, and con•
trolling of the batch, including: Dates:
individual mrJor equipment and lines
employed; specific 'identification of
each batch of components used;
weights and measures of components
and products used In the course of
processing; in-process and laboratory
control results; and identifications of
the Individual(s) actively performing
and the individual(s) directly supervis-
ing or checking each significant step
in the operation.
(3) A batch number that identifies
all the production and control docu-
ments relating to the history of the
batch and all lot or control numbers
associated with the batch.
(4) A record of any investigation
made according to 3 211.40(h).
J211.110 Distribution records.
(a) Finished goods warehouse con-
trol and distribution procedure, shall
include a system by which the distri.
bution of each lot of drug can be read-
ily determined to facilitate its recall if
necessary. ,records within the system
shall contain the name and address of
the consi gnee, date and quantity
shipped, and lot or control number of
the drug. Records shall be retained for
at least 2 years after the distribution
of the drug has been completed or 1
year after the expiration date of the
drug, whichever is longer.
(b) To assure the quality of the
product, finished goods warehouse
control shall also include a system
whereby the oldest approved stock is
distributed first whenever possible.
(See 21 CF'R 1304 for regulations re
lating to manufacturing and distribu-
tion records of drubs subject to the
Drug Abuse Control Amendments of
1965; Public Law 89-74.)
1211.115 Complaint files.
Records shall be maintained of all
written and oral complaints regrading
Title 21 —Feed and Orup•
each product. An investigation of each
complaint shall be made in accordance
with 1211.40(h), The record of each
investigation shall be maintained for
at least 2 years after distribution of
the drug has been completed or 1 year
after the expiratton date of the drug,
whichevm, is longer,
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PROCESS PROTOCOL - ERYTHROPOIETIN
r
r	 }
i	 •
a n
III '-
I	 ^^
1
Y--5	 - C-1/C- 2
MCaONIMLL DOIJOLAS A&r0W 9NAIJTEC= C®MPANV-&T. LOL18 ®IVISION
JIM
r. 	 •	
.Y.	 i:, r....	 _ -	 -'	 . 1-..iifi	 ^ '£!V" fir.- •.G ^'.	 1 ^.	 ^	 ^. • ^ ^1r .^.. 1..•.
I
REPORT MDC E2104
vi
ls:ACEVOLUMEII
 9 NOVEM9ER 1971
ANUFACTURING
PROTOCOL
°	 ERYTHROPOIETIN PRODUCTION IN SPACE
A. PREFLIGHT OPERATIONS
1. CELL SOURCE: Kidney cortex can be either minced and partially purified to
separate glomeruli using a sieving technique or the needed (not purified
strain) cells can be purchased from tissue culture supply houses if available.
2. FROZEN-STORAGE; Immediately after obtaining cells by the sieving method
above, the cells must be frozen in a medium that will protect them from
m	
internal chemical distortion and possible cell rupture during the freeze/
AJ	 thaw cycle as well as providing a nutrient source for the very low cellular
K.. metabolism while in the stored state. Additives such as glycerol, dimethyl
sulphoxide, sucrose and phosphates are typical preservatives. The cells
should be rate frozen to -196°C for storage up to one year; -96°C for storage
up to six months; -56"C for storage up to two months and -20°C for storage
up to two weeks:
3. SYSTEM STERILIZATION: The system must be sterilized prior to flight and
remain in that sterile condition during storage and flight.
B.	 FLIGHT OPERATIONS
1.	 THAWING CELL SAMPLE:	 Cells must be quick-thawed for best survival.
	 They
should be brought from the frozen storage temperature to 4°C at a rate of 2 ml
of sample per minute.
2.	 BUFFER EXCHANGE:	 Immediately a ter	 a	 the cell	 suspension must be_ 	 f	 th wing
	
r washed
	 of the	 cryoprotectant substances, and a buffered nutrient media added
to allow the cells
	 to survive for several
	
days	 if not directly followed by
the electrophoretic procedure.	 Immediately prior to processing the cell
sample through the electrophoresis system,
	 the sample must be
	 "cleansed"
of any constituents that would interfere with the electric field and separa-
tion capabilities of the unit. 	 At the same time as these constituents are'
removed, additional
	 nonreactive constituents must be added to the sample to
restore and maintain osmotic equilibrium within the cell.
	 During this
exchange process all operations,nust be conducted in a 4°C +2°C environment.
The sample volume should be adjusted to 85 milliliters containing 1
	 x 108
µr cells/ml.
k
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3, CELL ELECTROPHORETIC SEPARATION: Once these cells have gone through the
buffer exchange procedure they must be processed through the electrophoretic
system as soon as possible to maintain their viability; preferably entering
the separation chamber within several minutes and no longer than 20 minutes
after completion of the fluid replacement. The exchanged buffer must have
some but only minimal,protective ability. It cannot contain nutrients to
maintain cell viability.
Residence time of each cell in the electrophoresis chamber will be
approximately 50 miutes. As long as the electrophoretic separation pro-
cess is conducted at 4-8°C, a cell viability loss of less than 10°I is
anticipated. The total separation time for the full sample is expected
to be 85 hours.
3.1 BUFFER RECLAMATION: Each electrophoretic chamber outlet tube must be
monitored to detect the presence of the cellular material of interest.
The central 50% of this bandspread of each outlet tube must be collected.
The effluent of the remaining outlet ports will be collected and subjected
to a "cleansing" process to remove particulates, organics, and ionicelements.
The resultant water must then be held until a preselected volume is obtained.
Preweighed and packaged chemicals must then be mixes into this volume of
water in order to produce additional buffer material for continuous opera-
tion of the electrophoresis chamber.
4. COLLECTED SAMPLE MEDIA EXCHANGE: As the separated cells emerge from the
electrophoresis chamber outlet tubes they must be transferee into a more
protective nutrient media which will allow cell growth. This media must
contain all essential growth factors (solids and gases) and be of sufficient
quantity te, keep the collected cells viable until the complete sample has
been collected and transfered to the erythropoietin-producing cell culturing
vessel.
5. CELL CULTURE INOCULATION: The collected cells are transfered to a small
culture vessel of 500 ml volume. This initial inoculation must have a
minimum concentration of 4.4 x 10 5
 cells/ml. Nutrient media must be con-
tinuously cycled through the vessel while temperature, pH and oxygen con-
centrations are maintained within controlled intervals. There is a growth
lag phase of about three days as the cells acclimatize to their new environ-
ment. Once growth begins, the cells will double approximately every 35 hours.
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Cells must be cultured until they reach a population of 3 x 10
6
 /ml. This
will require about 7 days. When this population density is reached the entire 	 j
contents of the vessel is used to inoculate a second culture vessel of 3.5 	
l
liter volume. Again, after a 3 day lag and 4 day cell growth period (with
care given to controllingcell environment described above) the vessel con-
tents are transfered into a 25 liter vessel for the third expansion of
culture volume. When the three day lag and 4 day growth period are completed 	 i
in this vessel, the contents are transfered to a final production tank of
125 liters. Each transfer and dilution results in an initial inoculation of 	 1
1
4.4 x 10 5 cell/ml.
6. PRODUCTION CELL CULTURING AND HARVESTING: In the production tank there will
be a seven day period of cell acclimalization and growth until the cell
concentration reaches 3.6 x 106 cells/ml.. When this population density has
been achieved, the nutrient media will be changed to that more desirable for
erythropoietin production and cell reproduction will rapidly diminish.
	
The
culture vessel is continuously drained at the rate of 8.5% of volume
per day through a 0.2 micron filter and the effluent collected. The chamber
culture volume is maintained by the simultaneous admission of fresh
replacement media. The culture vessel is maintained at the optimum
TL	
temperature, pH and chemical composition required for maximum cell production.
The production cycle will continue for 14 days. At that point in time,
the cell population in the culture vessel will be cut back to 10% (the
4
remainder of the cells disrupted with the membranes and organelles discarded)
and the growth phase restarted. This cut back in density will allow removal
of any metabolic wastes that may not have been removed with continuous media
replacement. The 7 day growth, '14 day production cycle will be repeated three
T	 additional times. At the end of the fourth cycle, the tank is drained,
r,,	 cleaned, sterilized and a new cycle with new cultures begun.
7. PROTEIN PRODUCT CONC ENTRATION:	 The resultant harvested media contains the
erythropoietin product in very dilute form alcn g with proteins from the
growth media. The protein must be concentrated for further purification
by another electrophoretic separation. The fluid must be concentrated
approximately 15 times to provide a new electrophoresis sample flow rate of
36 ml/hours. The sample must contain about 10% protein per milliliter.
!j
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7.1 CULTURE MEDIA RECLAMATION: The excess production culture media available
from the concentration procedure will be collected and cleansed of particu-
lates, organics, and ionic elements. This polished water must be mixed
with preweighed and packaged chemicals to form additional nutrient media for
continues operation of the culture vessel. Because water is lost each
day for the electrophoretic sample, make up water must be added to this
additional nutrient media to restore volume and chemical concentration.
8. ERYTHROPOIETIN ELECTROPHORETIC SEPARATION: At 4°C the collected and
concentrated media must be processed through the continuous flow electro-
phoresis chamber at the rate of 36 ml/hour.
9. FRACTION COLLECTION AND CONCENTRATION: As the separated proteins emerge
from the electrophoresis chamber outlet tubes, they must be continuously
analyzed to determine their identity. Only the middle 90% of each fraction
bandwidth must be collected. All collected fractions are subjected to a
protein concentration procedure in order to reduce the volume by a ratio of
100:1.
9.1 BUFFER RECLAMATION: The effluent of the remaining chamber outlet ports
and the fluid from the concentration fraction must be subjected to a cleansing
process to remove particles, organics and ionic elements. The resultant water
must be held until a preselected volume is obtained. Make up water will be
required since a certain amount is lost for concentration in step 9. Pre-
weighed and packaged chemicals must then be mixed into this volume of water
in order to produce additional buffer material for continuous operation of
the electrophoresis chamber.
10. PRODUCT LYOPHILIZATION: The erythropoietin must be bulk lyophilized to its
powder form. The fluid removed in this process is dumped overboard.
11. BULK STORAGE: The lyophilized material must be held in bulk sterile
storage to be brought back to earth for further processing, packaging and sale.
'12. SYSTEM STERILIZATION: Since the system remains closed after ground ster-
ilization, there should be no contamination problems. Final product samples
must be collected every other day to verify freedom from microbiological
contamination and pyrogenicity.
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PROCESS PROTOCOL-ANTIHEMOPHILIC FACTOR
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PROTOCOL
FOR
ANTIHEMOPHILIC FACTOR PRODUCTION IN SPACE
A. PRE-FLIGHT OPERATIONS
I. ANT IHEMOPHI L.IC FACTOR SOURCE: Cryoprecipitate (the source of AHF) is
obtained in its bulk frozen form from the supplier.
2. STORAGE.: AHF must be stored at -30°C or below to prevent deterioration.
B. FLIGHT OPERATIONS
1, THAWIN G AND DILUT I ON OF MATERIAL: The material is allowed to thaw at 10"C
and diluted in a 1:1 ratio with the proper buffer to be used for electro-
phoretic separation.
2. ELECTROPHORET IC SEPARATION: At 4°C, the diluted cryoprecipitate is processed
through the continuous flow electrophoresis chamber at the rate of 36 nil/
hour.
3. FRACTION COLLECTION AND CONCENTRATION: As the separated proteins emerge
from the electrophoretic chamber outlet tubes they must be analyzed continu-
ously to determine their identity. Only the middle 90% of each fraction
bandwidth must be collected. All collected fractions are subjected to a
protein concentration procedure in order to reduce the volume by a ratio
of 100:1 .
3.1 BUFFER RECLAMATION: The effluent of the remaining chamber outlet ports and
the fluid from the concentration fractions are subjected to a cleansing
process to remove particulates, organics and ionic elements. The resultant
water must then be held until a preselected volume is obtained. Makeup
water will be required to compensate for that lost during reclamation and
lyophilization.
	 Preweighed and packaged chemicals must then be mixed into
this volume of water in order to produce additional buffer material for
continuous operation of the electrophoresis chamber.
4.0 PRODUCT LYOPHILIZATION: Each concentrated protein fraction is separ-
ately bulk lyophilized to its powder form. The fluid removed in this pro-
cess is dumped overboard.
5.0 BULK STORAGE: The lyophilized material is held in bulk sterile
storage to be brought back to earth for further processing, packaging and
sale.
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6.0 SYSTEM STERILIZATION: Since the system remains closed after ground
sterilization, there should be no contamination problems. Final product
samples must be collected every other day to verify freedom from micro-
biological contamination and pyrogenicity.
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PROTOCOL
FOR
I 'f	 BETA CELL PRODUCTION IN .SPACE
A. PREFLIGHT OPERATIONS
1. CELL SOURCE: The human pancreas must be minced and partially purified to
separate the Islets of Langerhans or Beta cells from the surrounding
acinar and connective tissue. This can be accomplished using enzymatic
disruption and washed sedimentation techniques. Approximately 7.0 x 10 
cells in 68 nil should be collected for this activity.
2. FROZEN STORAGE: Immediately after obtaining the partially purified cells,
they must be frozen in a medium that will protect them from internal
chemical distortion and possible cell rupture during the freeze/thaw cycle
1	 as well as providing a nutrient source for their very low cellular metabolism
while in the stored state. Additives such as glyceral, dimethyl sulphoxide,
sucrose and phosphates are typical preservatives. The cells should be rate
frozen for storage. The depth of freezing and the length of storage via-
bility must still be determined.
r	 3. SYSTEM STERILIZATION: The system must be sterilized prior to flight and
remain in that sterile condition during storage and flight.
B. FLIGHT OPERATIONSk	 -^
I. THAWING CELL SAMPLE: Cells must be quick-thawed for best survival. They
S	 should be brought from the frozen storage temperature to 4°C at a rate of
w	
2 nil of sample per minute.
2. BUFFER EXCHANGE: Immediately after thawing, the cell suspension must be
washed of the cryoprotectant substances and a buffered nutrient media added
to allow the cells to survive for several days if not directly followed by
the electrophoretic procedure.
Immediately prior to processing the cell sample through the electro-
phoresis system, that sample must be "cleansed" of any constituents that would
interfere with the electrical field and separation capabilities of the unit.
At the same time as these constituents are removed, additional nonreactive
constituents must be added to the sample to restore and maintain osmotic
C-13
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equilibrium within the cell. During this exchange process, all operations
must be conducted in a 4°C +2°C environment. fhe sample volume should be
adjusted to 68 milliliters.
3. CELL ELECTROPHORETIC SEPARATION: Once these cells have gone through the
buffer exchange procedure, they must be processed through the electro-
phoretic system as soom as possible to maintain their viability; prefer-
ably entering the separation chamber within several minutes and no longer,
than 20 minutes after completion of the fluid replacement. The exchanged
buffer must have some, but only minimal, protective ability. It can not
contain nutrients to maintain cell viability.
Residence time of each cell in the electrophoretic chamber will be
approximately 50 minutes. As long as the electrophoretic separation process
is conducted at 4-8°C, a cell viability loss of less than 10% is antici-
pated. Total separation time for the full sample is expected to be 68-70 hours.
3.1 BUFFER RECLAMATION: Each electrophoretic chamber outlet tube must be
monitored to detect the presence of the cellular material of interest.
The central 50°0 of this band spread of outlet tubes is collected. The
effluent of the remaining outlet ports will be collected and subjected
to a "cleaning" process to remove particulates, organics and ionic elements.
The resultant water must then be held until a preselected volume is obtained.
Preweighed and packaged chemicals must then be mixed into this volume of
water in order to produce additional buffer material for continuous opera-
tion of the electrophoresis chamber.
4. COLLECTED SAMPLE MEDIA EXCHANGE: As the separated cells emerge from the
electrophoresis chamber outlet tubes, they are transfered into a more
protective nutrient media which will allow cell growth. This media
containsall essential growth factors (solids and gases) and is of sufficient
quantity to keep the collected cells viable until the complete sample has
been collected and transfered to the Beta Cell culturing vessel.
5. CELL CULTURE INOCULATION: The collected cells are transfered to a small
culture vessel of 235 ml volume. This initial inoculation has a min-
imum concentration of 4.4 x 10 5
 cells/ml. Nutrient media must be continu-
ously cycled through the vessel while temperature, pH and oxygen concentra-
tions are maintained within controlled intervals. 	 There is a growth lag
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phase of about three days as the cells acclimatize to their new environ-
ment. Once growth begins the cells will double approximately every 35
hours. Three reproductive cycles (about 105 hours) will result in a
total production of 8.4 x 10 8 cells in this culture vessel.
When this cell concentration is reached, the culture vessel volume
is increased to 1000 ml while new culture media is added until the vessel
is full. This dilution results in an inoculation of 4.4 x 10 5 Beta cells
per millimeter • for the larger production vessel.
6.	 PRODUCTION CELL CULTURING AND HARVESTING:	 After another three day cell
acclimatization	 phase,	 the cells will	 again reproduce at a doubling rate
of 35 hours.	 When the culture has reached a concentration of 3.6 x 106
cells	 per milliliter	 (approximately 4 days),	 the culture vessel
	
is
continuously drained at the rate of 50% of volume each 35 hours. 	 At the
4^
end of each 15th cell
	
culture, the culture is reduced to one-tenth of its
1
original
	 volume to preclude buildup of toxic products.
	
The chamber culture
volume is maintained by simultaneous admission of fresh replacement
media.	 The culture vessel will	 be maintained at the optimum temperature,
pH and chemical	 composition required for maximum cell
	
production.
7.	 HARVESTED CELL CONCENTRATION:
	 The resultant harvested cells must be concen-
trated for further purification by another electrophoretic separation.
	 The
651 mi	 of tissue culture is concentrated approximately 30 times to
	
provide
an electrophoresis sample rate of 1 	 ml/hr.	 This	 sample concentration	 is
approximately
	 1	 x 10 	 cells/ml.
7.1	 CULTURE MFDIA RECLAMATION:	 The excess culture media available from the
concentration procedure is collected and 	 "cleansed"	 of particulates,	 organic
and	 ionic elements.	 This	 polished	 eater must be mixed with pre-
weighed and packaged chemicals
	 to form additional
	 nutrient media for con-
tinuous operation of the culture vessel.
	 Because about 20 ml
	 of water are
lost each day for the electrophoretic sample, make-up water
	 is added
to this additional
	 nutrient media to restore volume and chemical
	 concentra-
tion.
8.	 BUFFER EXCHANGE:	 Immediately prior to processing the cell
	 sample through
the electropnoresis system, the sample is
	 "cleansed" of any constituents
that would interfere with the electrical
	 field and separation capabilities
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of the unit. At the same time as these constituents are removed, additional
nonreactive constituents must be added to the sample to restore and maintain
osmotic equilibrium within the cell. During this exchange process all
operations must be conducted in a 4°C +2°C environment.
9. CELL ELECTROPHORETIC SEPARATION: Once these cells have gone through the
buffer exchange procedure,they must be processed through the electrophoresis
chamber as soon as possible to maintain their viability, preferably enter-
ing the separation chamber within several minutes and no longer than 20
minutes after completion of the fluid replacement. The exchanged buffer
must have some, but only minimal, protc ,x:tive ability. Residence time of
each cell in the electrophoresis chamber will be approximately 50 minutes,
As long as this separation is conducted at 4°-8°C a cell viability 'loss of
less than 101 is anticipated.
10. FINAL PRODUCT CONCENTRATION AND MEDIA E XCHANGE: As the separated cells
emerge from the electrophoretic chamber tubes, they are transfered
immediately into a more protective nutrient med-;a and cryoprotectant that
will allow cell nutrition and preserve viability during frozen storage.
During this phase of the process the central 90% of the band spread of the
outlet tubes of interest will be collected for final product. All other
tubes will be subject to reclamation. Those tubes containing'final product
will be mixed together and subjected to concentration procedures of Step 7.1
until the sample contains 1 x 10 8 cells/ml.
10.1 BUFFER RECLAMATION: Identical to step 3.1.
11. FINAL PRODUCT FREEZING AND STORAGE: The final product is rate frozen to
prevent cell damage while in the stored state.
12. SYSTEM STERILI ZATION : As the system remains closed after ground sterilization,
there should be no contamination problems. Final product samples must be
collected every other day to verify freedom from microbiological contamina-
tion and pyrogenicity.
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